Supplemental Online Content

MARVEL Trial Authors for the MARVEL Investigators. Methylprednisolone as adjunct to endovascular thrombectomy for large vessel occlusion stroke: the MARVEL randomized clinical trial. *JAMA*. doi:10.1001/jama.2024.0626

- eMethods 1. Detailed Inclusion and Exclusion Criteria
- eMethods 2. Definition of Analyzed Population
- eMethods 3. Handling of Missing Values and Sensitivity Analyses
- **eTable 1.** Demographic and Clinical Characteristics of Patients at Baseline (Per-Protocol Population)
- eTable 2. Detailed Analysis of Primary and Secondary Outcomes (Full Analysis Set)
- eTable 3. Primary and Secondary Efficacy Outcomes (Per-Protocol Population)
- eTable 4. Primary Efficacy Outcomes—Sensitivity Analysis
- eTable 5. Summary of Adverse Events With Special Interest (Safety Population)
- eTable 6. Summary of Main Outcome by Participating Centers
- **eFigure 1.** Flowchart
- eFigure 2. Distribution of 82 Enrolling Centers in 17 Provinces in China
- **eFigure 3.** Distribution of the Modified Rankin Scale Score at 90 Days (Per-Protocol Population)
- eFigure 4. Kaplan-Meier Estimates of Survival Probability (Full Analysis Set)
- **eFigure 5.** Subgroup Analysis of Death (Safety Population)
- **eFigure 6.** Subgroup Analysis of sICH (Safety Population)

This supplemental material has been provided by the authors to give readers additional information about their work.

List of Investigators

Enrolling Clinical Centers (number of patients enrolled), Principal Investigators

Qujing First People's Hospital (133) Yifei Chen;

Longvan First Hospital (126) Chong Zheng;

Xinqiao Hospital and The Second Affiliated Hospital (98) Wenjie Zi;

Jingdezhen NO.1 People's Hospital (78) Shunfu Jiang;

The First Affiliated Hospital of University of South China (48) Zhongfan Ruan;

Jiangmen Central Hospital (46) Min Zhang;

Hospital 302 Attached to Anshun Group (44) Dengwen Song;

Guangyuan Central Hospital (41) Xiaojun Luo;

Qian Xi Nan People's Hospital (40) Yaoyu Tian;

Dali Bai Autonomous Prefecture People's Hospital (36) Mei Yang;

People's Hospital of Wushen County (36) Shenglin Deng;

The people's Hospital of Hechi and the Hechi Hospital Affiliated to Youjiang

Medical University For Nationalities (35) Shirong Wei;

Chongzhou Hospital (34) Youlin Wu;

Mianyang Central Hospital (33) Yufeng Tang;

Chongqing University Fuling Hospital (32) De Yang;

Ganzhou People's Hospital (32) Guoyong Zeng;

Meishan Second People's Hospital (31) Xiaolin Tan;

Xingyi People's Hospital (31) Daoyou Cheng;

Wuhan Hospital of Traditional Chinese And Western Medicine (31) Wenhua Liu;

Guiping People's Hospital (30) Wencheng He;

Yunyang County People's Hospital (27) Tieying Cai;

People's Hospital of Chongqing Banan District (24) Chengde Pan;

Suining First People's Hospital (24) Jiasheng Liao;

The People's Hospital Of Leshan (24) Bo Lei;

Affiliated Hospital of North Sichuan Medical College (24) Shengxiong Pu;

Jiangmen Wuyi Hospital of traditional Chinese Medicine (22) Zhenglong Jin;

The Affiliated Hospital of Southwest Medical University (20) Jinglun Li;

Jiujiang University Affiliated Hospital (20) Zhongbin Xia;

The People's Hospital Of Danzhai (20) Guling Zhang;

Sichuan Mianyang 404 Hospital (19) Jun Luo;

Shanxi Provincial People's Hospital (19) Yaxuan Sun;

Chongqing University Qianjiang Hospital (16) Xiaoping Xiong;

Yaan People's Hospital (16) Jian Wang;

Bazhong Central Hospital (16) Bo Li;

Sichuan Science City Hospital (16) Yuqi Peng;

Zhangjiagang First Peole's Hospital (16) Kechun Chen;

Xiangyang No.1 People's Hospital (16) Peiyang Zhou;

The Affiliated Baiyun Hospital of Guizhou Medical University (16) Xinyuan Huang;

Jieyang People's Hospital (16) Shiwei Luo;

Zhejiang Provincial People's Hospital Bijie Hospital (16) Jie Zhang:

Xiangzhou District People's Hospital (15) Yuanjun Shan;

Hubei Provincial Hospital of TCM (14) Jie Pu;

Xi Chang People's Hospital (13) Yang Ni;

Taihe Hospital of Traditional Chinese Medicine (13) Zongtao Liu;

The third Hospital of Mianyang (12) Xin Zou;

Chengdu Second People's Hospital (12) Changchuan Wu;

Dazhou Central Hospital (10) Jiazuo Liu;

The 924th Hospital of The Chinese People's Liberation Army (10) Li Qi;

Yuebei People's Hospital (10) Junbin Chen;

Weihai Municipal Hospital (9) Pengfei Wang;

Chognging Sanbo Changan Hospital (8) Jianfang Luan;

The First People's Hospital of Yunnan Province (8) Da Liu;

Xianyang Hospital of Yan'an University (8) Bo Song;

Dushu Lake Hospital Affiliated to Soochow University and The Medical

Center of Soochow University (8) Yonggang Hao; © 2024 American Medical Association. All rights reserved.

Zigong First People's Hospital (8) Tao Qiu;

Jintang People's Hospital (8) Kuiyun Wang;

Changzhi People's Hospital (8) Zuopeng Li;

The People's Hospital of Pingchang (8) Junsheng Liu;

Ningbo Medical Center Lihuili Hospital (8) Zhenqiang Li;

Shenqiu County People's Hospital (8) Yanling Li;

People's Hospital of Zunyi City Bo Zhou District (8) Shuang Yang;

Nanping First Hospital (8) Xiaoli Lin;

Affiliated Hospital of Chengdu University (8) Wen Cheng;

The Third People's Hospital of Guiyang (7) Anaiang Chen;

Dianjiang People's Hospital of Chongqing (5) Shiqiang Yan;

Yongchuan Hospital of Chongqing Medical University (4) Shudong Liu;

The People's Hospital of Kaizhou District (4) Jie Du;

Mianzhu People's Hospital (4) Zhuo Chen;

Meishan City People's Hospital (4) Bo Song;

Xian XD Group Hospital (4) Li Yao;

The Second Affiliated Hospital of Guangxi Medical University (4) Deyan Kong;

Chongqing Fengdu People's Hospital (3) Hongiun Wang;

The First Bethune Hospital of Jilin University (3) Shouchun Wang;

Guiyang Huaxi District People's Hospital (3) Xunfeng Zhu;

The Third People's Hospital of Hubei Province (2) Yue Wan;

The Second People's Hospital of Mengjin District (2) Haojin Zhao;

GaoZhou People's Hospital (2) Qingchun Mou;

Luxian People's Hospital (1) Ling Dai;

The People's Hospital of Dujiangyan (1) Shui Yu;

Songyuan Jinlin Oilfield Hospital (1) Dongsheng Ju;

Maoming Hospital of traditional Chinese Medicine (1) Wenguo Huang;

Houjie Hospital of Dongguan (1) Yihong Huang.

eMethods

eMethod 1. Detailed Inclusion and Exclusion Criteria:

Inclusion criteria

- 1. Age \geq 18 years;
- 2. The time from onset to randomization was within 24 hours;
- Anterior circulation ischemic stroke was preliminarily determined according to clinical symptoms or imaging examination;
- 4. Baseline National Institutes of Health Stroke Scale (NIHSS) \geq 6
- 5. Baseline Alberta Stroke Program Early CT Score (ASPECTS)≥ 3;
- 6. Computed tomography angiography (CTA) /magnetic resonance angiography (MRA) /digital subtraction angiography (DSA) confirmed occlusion of the intracranial segment of the internal carotid artery or middle cerebral artery, and decision to undergo endovascular therapy;
- 7. Written informed consent signed by patient or their family member.

Exclusion Criteria:

Patients meeting any of the following criteria were excluded from study enrolment.

 Intracranial hemorrhage confirmed by cranial computed tomography (CT) or magnetic resonance imaging (MRI);

- mRS score \geq 2 before onset;
- Pregnant or lactating women;
- Allergic to contrast agents;
- Allergic to glucocorticoids;
- Participating in other clinical trials;
- Systolic blood pressure > 185 mmHg or diastolic pressure > 110 mmHg, and unable to control with oral antihypertensive drugs;
- Genetic or acquired bleeding diathesis, lack of anticoagulant factors; or oral anticoagulants and INR > 1.7;
- Blood sugar < 2.8 mmol/L (50 mg/dl) or > 22.2 mmol/L (400 mg/dl), platelet <
 90 x 10^9/L;
- Arterial tortuosity such that the thrombectomy device cannot reach the target vessel;
- Bleeding history (gastrointestinal and urinary tract bleeding) in recent 1 month;
- Chronic hemodialysis and severe renal insufficiency (glomerular filtration rate <
 30 ml/min or serum creatinine > 220 umol/L [2.5 mg/ dL]);
- Life expectancy due to any advanced disease < 6 months;
- Follow-up is not expected to be completed;
- Intracranial aneurysm and arteriovenous malformation;

- Brain tumor with imaging mass effect;
- Severe systemic infectious disease.

Inclusion and exclusion criteria will be assessed based on information available during the screening period.

eMethod 2. Definition of Analyzed Population

Full Analysis Set as randomized

The full analysis set (FAS) as randomized includes all patients randomized into the trial except 7 patients who withdrew consent immediately after randomization. The analysis of the primary endpoint will be a complete case analysis of the FAS which patients missing day 90 assessments will be censored (deleted).

The Per-Protocol (PP) Population

The PP population is defined as the subset of the ITT population excluding major protocol violators deemed to have the potential to affect patient outcome in terms of efficacy.

The PP population includes patients who actually received the assigned treatment and do not have major protocol violations or deviations. Major protocol violations or deviations were identified in a blinded fashion prior to database lock. More specifically, patients with any one of the following criteria were excluded from the PP population. These deviations were determined based on the medical monitors' records, as well as programmatically, using the following criteria at a minimum:

- Received but did not complete treatment with study drug, or dose of study drug administered outside recommended dose.
- Received any additional anti-platelet therapy (e.g., oral clopidogrel)
- Violated inclusion or exclusion criteria.

A list of patients to be excluded from the randomized patients to create the PP-Efficacy analysis will be established and validated by the Steering Committee prior to unblinding.

Safety Population

The Safety Population included all patients who received any amount of study drug. In case of violation of the randomization scheme, patients were classified according to the treatment they received. Patients were assigned to the different populations prior to unblinding of the database. Patients who withdrew informed consent immediately after randomization and did not to receive any treatment were excluded from the Safety Populations. The safety population is identical to the ITT population in this study.

eMethod 3. Handling of Missing Values and Sensitivity Analyses

The primary analysis of the primary endpoint was a complete case analysis under which patients missing day 90 assessments were censored (deleted).

To assess the influence of the missing primary endpoints on the treatment effect estimate, sensitivity analyses were performed using the same statistical methods as in the primary analysis, considering several situations:

(1) Worst-case scenario:

All patients with a missing primary endpoint were considered as a mRS of 6 in both treatment groups.

(2) Best-case scenario:

All patients with a missing primary endpoint were considered as a mRS of 0 in both treatment groups.

(3) Multiple imputation:

Missing mRS score were imputed using the multiple imputation method via SAS PROC MI. The imputation procedure was performed under the missing-at-random (MAR) assumption. Fully conditional method (FCS) was used to predict missing mRS score by fitting an ordered logistic regression model with the following predictors: treatment group, age, baseline NIHSS score, pre-stroke mRS, baseline ASPECTS score, use of intravenous thrombolysis, time from onset to randomization, and occlusion location, and last observed NIHSS if available. The seed was 128. A total of 10 imputed datasets were generated. GenOR was estimated for each dataset separately, and pooled together to calculate the final pooled genOR and 95% confidence interval using Robin's role.

- (4) Proportional odds model. A proportional odds model was employed in the sensitivity analysis. Both the unadjusted and adjusted results were presented. The adjusted model included age, baseline NIHSS score, pre-stroke mRS, baseline ASPECTS, the use of intravenous thrombolysis, time from onset to randomization, and occlusion location as covariates.
- (5) Proportional odds model with random effect: A proportional odds model with random effect was fitted to estimate the common odds ratio between the methylprednisolone and placebo treatment with treatment as fixed effect, age, baseline NIHSS score, pre-stroke mRS, baseline ASPECTS score, use of intravenous thrombolysis, time from onset to randomization, and occlusion location as covariates, and the center as a random effect.
- (6) Post-hoc worst-best scenario analysis: Patients with a missing primary endpoint in the placebo group were considered as a mRS of 0 while patients with a missing primary outcome in the methylprednisolone group were considered a mRS of 6.

eTables

eTable 1. Demographic and Clinical Characteristics of Patients at Baseline (Per-Protocol Population). ^a

Characteristics	Methylprednisolone (N=761)	Placebo (N=779)
Age, median (IQR), y	68.0 (59.0,75.0)	69.0 (59.0,77.0)
Fale sex, No. (%)	435 (57.2)	435 (55.8)
Medical history, No. (%)		
Hypertension	455 (59.8)	485 (62.3)
Hyperlipidemia	245 (32.2)	225 (28.9)
Atrial fibrillation	313 (41.1)	323 (41.5)
Coronary heart disease	137 (18.0)	157 (20.2)
Valvular heart disease	100 (13.1)	105 (13.5)
Diabetes mellitus	158 (20.8)	137 (17.6)
Transient ischemic attack	6 (0.8)	4 (0.5)
Cerebral ischemia	118 (15.5)	103 (13.2)
Intracranial hemorrhage	9 (1.2)	8 (1.0)
Smoking	217 (28.5)	217 (27.9)
Pre-stroke Modified Rankin Scale score, No. (%)		
0	736 (96.7)	765 (98.2)
1	25 (3.3)	14 (1.8)
Baseline NIHSS score (IQR) b	19.0 (16.0, 21.0)	19.0 (16.0, 21.0)
Baseline ASPECTS value, median (IQR) °	6.0 (4.0, 7.0)	6.0 (4.0, 7.0)
Side of hemisphere, No./total (%) d		
left	383/761 (50.3)	386/778 (49.6)
right	378/761 (49.7)	392/778 (50.4)
TOAST etiology, No. (%) e		
LAA	284 (37.3)	311 (39.9)
CE	381 (50.1)	363 (46.6)
Other	26 (3.4)	38 (4.9)
Unknown	70 (9.2)	67 (8.6)
Occlusion site on CT or MR angiography, No. (%)		
Intracranial internal carotid artery	245 (32.2)	265 (34.0)
M1 middle cerebral artery segment	421 (55.3)	398 (51.1)
M2 middle cerebral artery segment	95 (12.5)	116 (14.9)
IV thrombolysis, No. (%)	272 (35.7)	314 (40.3)
Median time from onset to puncture, median (IQR), min	343.0 (230.0, 605.0)	352.0 (237.0, 577.0)
Median time from onset to randomization, median (IQR), min	346.0 (235.0, 604.0)	357.0 (236.0, 572.0)
Median time from onset to recanalization, median (IQR), min $^{\rm f}$	423.0 (310.0, 689.0	435.0 (311.0, 668.0)
Median time from randomization to initial treatment, median (IQR), min ^g	8.0 (6.0, 13.0)	8.0 (6.0, 13.0)
Median systolic blood pressure at hospital arrival, median (IQR), mm Hg	142.0 (127.0, 160.0)	145.0 (127.0, 160.0)
Median diastolic blood pressure at hospital arrival, median (IQR), mm Hg	82.0 (74.0, 92.0)	84.0 (74.0, 94.0)
Median glucose level at hospital arrival, median (IQR), mmol/liter h	7.2 (6.2, 8.9)	7.1 (6.0, 8.6)

Abbreviations: ASPECTS, Alberta Stroke Program Early Computed Tomography Score; CI, confidence interval; CT, Computed Tomography; IQR, interquartile range; MR, Magnetic Resonance; NIHSS National Institutes of Health Stroke Scale; IV, intravenous; M1, main trunk of the middle cerebral artery; M2, segment first-order branch of the main trunk.

^a There was no significant difference between the two groups.

- ^b Scores on the National Institutes of Health Stroke Scale (NIHSS) range from 0 to 42, with higher scores indicating more severe neurological deficits.
- ^e The Alberta Stroke Program Early Computed Tomography Score (ASPECTS) is an imaging measure of the extent of ischemic stroke. Scores range from 0 to 10, with higher scores indicating a smaller infarct core. Listed are values for the core laboratory assessment.
- ^d Data on Side of Hemisphere at baseline were missing for 1 patient in placebo group.
- ^e The TOAST (Trial of Org 10172 in Acute Stroke Treatment) classification system is a widely used method for classifying ischemic strokes and transient ischemic attacks (TIAs). It divides ischemic strokes and TIAs into five subtypes based on their likely causes: Large-artery atherosclerosis (LAA), Cardioembolism (CE), Small-artery occlusion (SAO), Other determined etiology (Other), Undetermined etiology (Unknown).
- f Data on the time from onset to recanalization at baseline were missing for 1 patient in Placebo group.
- ^g Data on the time from randomization to initial treatment at baseline were missing for 1 patient in the Placebo group.
- ^h To convert the values to milligrams per deciliter, divide by 0.05551. Data were missing for 94 patients in the Methylprednisolone group and 99 patients in the Placebo group.

eTable 2. Detailed Analysis of Primary and Secondary Outcomes (Full Analysis set as randomized). ^a

Outcomes	Methylprednisolo ne (N=839)	Placebo (N=841)	Treatment Effect	Unadjusted Value (95% CI)	P	Adjusted Value (95% CI) †	р
Primary efficacy outcomes							
mRS score at 90 days — Win proportion (%) $^{\rm b}$	43.96	39.25	GenOR ^c	1.12(0.98 to 1.28)	0.09	1.10 (0.96 to 1.25)	0.17
			cOR	1.16 (0.98 to 1.37)	0.09	1.06 (1 to 1.13)	0.0496
Secondary efficacy outcomes							
mRS score of 0 to 4 at 90 days, No./total (%)	597/835 (71.5)	555/838 (66.2)	Risk ratio	1.08 (1.01 to 1.15)	0.02	1.07 (1.00 to 1.14)	0.04
			Risk difference	0.05 (0.01 to 0.1)	0.02	0.05 (0.01 to 0.08)	0.004
			Odds ratio	1.28 (1.04 to 1.57)	0.02	1.24 (1.07 to 1.43)	0.004
mRS score of 0 to 3 at 90 days, No./total (%)	496/835 (59.4)	459/838 (54.8)	Risk ratio	1.08 (1 to 1.18)	0.056	1.07 (0.98 to 1.16)	0.11
			Risk difference	0.05 (0 to 0.09)	0.056	0.04 (0.01 to 0.07)	0.02
			Odds ratio	1.21 (1 to 1.47)	0.06	1.17 (1.02 to 1.34)	0.02
mRS score of 0 to 2 at 90 days, No./total (%)	368/835 (44.1)	343/838 (40.9)	Risk ratio	1.08 (0.96 to 1.20)	0.19	1.07 (0.95 to 1.19)	0.26
			Risk difference	0.03 (-0.02 to 0.08)	0.19	0.03 (-0.01 to 0.06)	0.11
			Odds ratio	1.14 (0.94 to 1.38)	0.19	1.12 (0.97 to 1.28)	0.11
mRS score of 0 to 1 at 90 days, No./total (%)	223/835 (26.7)	222/838 (26.5)	Risk ratio	1.01 (0.86 to 1.18)	0.92	0.99 (0.84 to 1.16)	0.89
			Risk difference	0 (-0.04 to 0.04)	0.92	0 (-0.03 to 0.03)	0.85
			Odds ratio	1.01 (0.81 to 1.26)	0.92	0.98 (0.84 to 1.15)	0.85
NIHSS score at 5-7 days or earlier charge, median (IOR) ^d	11.0 (4.0 to 23.0)	12.0 (4.0 to 28.0)	Win Ratio	1.08 (0.96 to 1.21)	0.20	1.07 (0.95 to 1.20)	0.25
EQ-5D-VAS score at 90 days, median (IQR) °	55.0 (5.0 to 80.0)	50.0 (0.0 to 80.0)	Win Ratio	1.13(1.00 to 1.28)	0.051	1.11(0.98 to 1.25)	0.10

Abbreviations: mRS, modified Rankin scale; IQR, interquartile range; NIHSS, National Institutes of Health Stroke Scale; an EQ-5D-VAS, EuroQol-5 VAS score.

- ^a The widths of the confidence intervals for the secondary outcomes were not adjusted for multiple comparisons, and the reported confidence intervals should not be used for hypothesis testing.
- ^b The modified Rankin Scale of functional disability ranges from 0 (no symptoms) to 6 (death). Data were missing for four patients in the methylprednisolone group and 3 patients in the placebo group. The win proportion was calculated by the number of wins in the Methylprednisolone group over the Placebo group in mRS among all possible pairs of mRS taking one patient from the Methylprednisolone group and one patient from the Placebo group divided by the total number of pairs.
- ^c The GenOR indicated the probability of modified Rankin Scale score was lower than the other group. Generalized Odds Ratio, common odds ratio, risk ratio, and risk difference were adjusted for age, baseline NIHSS score, pre-stroke mRS, baseline ASPECTS score, use of intravenous thrombolysis, time from onset to randomization, and occlusion location using the inverse probability treatment weighting method and were not adjusted for multiple comparisons.
- ^d Scores on the NIHSS range from 0 to 42, with higher values reflecting more severe neurologic impairment.
- ^c The EuroQoL Group 5-Dimension Self-Report Questionnaire (EQ-5D) visual-analogue scale is a continuous scale measure of self-reported quality of life. Scores range from 0 to 100, with 0 indicating the worst possible quality of life and 100 the best possible quality of life. Data were missing for four patients in the methylprednisolone group and 3 patients in the placebo group.

eTable 3. Primary and Secondary Efficacy Outcomes (Per-Protocol Population) ^a

Outcome	Methylprednisol one (N=761)	Placebo (N=779)	Treatment Effect	Unadjusted Value (95% CI)	P	Adjusted Value (95% CI)	p
Primary efficacy outcomes							
mRS score at 90 days, Win probability (%) b	44.29	39.34	GenOR °	1.13 (0.98 to 1.29)	0.09	1.11 (0.96 to 1.27)	0.15
			cOR	1.17 (0.98 to 1.39)	0.09	1.07 (1 to 1.14)	0.04
Secondary efficacy outcomes							
mRS score of 0 to 4 at 90 days, No. (%)	565 (74.2)	530 (68.0)	Risk ratio	1.09 (0.02 to 1.16)	0.007	1.08 (1.01 to 1.15)	0.02
			Risk difference	0.06 (0.02 to 0.11)	0.007	1.31 (1.12 to 1.53)	0.001
			Odds ratio	1.35 (1.09 to 1.69)	0.007	0.06 (0.02 to 0.09)	0.001
mRS score of 0 to 3 at 90 days, No. (%)	469 (61.6)	441 (56.6)	Risk ratio	1.09 (1.00 to 1.18)	0.045	1.08 (0.99 to 1.17)	0.09
			Risk difference	0.05 (0 to 0.10)	0.045	0.04 (0.01 to 0.08)	0.02
			Odds ratio	1.23 (1 to 1.51)	0.045	1.2 (1.04 to 1.38)	0.02
mRS score of 0 to 2 at 90 days, No./total (%)	347 (45.6)	335 (43.0)	Risk ratio	1.06 (0.95 to 1.19)	0.31	1.05 (0.94 to 1.18)	0.39
			Risk difference	0.03 (-0.02 to 0.08)	0.31	0.02 (-0.01 to 0.06)	0.22
			Odds ratio	1.11 (0.91 to 1.36)	0.31	1.09 (0.95 to 1.26)	0.22
mRS score of 0 to 1 at 90 days, No. (%)	207 (27.2)	215 (27.6)	Risk ratio	0.99 (0.84 to 1.16)	0.86	0.97 (0.83 to 1.15)	0.74
			Risk difference	0 (-0.05 to 0.04)	0.86	-0.01 (-0.04 to 0.02)	0.64
			Odds ratio	0.98 (0.78 to 1.23)	0.86	0.96 (0.82 to 1.13)	0.64
NIHSS score at 5-7 days or earlier if discharge, median (IQR) ^d	10.0 (3.0, 21.5)	11.0 (4.0, 26.0)	Win Ratio	1.10 (0.97 to 1.24)	0.13	1.09 (0.97 to 1.23)	0.14
EQ-5D-VAS score at 90 days, median (IQR) °	55.0 (5.0, 85.0)	50.0 (0.0, 80.0)	Win Ratio	1.13 (1.00 to 1.28)	0.056	1.11 (0.98 to 1.26)	0.11

 $Abbreviations: mRS, modified Rankin scale; IQR, interquartile \, range; NIHSS, National \, Institutes \, of \, Health \, Stroke \, Scale; an \, EQ-5D-VAS, EuroQol-5 \, VAS \, score.$

^aThe widths of the confidence intervals for the secondary outcomes were not adjusted for multiple comparisons, and the reported confidence intervals should not be used for hypothesis testing.

^b The modified Rankin Scale of functional disability ranges from 0 (no symptoms) to 6 (death). Win proportion was calculated by the number of wins in Methylprednisolone group overPlacebo group in mRS among all possible pairs of mRS taking one patient from the Methylprednisolone group and one patient from the Placebo group divided by the total number of pairs.

^c The GenOR indicated the probability of modified Rankin Scale score was lower than the other group. Generalized Odds Ratio, common odds ratio, risk ratio, and risk difference were adjusted for age, baseline NIHSS score, pre-stroke mRS, baseline ASPECTS score, use of intravenous thrombolysis, time from onset to randomization, and occlusion location using the inverse probability treatment weighting method and were not adjusted for multiple comparisons.

^d Scores on the NIHSS range from 0 to 42, with higher values reflecting more severe neurologic impairment.

^c The EuroQoL Group 5-Dimension Self-Report Questionnaire (EQ-5D) visual-analogue scale is a continuous scale measure of self-reported quality of life. Scores range from 0 to 100, with 0 indicating the worst possible quality of life and 100 the best possible quality of life.

eTable 4. Primary Efficacy Outcomes—Sensitivity Analysis

D	Treatment Effect	Adjusted Effect Size
Primary efficacy outcome		(95% CI)
Full Analysis Set		_
mRS score at 90 days ^a		
Worst-case scenario ^b	GenOR	1.10 (0.96 - 1.25)
Best-case scenario ^c	GenOR	1.10 (0.96 - 1.25)
Multiple imputation ^d	GenOR	1.09 (0.96 - 1.25)
Mixed-effect model ^e	Common OR	1.15 (0.97 to 1.37)
Worst-best scenario (post-hoc)f	GenOR	1.08 (0.95 - 1.23)

Abbreviations: mRS, modified Rankin scale;

^a The modified Rankin Scale of functional disability ranges from 0 (no symptoms) to 6 (death). Generalized odds ratios were adjusted for age, baseline NIHSS score, pre-stroke mRS, baseline ASPECTS, use of intravenous thrombolysis, time from onset to randomization, and occlusion location using the inverse probability treatment weighting method, and common odds ratio was adjusted for age, baseline NIHSS score, pre-stroke mRS, baseline ASPECTS, use of intravenous thrombolysis, time from onset to randomization, and occlusion location.

^b Worst-case scenario imputed all patients with a missing primary endpoint and considered as the worst status (mRS = 6) in both treatment groups.

^c Best-case scenario imputed all patients with a missing primary endpoint and considered as a success mRS 0 in both treatment groups.

^d Missing mRS score were imputed using multiple imputation methods via SAS PROC MI. Imputation procedure will be performed under the missing-at-random (MAR) assumption. Fully conditional method (FCS) was used to predict missing mRS score by fitting an ordered logistic regression model with following predictors: treatment group, age, baseline NIHSS score, pre-stroke mRS, baseline ASPECTS score, use of intravenous thrombolysis, time from onset to randomization, and occlusion location, and last observed NIHSS if available. The seed was 128. A total of 10 imputed datasets were generated. GenOR was estimated for each dataset separately, and the pooled together to calculate the final pooled genOR and 95% confidence interval using the Robin's role.

^e A proportional odds model with random effect will be fitted to estimate the common odds ratio between the methylprednisolone sodium succinate and placebo treatment with treatment as fixed effect, age, baseline NIHSS score, pre-stroke mRS, baseline ASPECTS score, use of intravenous thrombolysis, time from onset to randomization, and occlusion location as covariates, and the centre as a random effect

f Post-hoc worst-best scenario analysis: Patients with a missing primary endpoint in the placebo group was considered as a mRS of 0 while patients with a missing primary outcome in the methylprednisolone group was considered a mRS of 6.

eTable 5. Summary of Adverse Events (Safety Population).

	Methylprednisolone	Placebo	D. V. 1 . 0
Adverse Event	(N=839)	(N=841)	P-Value ^a
New Hyperglycemia	320 (38.1)	288 (34.2)	0.10
Hypernatremia	94 (11.2%)	116 (13.8)	0.11
New Diabetes	40 (4.8)	24 (2.9)	0.04
Hyperosmolar Hyperglycemic Syndrome	2 (0.2)	4 (0.5)	0.41
Insulin Use in Hospital Stay	165 (19.7)	110 (13.1)	0.0003
Craniectomy	40 (4.8)	45 (5.4)	0.59
Respiration Failure	200 (23.8)	226 (26.9)	0.15
Circulation Failure	114 (13.6)	158 (18.8)	0.004
Urinary tract infection	53 (6.32)	56 (6.66)	0.78
Other Infection	20 (2.38)	16 (1.90)	0.50
Deep Vein Thrombosis	42 (5.0)	44 (5.2)	0.83
Puncture site complication			0.39
Puncture site hematoma	4 (0.5)	9 (1.1)	
Pseudoaneurysm	9 (1.1)	10 (1.2)	
Embolism in other locations	0 (0)	1 (0.1)	

^a post-hoc Chi-square/Fisher exact tests.

eTable 6 Summary of main outcome by participating centers.

	C	enter Order	
	1		
	Group		
	Methylprednisolone	Placebo	Total
	(N=4)	(N=4)	(N=8)
modified Rankin Scale score at 90 days,n (%)			
0	1 (25.0%)	0 (0.0%)	1 (12.5%
1	1 (25.0%)	0 (0.0%)	1 (12.5%
2	0 (0.0%)	0 (0.0%)	0 (0.0%
3	0 (0.0%)	1 (25.0%)	1 (12.5%
4	0 (0.0%)	2 (50.0%)	2 (25.0%
5	2 (50.0%)	0 (0.0%)	2 (25.0%
6	0 (0.0%)	1 (25.0%)	1 (12.5%
Missing	0	0	0
Symptomatic intracranial hemorrhage, n (%)			
No	3 (75.0%)	4 (100.0%)	7 (87.5%
Yes	1 (25.0%)	0 (0.0%)	1 (12.5%
Missing	0	0	0
Pneumonia,n (%)	0 (0 00()	0 (50 00()	0 (05 00)
No	0 (0.0%)	2 (50.0%)	2 (25.0%
Yes	4 (100.0%)	2 (50.0%)	6 (75.0%
Jrinary tract infection,n (%)			
No	4 (100.0%)	4 (100.0%)	8 (100.0%
Yes	0 (0.0%)	0 (0.0%)	0 (0.0%
Other Infection,n (%)	4 (100 09/)	A (100 00/)	g (100 00
No Yes	4 (100.0%) 0 (0.0%)	4 (100.0%)	8 (100.0% 0 (0.0%
res	0 (0.0%)	0 (0.0%)	0 (0.0%)
Gastrointestinal bleeding within 7 days after EVT,n			
%)			
No	2 (50.0%)	4 (100.0%)	6 (75.0%
Yes	2 (50.0%)	0 (0.0%)	2 (25.0%
Puncture site hematomancture site complication,n			

Embolism in other locations	0 (0.0%)	0 (0.0%)	0 (0.0%)
No	4 (100.0%)	4 (100.0%)	8 (100.0%)
Pseudoaneurysm	0 (0.0%)	0 (0.0%)	0 (0.0%)
Puncture site hematoma	0 (0.0%)	0 (0.0%)	0 (0.0%)
Insulin Use in Hospital Stay,n (%)			
No	3 (75.0%)	4 (100.0%)	7 (87.5%)
Yes	1 (25.0%)	0 (0.0%)	1 (12.5%)
Craniectomy,n (%)			
No	4 (100.0%)	3 (75.0%)	7 (87.5%)
Yes	0 (0.0%)	1 (25.0%)	1 (12.5%)
Respiration Failure,n (%)			
No	1 (25.0%)	1 (25.0%)	2 (25.0%)
Yes	3 (75.0%)	3 (75.0%)	6 (75.0%)
Circulation Failure, n (%)			
No	4 (100.0%)	3 (75.0%)	7 (87.5%)
Yes	0 (0.0%)	1 (25.0%)	1 (12.5%)
1Chi Square n value:			

	Ce	enter Order		
		2		
	Group	Group		
	Methylprednisolone	Placebo	Total	
	(N=12)	(N=12)	(N=24)	
modified Rankin Scale score at 90 days,n (%)				
0	0 (0.0%)	0 (0.0%)	0 (0.0%)	
1	3 (25.0%)	1 (8.3%)	4 (16.7%)	
2	1 (8.3%)	4 (33.3%)	5 (20.8%)	
3	1 (8.3%)	1 (8.3%)	2 (8.3%)	
4	2 (16.7%)	3 (25.0%)	5 (20.8%)	
5	1 (8.3%)	0 (0.0%)	1 (4.2%)	
6	4 (33.3%)	3 (25.0%)	7 (29.2%)	
Missing	0	0	0	
Symptomatic intracranial hemorrhage, n (%)				
No	10 (90.9%)	11 (91.7%)	21 (91.3%	
Yes	1 (9.1%)	1 (8.3%)	2 (8.7%)	
Missing	1	0	1	

Pneumonia,n (%)	7 (50 00/)	F (44 70/)	40 (50 00
No	7 (58.3%)	5 (41.7%)	12 (50.0%
Yes	5 (41.7%)	7 (58.3%)	12 (50.0%
Jrinary tract infection,n (%)			
No	11 (91.7%)	12 (100.0%)	23 (95.8%
Yes	1 (8.3%)	0 (0.0%)	1 (4.2%)
Other Infection,n (%)			
No	12 (100.0%)	12 (100.0%)	24 (100.09
Yes	0 (0.0%)	0 (0.0%)	0 (0.0%)
Sastrointestinal bleeding within 7 days after EVT,n			
%)			
No	12 (100.0%)	12 (100.0%)	24 (100.0
Yes	0 (0.0%)	0 (0.0%)	0 (0.0%)
Puncture site hematomancture site complication,n			
%) Embolism in other locations	0 (0.0%)	0 (0.0%)	0 (0.0%
No.	12 (100.0%)	12 (100.0%)	24 (100.0)
Pseudoaneurysm	0 (0.0%)	0 (0.0%)	0 (0.0%)
Puncture site hematoma	0 (0.0%)	0 (0.0%)	0 (0.0%)
	5 (5.5.1)	2 (2.2)	(0.01)
nsulin Use in Hospital Stay,n (%)			
No	7 (58.3%)	12 (100.0%)	19 (79.2%
Yes	5 (41.7%)	0 (0.0%)	5 (20.8%
Craniectomy,n (%)			
No	10 (83.3%)	12 (100.0%)	22 (91.7%
Yes	2 (16.7%)	0 (0.0%)	2 (8.3%)
	2 (10.770)	0 (0.070)	2 (0.070)
Respiration Failure,n (%)			
No	8 (66.7%)	11 (91.7%)	19 (79.2%
Yes	4 (33.3%)	1 (8.3%)	5 (20.8%
Circulation Failure, n (%)			
No	10 (83.3%)	12 (100.0%)	22 (91.7%
Yes	2 (16.7%)	0 (0.0%)	2 (8.3%)
	= (: • : : / • /	= (3.070)	= (0.070)

Center Order

	Group			
	Methylprednisolone	Placebo	Total	
	(N=8)	(N=8)	(N=16)	
modified Rankin Scale score at 90 days,n (%)				
0	1 (12.5%)	1 (12.5%)	2 (12.5%	
1	0 (0.0%)	2 (25.0%)	2 (12.5%	
2	0 (0.0%)	0 (0.0%)	0 (0.0%	
3	2 (25.0%)	1 (12.5%)	3 (18.8%	
4	3 (37.5%)	0 (0.0%)	3 (18.8%	
5	0 (0.0%)	0 (0.0%)	0 (0.0%	
6	2 (25.0%)	4 (50.0%)	6 (37.5%	
Missing	0	0	0	
Symptomatic intracranial hemorrhage, n (%)				
No	8 (100.0%)	6 (75.0%)	14 (87.59	
Yes	0 (0.0%)	2 (25.0%)	2 (12.5%	
Missing	0	0	0	
Pneumonia,n (%)				
No	3 (37.5%)	5 (62.5%)	8 (50.0%	
Yes	5 (62.5%)	3 (37.5%)	8 (50.0%	
163	3 (02.370)	3 (37.370)	0 (30.07)	
Urinary tract infection,n (%)				
No	7 (87.5%)	8 (100.0%)	15 (93.8%	
Yes	1 (12.5%)	0 (0.0%)	1 (6.3%)	
Other Infection,n (%)				
No	8 (100.0%)	8 (100.0%)	16 (100.0	
Yes	0 (0.0%)	0 (0.0%)	0 (0.0%	
Gastrointestinal bleeding within 7 days after EVT,n				
No	7 (87.5%)	7 (87.5%)	14 (87.5%	
Yes	1 (12.5%)	1 (12.5%)	2 (12.5%	
Puncture site hematomancture site complication,n				
%)				
Embolism in other locations	0 (0.0%)	0 (0.0%)	0 (0.0%	
No	8 (100.0%)	8 (100.0%)	16 (100.0	
Pseudoaneurysm	0 (0.0%)	0 (0.0%)	0 (0.0%	
Puncture site hematoma	0 (0.0%)	0 (0.0%)	0 (0.0%	
nsulin Use in Hospital Stay,n (%)				

No	8 (100.0%)	8 (100.0%)	16 (100.0%)
Yes	0 (0.0%)	0 (0.0%)	0 (0.0%)
Craniectomy,n (%)			
No	8 (100.0%)	6 (75.0%)	14 (87.5%)
Yes	0 (0.0%)	2 (25.0%)	2 (12.5%)
Respiration Failure,n (%)			
No	8 (100.0%)	7 (87.5%)	15 (93.8%)
Yes	0 (0.0%)	1 (12.5%)	1 (6.3%)
Circulation Failure, n (%)			
No	8 (100.0%)	7 (87.5%)	15 (93.8%)
Yes	0 (0.0%)	1 (12.5%)	1 (6.3%)

¹Chi-Square p-value;

	Ce	enter Order	
	4		
	Group		
	Methylprednisolone	Placebo	Total
	(N=4)	(N=4)	(N=8)
nodified Rankin Scale score at 90 days,n (%)			
0	0 (0.0%)	0 (0.0%)	0 (0.0%)
1	2 (50.0%)	1 (25.0%)	3 (37.5%
2	1 (25.0%)	0 (0.0%)	1 (12.5%
3	1 (25.0%)	1 (25.0%)	2 (25.0%
4	0 (0.0%)	0 (0.0%)	0 (0.0%
5	0 (0.0%)	1 (25.0%)	1 (12.5%
6	0 (0.0%)	1 (25.0%)	1 (12.5%
Missing	0	0	0
Symptomatic intracranial hemorrhage, n (%)			
No	4 (100.0%)	3 (75.0%)	7 (87.5%
Yes	0 (0.0%)	1 (25.0%)	1 (12.5%
Missing	0	0	0
Pneumonia,n (%)			
No	4 (100.0%)	2 (50.0%)	6 (75.0%
Yes	0 (0.0%)	2 (50.0%)	2 (25.0%
Jrinary tract infection,n (%)			
No	4 (100.0%)	4 (100.0%)	8 (100.09

Yes	0 (0.0%)	0 (0.0%)	0 (0.0%)
Other Infection,n (%)			
No	4 (100.0%)	4 (100.0%)	8 (100.0%
Yes	0 (0.0%)	0 (0.0%)	0 (0.0%)
Gastrointestinal bleeding within 7 days after EVT,n			
%)			
No	4 (100.0%)	4 (100.0%)	8 (100.0%
Yes	0 (0.0%)	0 (0.0%)	0 (0.0%)
Puncture site hematomancture site complication,n			
%) Embolism in other locations	0 (0.0%)	0 (0.0%)	0 (0.0%)
No.	4 (100.0%)	4 (100.0%)	8 (100.0%)
Pseudoaneurysm	0 (0.0%)	0 (0.0%)	0 (0.0%)
Puncture site hematoma	0 (0.0%)	0 (0.0%)	0 (0.0%)
Turicture site fichilatoria	0 (0.070)	0 (0.070)	0 (0.070)
nsulin Use in Hospital Stay,n (%)			
No	4 (100.0%)	4 (100.0%)	8 (100.0%
Yes	0 (0.0%)	0 (0.0%)	0 (0.0%)
Craniectomy,n (%)			
No	4 (100.0%)	4 (100.0%)	8 (100.0%
Yes	0 (0.0%)	0 (0.0%)	0 (0.0%)
Respiration Failure,n (%)			
No	4 (100.0%)	4 (100.0%)	8 (100.0%
Yes	0 (0.0%)	0 (0.0%)	0 (0.0%)
	- (/	- (/	,
Circulation Failure, n (%)			
No	4 (100.0%)	3 (75.0%)	7 (87.5%
Yes	0 (0.0%)	1 (25.0%)	1 (12.5%
Chi-Square p-value;			
	C	enter Order	
	5 Group		
	•	Placebo	Total
	Methylprednisolone		
	Methylprednisolone		
	Methylprednisolone (N=7)	(N=5)	(N=12)
modified Rankin Scale score at 90 days,n (%)			

1	0 (0.0%)	2 (40.0%)	2 (16.7%)
2	2 (28.6%)	1 (20.0%)	3 (25.0%)
3	0 (0.0%)	1 (20.0%)	1 (8.3%)
4	1 (14.3%)	0 (0.0%)	1 (8.3%)
5	1 (14.3%)	0 (0.0%)	1 (8.3%)
6	2 (28.6%)	1 (20.0%)	3 (25.0%)
Missing	0	0	0
Symptomatic intracranial hemorrhage, n (%)			
No	6 (85.7%)	4 (80.0%)	10 (83.3%
Yes	1 (14.3%)	1 (20.0%)	2 (16.7%)
Missing	0	0	0
Pneumonia,n (%)			
No	3 (42.9%)	2 (40.0%)	5 (41.7%
Yes	4 (57.1%)	3 (60.0%)	7 (58.3%
Jrinary tract infection,n (%)	= (100 00()	= (400 00()	10 (100 00
No	7 (100.0%)	5 (100.0%)	12 (100.09
Yes	0 (0.0%)	0 (0.0%)	0 (0.0%)
Other Infection o (0/)			
Other Infection,n (%) No	7 (100.0%)	5 (100.0%)	12 (100.09
Yes	0 (0.0%)	0 (0.0%)	0 (0.0%)
103	0 (0.070)	0 (0.070)	0 (0.070)
Gastrointestinal bleeding within 7 days after EVT,n			
(%)			
No	7 (100.0%)	5 (100.0%)	12 (100.09
Yes	0 (0.0%)	0 (0.0%)	0 (0.0%)
Puncture site hematomancture site complication,n			
%)			
Embolism in other locations	0 (0.0%)	0 (0.0%)	0 (0.0%)
No	7 (100.0%)	4 (80.0%)	11 (91.7%
Pseudoaneurysm	0 (0.0%)	1 (20.0%)	1 (8.3%)
Puncture site hematoma	0 (0.0%)	0 (0.0%)	0 (0.0%)
nsulin Use in Hospital Stay,n (%)			
No	7 (100.0%)	5 (100.0%)	12 (100.09
Yes	0 (0.0%)	0 (0.0%)	0 (0.0%)
Craniectomy,n (%)			
No	6 (85.7%)	5 (100.0%)	11 (91.7%
Yes	1 (14.3%)	0 (0.0%)	1 (8.3%)

Respiration Failure,n (%)			
No	5 (71.4%)	4 (80.0%)	9 (75.0%)
Yes	2 (28.6%)	1 (20.0%)	3 (25.0%)
Circulation Failure, n (%)			
No	7 (100.0%)	4 (80.0%)	11 (91.7%)
Yes	0 (0.0%)	1 (20.0%)	1 (8.3%)

¹Chi-Square p-value;

	Center Order		
	6		
	Group		
	Methylprednisolone	Placebo	Total
	(N=4)	(N=4)	(N=8)
modified Rankin Scale score at 90 days,n (%)			
0	0 (0.0%)	0 (0.0%)	0 (0.0%
1	0 (0.0%)	1 (25.0%)	1 (12.5%
2	1 (25.0%)	1 (25.0%)	2 (25.0%
3	0 (0.0%)	0 (0.0%)	0 (0.0%
4	0 (0.0%)	0 (0.0%)	0 (0.0%
5	0 (0.0%)	0 (0.0%)	0 (0.0%
6	3 (75.0%)	2 (50.0%)	5 (62.5%
Missing	0	0	0
Symptomatic intracranial hemorrhage, n (%)			
No	3 (100.0%)	4 (100.0%)	7 (100.09
Yes	0 (0.0%)	0 (0.0%)	0 (0.0%
Missing	1	0	1
Pneumonia,n (%)			
No	1 (25.0%)	2 (50.0%)	3 (37.5%
Yes	3 (75.0%)	2 (50.0%)	5 (62.5%
Jrinary tract infection,n (%)			
No	4 (100.0%)	4 (100.0%)	8 (100.09
Yes	0 (0.0%)	0 (0.0%)	0 (0.0%
Other Infection,n (%)			
No	4 (100.0%)	4 (100.0%)	8 (100.09
Yes	0 (0.0%)	0 (0.0%)	0 (0.0%

%)			
No	4 (100.0%)	3 (75.0%)	7 (87.5%
Yes	0 (0.0%)	1 (25.0%)	1 (12.5%
Puncture site hematomancture site complication,n			
%)			
Embolism in other locations	0 (0.0%)	0 (0.0%)	0 (0.0%)
No	4 (100.0%)	4 (100.0%)	8 (100.0%
Pseudoaneurysm	0 (0.0%)	0 (0.0%)	0 (0.0%)
Puncture site hematoma	0 (0.0%)	0 (0.0%)	0 (0.0%
nsulin Use in Hospital Stay,n (%)			
No	2 (50.0%)	3 (75.0%)	5 (62.5%
Yes	2 (50.0%)	1 (25.0%)	3 (37.5%
Craniectomy,n (%)			
No	4 (100.0%)	4 (100.0%)	8 (100.0%
Yes	0 (0.0%)	0 (0.0%)	0 (0.0%
Respiration Failure,n (%)			
No	2 (50.0%)	3 (75.0%)	5 (62.5%
Yes	2 (50.0%)	1 (25.0%)	3 (37.5%
Circulation Failure, n (%)			
No	2 (50.0%)	3 (75.0%)	5 (62.5%
Yes	2 (50.0%)	1 (25.0%)	3 (37.5%

	Center Order		
		8	
	Group		
	Methylprednisolone	Placebo	Total
	(N=16)	(N=16)	(N=32)
modified Rankin Scale score at 90 days,n (%)			
0	0 (0.0%)	2 (12.5%)	2 (6.3%)
1	2 (12.5%)	1 (6.3%)	3 (9.4%)
2	4 (25.0%)	4 (25.0%)	8 (25.0%)
3	1 (6.3%)	5 (31.3%)	6 (18.8%)
4	1 (6.3%)	1 (6.3%)	2 (6.3%)
5	3 (18.8%)	0 (0.0%)	3 (9.4%)
6	5 (31.3%)	3 (18.8%)	8 (25.0%)

Missing	0	0	0
Symptomatic intracranial hemorrhage, n (%)			
No	15 (93.8%)	14 (87.5%)	29 (90.6%)
Yes	1 (6.3%)	2 (12.5%)	3 (9.4%)
Missing	0	0	0
Pneumonia,n (%)			
No	5 (31.3%)	3 (18.8%)	8 (25.0%)
Yes	11 (68.8%)	13 (81.3%)	24 (75.0%)
Urinary tract infection,n (%)			
No	14 (87.5%)	15 (93.8%)	29 (90.6%)
Yes	2 (12.5%)	1 (6.3%)	3 (9.4%)
Other Infection,n (%)			
No	16 (100.0%)	16 (100.0%)	32 (100.0%)
Yes	0 (0.0%)	0 (0.0%)	0 (0.0%)
Gastrointestinal bleeding within 7 days after EVT,n			
(%)			
No	14 (87.5%)	15 (93.8%)	29 (90.6%)
Yes	2 (12.5%)	1 (6.3%)	3 (9.4%)
Puncture site hematomancture site complication,n (%)			
Embolism in other locations	0 (0.0%)	0 (0.0%)	0 (0.0%)
No	16 (100.0%)	15 (93.8%)	31 (96.9%)
Pseudoaneurysm	0 (0.0%)	0 (0.0%)	0 (0.0%)
Puncture site hematoma	0 (0.0%)	1 (6.3%)	1 (3.1%)
Insulin Use in Hospital Stay,n (%)			
No	11 (68.8%)	14 (87.5%)	25 (78.1%)
Yes	5 (31.3%)	2 (12.5%)	7 (21.9%)
Craniectomy,n (%)			
No	16 (100.0%)	16 (100.0%)	32 (100.0%
Yes	0 (0.0%)	0 (0.0%)	0 (0.0%)
Respiration Failure,n (%)			
No	10 (62.5%)	15 (93.8%)	25 (78.1%)
Yes	6 (37.5%)	1 (6.3%)	7 (21.9%)
Circulation Failure, n (%)			
On Culation Familie, II (70)			

No	14 (87.5%)	15 (93.8%)	29 (90.6%)
Yes	2 (12.5%)	1 (6.3%)	3 (9.4%)

¹Chi-Square p-value;

	Ce	enter Order	
		9	
	Group		
	Methylprednisolone	Placebo	Total
	(N=8)	(N=8)	(N=16)
modified Rankin Scale score at 90 days,n (%)			
0	0 (0.0%)	0 (0.0%)	0 (0.0%)
1	3 (37.5%)	0 (0.0%)	3 (18.8%
2	1 (12.5%)	1 (12.5%)	2 (12.5%
3	2 (25.0%)	0 (0.0%)	2 (12.5%
4	2 (25.0%)	1 (12.5%)	3 (18.8%
5	0 (0.0%)	0 (0.0%)	0 (0.0%
6	0 (0.0%)	6 (75.0%)	6 (37.5%
Missing	0	0	0
Symptomatic intracranial hemorrhage, n (%)			
No	8 (100.0%)	6 (75.0%)	14 (87.5%
Yes	0 (0.0%)	2 (25.0%)	2 (12.5%
Missing	0	0	0
Pneumonia,n (%)			
No	3 (37.5%)	0 (0.0%)	3 (18.8%
Yes	5 (62.5%)	8 (100.0%)	13 (81.39
Urinary tract infection,n (%)			
No	8 (100.0%)	8 (100.0%)	16 (100.0
Yes	0 (0.0%)	0 (0.0%)	0 (0.0%
Other Infection,n (%)			
No	8 (100.0%)	8 (100.0%)	16 (100.0
Yes	0 (0.0%)	0 (0.0%)	0 (0.0%
Gastrointestinal bleeding within 7 days after EVT,n			
(%)			
No	8 (100.0%)	8 (100.0%)	16 (100.0
Yes	0 (0.0%)	0 (0.0%)	0 (0.0%

6)			
Embolism in other locations	0 (0.0%)	0 (0.0%)	0 (0.0%
No	8 (100.0%)	8 (100.0%)	16 (100.0
Pseudoaneurysm	0 (0.0%)	0 (0.0%)	0 (0.0%
Puncture site hematoma	0 (0.0%)	0 (0.0%)	0 (0.0%
nsulin Use in Hospital Stay,n (%)			
No	6 (75.0%)	7 (87.5%)	13 (81.39
Yes	2 (25.0%)	1 (12.5%)	3 (18.8%
Franiectomy,n (%)			
No	8 (100.0%)	8 (100.0%)	16 (100.0
Yes	0 (0.0%)	0 (0.0%)	0 (0.0%
Respiration Failure,n (%)			
No	5 (62.5%)	1 (12.5%)	6 (37.5%
Yes	3 (37.5%)	7 (87.5%)	10 (62.5%
Firculation Failure, n (%)			
No	8 (100.0%)	6 (75.0%)	14 (87.5%
Yes	0 (0.0%)	2 (25.0%)	2 (12.5%

	Co	Center Order		
	10			
	Group	Group		
	Methylprednisolone	Placebo	Total	
	(N=18)	(N=16)	(N=34)	
modified Rankin Scale score at 90 days,n (%)				
0	2 (11.1%)	2 (12.5%)	4 (11.8%)	
1	3 (16.7%)	6 (37.5%)	9 (26.5%)	
2	3 (16.7%)	5 (31.3%)	8 (23.5%)	
3	3 (16.7%)	0 (0.0%)	3 (8.8%)	
4	3 (16.7%)	2 (12.5%)	5 (14.7%)	
5	0 (0.0%)	0 (0.0%)	0 (0.0%)	
6	4 (22.2%)	1 (6.3%)	5 (14.7%)	
Missing	0	0	0	
Symptomatic intracranial hemorrhage, n (%)				
No	17 (94.4%)	16 (100.0%)	33 (97.1%)	

1 (5.6%)

0 (0.0%)

1 (2.9%)

Yes

Missing	0	0	0
	ÿ	•	
Pneumonia,n (%)			
No	11 (61.1%)	12 (75.0%)	23 (67.6%
Yes	7 (38.9%)	4 (25.0%)	11 (32.4%
Urinary tract infection,n (%)			
No	17 (94.4%)	14 (87.5%)	31 (91.2%
Yes	1 (5.6%)	2 (12.5%)	3 (8.8%)
Other Infection,n (%)			
No	17 (94.4%)	16 (100.0%)	33 (97.1%
Yes	1 (5.6%)	0 (0.0%)	1 (2.9%)
Gastrointestinal bleeding within 7 days after EVT,n (%)			
No	17 (94.4%)	16 (100.0%)	33 (97.1%
Yes	1 (5.6%)	0 (0.0%)	1 (2.9%)
Puncture site hematomancture site complication,n			
(%)			
Embolism in other locations	0 (0.0%)	0 (0.0%)	0 (0.0%)
No	18 (100.0%)	16 (100.0%)	34 (100.09
Pseudoaneurysm	0 (0.0%)	0 (0.0%)	0 (0.0%)
Puncture site hematoma	0 (0.0%)	0 (0.0%)	0 (0.0%)
Insulin Use in Hospital Stay,n (%)			
No	13 (72.2%)	14 (87.5%)	27 (79.4%
Yes	5 (27.8%)	2 (12.5%)	7 (20.6%
Craniectomy,n (%)			
No	17 (94.4%)	16 (100.0%)	33 (97.1%
Yes	1 (5.6%)	0 (0.0%)	1 (2.9%)
Respiration Failure,n (%)			
No	16 (88.9%)	15 (93.8%)	31 (91.2%
Yes	2 (11.1%)	1 (6.3%)	3 (8.8%)
Circulation Failure, n (%)			
No	16 (88.9%)	13 (81.3%)	29 (85.3%
	. 5 (55.570)	13 (01.070)	_0 (00.07)

	Center Order		
	11 Group		
	Methylprednisolone	Placebo (N=17)	Total (N=36)
	(N=19)		
modified Rankin Scale score at 90 days,n (%)			
0	2 (10.5%)	3 (17.6%)	5 (13.9%)
1	5 (26.3%)	4 (23.5%)	9 (25.0%)
2	0 (0.0%)	2 (11.8%)	2 (5.6%)
3	6 (31.6%)	2 (11.8%)	8 (22.2%)
4	3 (15.8%)	2 (11.8%)	5 (13.9%)
5	0 (0.0%)	0 (0.0%)	0 (0.0%)
6	3 (15.8%)	4 (23.5%)	7 (19.4%)
Missing	0	0	0
Symptomatic intracranial hemorrhage, n (%)			
No	17 (89.5%)	14 (82.4%)	31 (86.1%)
Yes	2 (10.5%)	3 (17.6%)	5 (13.9%)
Missing	0	0	0
Pneumonia,n (%)			
No	10 (52.6%)	7 (41.2%)	17 (47.2%)
Yes	9 (47.4%)	10 (58.8%)	19 (52.8%)
100	3 (47.470)	10 (30.070)	13 (32.070)
Urinary tract infection,n (%)			
No	18 (94.7%)	17 (100.0%)	35 (97.2%)
Yes	1 (5.3%)	0 (0.0%)	1 (2.8%)
04 15 4 (04)			
Other Infection,n (%)	40 (400 00()	47 (400 00()	00 (400 00)
No	19 (100.0%)	17 (100.0%)	36 (100.0%
Yes	0 (0.0%)	0 (0.0%)	0 (0.0%)
Gastrointestinal bleeding within 7 days after EVT,n			
(%)			
No	19 (100.0%)	15 (88.2%)	34 (94.4%)
Yes	0 (0.0%)	2 (11.8%)	2 (5.6%)
Puncture site hematomancture site complication,n			
(%)	0 (0 00)	0.(0.00()	0 (0 00()
Embolism in other locations	0 (0.0%)	0 (0.0%)	0 (0.0%)
No	19 (100.0%)	17 (100.0%)	36 (100.0%
Pseudoaneurysm	0 (0.0%)	0 (0.0%)	0 (0.0%)
Puncture site hematoma	0 (0.0%)	0 (0.0%)	0 (0.0%)

Insulin Use in Hospital Stay,n (%)			
No	11 (57.9%)	13 (76.5%)	24 (66.7%)
Yes	8 (42.1%)	4 (23.5%)	12 (33.3%)
Craniectomy,n (%)			
No	17 (89.5%)	13 (76.5%)	30 (83.3%)
Yes	2 (10.5%)	4 (23.5%)	6 (16.7%)
Respiration Failure,n (%)			
No	13 (68.4%)	11 (64.7%)	24 (66.7%)
Yes	6 (31.6%)	6 (35.3%)	12 (33.3%)
Circulation Failure, n (%)			
No	16 (84.2%)	11 (64.7%)	27 (75.0%)
Yes	3 (15.8%)	6 (35.3%)	9 (25.0%)

¹Chi-Square p-value;

	Center Order		
	12		
	Group		
	Methylprednisolone	Placebo	Total
	(N=4)	(N=6)	(N=10)
nodified Rankin Scale score at 90 days,n (%)			
0	0 (0.0%)	0 (0.0%)	0 (0.0%
1	1 (25.0%)	1 (16.7%)	2 (20.0%
2	2 (50.0%)	0 (0.0%)	2 (20.0%
3	0 (0.0%)	0 (0.0%)	0 (0.0%
4	0 (0.0%)	0 (0.0%)	0 (0.0%
5	0 (0.0%)	0 (0.0%)	0 (0.0%
6	1 (25.0%)	5 (83.3%)	6 (60.0%
Missing	0	0	0
ymptomatic intracranial hemorrhage, n (%)			
No	4 (100.0%)	2 (40.0%)	6 (66.7%
Yes	0 (0.0%)	3 (60.0%)	3 (33.3%
Missing	0	1	1
neumonia,n (%)			
No	4 (100.0%)	2 (33.3%)	6 (60.0%
Yes	0 (0.0%)	4 (66.7%)	4 (40.0%

Jrinary tract infection,n (%) No			
	4 (100.0%)	6 (100.0%)	10 (100.0
Yes	0 (0.0%)	0 (0.0%)	0 (0.0%
res	0 (0.0%)	0 (0.0%)	0 (0.0%)
Other Infection,n (%)			
No	4 (100.0%)	6 (100.0%)	10 (100.0
Yes	0 (0.0%)	0 (0.0%)	0 (0.0%
Gastrointestinal bleeding within 7 days after EVT,n			
(%)			
No No	4 (100.0%)	5 (83.3%)	9 (90.0%
Yes	0 (0.0%)	1 (16.7%)	1 (10.0%
	0 (0.070)	1 (10.7 70)	1 (10.07)
Puncture site hematomancture site complication,n			
%)			
Embolism in other locations	0 (0.0%)	0 (0.0%)	0 (0.0%
No	4 (100.0%)	6 (100.0%)	10 (100.0
Pseudoaneurysm	0 (0.0%)	0 (0.0%)	0 (0.0%
Puncture site hematoma	0 (0.0%)	0 (0.0%)	0 (0.0%
nsulin Use in Hospital Stay,n (%)			
No	4 (100.0%)	4 (66.7%)	8 (80.0%
Yes	0 (0.0%)	2 (33.3%)	2 (20.0%
Craniectomy,n (%)			
No	4 (100.0%)	6 (100.0%)	10 (100.0
Yes	0 (0.0%)	0 (0.0%)	0 (0.0%
165	0 (0.0%)	0 (0.0%)	0 (0.076
Respiration Failure,n (%)			
respiration randre, ir (70)	2 (75 00/)		
No	3 (75.0%)	1 (16.7%)	4 (40.0%
	1 (25.0%)	1 (16.7%) 5 (83.3%)	4 (40.0% 6 (60.0%
No Yes		, ,	
No		, ,	

nodified Rankin Scale score at 90 days,n (%)			
0	0 (0.0%)	0 (0.0%)	0 (0.0%)
1	0 (0.0%)	0 (0.0%)	0 (0.0%)
2	2 (66.7%)	0 (0.0%)	2 (40.0%)
3	0 (0.0%)	1 (50.0%)	1 (20.0%)
4	0 (0.0%)	0 (0.0%)	0 (0.0%)
5	0 (0.0%)	0 (0.0%)	0 (0.0%)
6	1 (33.3%)	1 (50.0%)	2 (40.0%)
Missing	0	0	0
symptomatic intracranial hemorrhage, n (%)			
No	3 (100.0%)	2 (100.0%)	5 (100.0%)
Yes	0 (0.0%)	0 (0.0%)	0 (0.0%)
Missing	0	0	0
Pneumonia,n (%)			
No	2 (66.7%)	0 (0.0%)	2 (40.0%)
Yes	1 (33.3%)	2 (100.0%)	3 (60.0%)
Jrinary tract infection,n (%)			
No	3 (100.0%)	2 (100.0%)	5 (100.0%)
Yes	0 (0.0%)	0 (0.0%)	0 (0.0%)
Other Infection,n (%)			
No	3 (100.0%)	2 (100.0%)	5 (100.0%)
Yes	0 (0.0%)	0 (0.0%)	0 (0.0%)
100	0 (0.070)	0 (0.070)	0 (0.070)
Gastrointestinal bleeding within 7 days after EVT,n			
(%)			
No	3 (100.0%)	2 (100.0%)	5 (100.0%)
Yes	0 (0.0%)	0 (0.0%)	0 (0.0%)
Puncture site hematomancture site complication,n			
(%)			
Embolism in other locations	0 (0.0%)	0 (0.0%)	0 (0.0%)
No	3 (100.0%)	2 (100.0%)	5 (100.0%)
Pseudoaneurysm	0 (0.0%)	0 (0.0%)	0 (0.0%)
Puncture site hematoma	0 (0.0%)	0 (0.0%)	0 (0.0%)
Insulin Use in Hospital Stay,n (%)			
No	2 (66.7%)	1 (50.0%)	3 (60.0%)
Yes	1 (33.3%)	1 (50.0%)	2 (40.0%)

Craniectomy,n (%)			
No	3 (100.0%)	2 (100.0%)	5 (100.0%)
Yes	0 (0.0%)	0 (0.0%)	0 (0.0%)
Respiration Failure,n (%)			
No	3 (100.0%)	1 (50.0%)	4 (80.0%)
Yes	0 (0.0%)	1 (50.0%)	1 (20.0%)
Circulation Failure, n (%)			
No	3 (100.0%)	1 (50.0%)	4 (80.0%)
Yes	0 (0.0%)	1 (50.0%)	1 (20.0%)
101: 0			

¹Chi-Square p-value;

	Center Order 14 Group		
	Methylprednisolone	Placebo	Total
	(N=4)	(N=4)	(N=8)
modified Rankin Scale score at 90 days,n (%)			
0	0 (0.0%)	1 (25.0%)	1 (12.5%
1	1 (25.0%)	0 (0.0%)	1 (12.5%
2	1 (25.0%)	2 (50.0%)	3 (37.5%
3	1 (25.0%)	1 (25.0%)	2 (25.0%
4	0 (0.0%)	0 (0.0%)	0 (0.0%
5	0 (0.0%)	0 (0.0%)	0 (0.0%)
6	1 (25.0%)	0 (0.0%)	1 (12.5%
Missing	0	0	0
Symptomatic intracranial hemorrhage, n (%)			
No	4 (100.0%)	4 (100.0%)	8 (100.0%
Yes	0 (0.0%)	0 (0.0%)	0 (0.0%
Missing	0	0	0
Draumania v (0/)			
Pneumonia,n (%) No	1 (25.00/)	2 (75 00/)	4 (50 09/
	1 (25.0%)	3 (75.0%)	4 (50.0%
Yes	3 (75.0%)	1 (25.0%)	4 (50.0%
Jrinary tract infection,n (%)			
No	3 (75.0%)	3 (75.0%)	6 (75.0%
Yes	1 (25.0%)	1 (25.0%)	2 (25.0%

No	4 (100.0%)	4 (100.0%)	8 (100.0%)
Yes	0 (0.0%)	0 (0.0%)	0 (0.0%)
Gastrointestinal bleeding within 7 days after EVT,n			
(%)			
No	4 (100.0%)	4 (100.0%)	8 (100.0%)
Yes	0 (0.0%)	0 (0.0%)	0 (0.0%)
Puncture site hematomancture site complication,n			
(%)			
Embolism in other locations	0 (0.0%)	0 (0.0%)	0 (0.0%)
No	4 (100.0%)	4 (100.0%)	8 (100.0%)
Pseudoaneurysm	0 (0.0%)	0 (0.0%)	0 (0.0%)
Puncture site hematoma	0 (0.0%)	0 (0.0%)	0 (0.0%)
Insulin Use in Hospital Stay,n (%)			
No	3 (75.0%)	4 (100.0%)	7 (87.5%)
Yes	1 (25.0%)	0 (0.0%)	1 (12.5%)
Craniectomy,n (%)			
No	4 (100.0%)	4 (100.0%)	8 (100.0%)
Yes	0 (0.0%)	0 (0.0%)	0 (0.0%)
Respiration Failure,n (%)			
No	4 (100.0%)	4 (100.0%)	8 (100.0%)
Yes	0 (0.0%)	0 (0.0%)	0 (0.0%)
Circulation Failure, n (%)			
No	4 (100.0%)	4 (100.0%)	8 (100.0%)
Yes	0 (0.0%)	0 (0.0%)	0 (0.0%)
¹Chi-Square p-value;			
	Co	enter Order	
		15	
	Group		
	Methylprednisolone	Placebo	Total
	(N=16)	(N=16)	(N=32)
modified Rankin Scale score at 90 days,n (%)			
0	2 (12.5%)	3 (18.8%)	5 (15.6%)
1	1 (6.3%)	2 (12.5%)	3 (9.4%)
2	3 (18.8%)	1 (6.3%)	4 (12.5%)
	, ,	, ,	, ,

2 (12.5%)

3 (18.8%)

5 (15.6%)

3

4	3 (18.8%)	4 (25.0%)	7 (21.9%)
5	2 (12.5%)	1 (6.3%)	3 (9.4%)
6	3 (18.8%)	2 (12.5%)	5 (15.6%)
Missing	0	0	0
Symptomatic intracranial hemorrhage, n (%)			
No	15 (93.8%)	16 (100.0%)	31 (96.9%
Yes	1 (6.3%)	0 (0.0%)	1 (3.1%)
Missing	0	0	0
Pneumonia,n (%)			
No	9 (56.3%)	7 (43.8%)	16 (50.0%
Yes	7 (43.8%)	9 (56.3%)	16 (50.0%
Jrinary tract infection,n (%)			
No	16 (100.0%)	14 (87.5%)	30 (93.8%
Yes	0 (0.0%)	2 (12.5%)	2 (6.3%)
Other Infection,n (%)			
No	16 (100.0%)	15 (93.8%)	31 (96.9%
Yes	0 (0.0%)	1 (6.3%)	1 (3.1%)
Gastrointestinal bleeding within 7 days after EVT,n			
(%)			
No	16 (100.0%)	15 (93.8%)	31 (96.9%
Yes	0 (0.0%)	1 (6.3%)	1 (3.1%)
Puncture site hematomancture site complication,n			
%)			
Embolism in other locations	0 (0.0%)	0 (0.0%)	0 (0.0%)
No	16 (100.0%)	16 (100.0%)	32 (100.09
Pseudoaneurysm	0 (0.0%)	0 (0.0%)	0 (0.0%)
Puncture site hematoma	0 (0.0%)	0 (0.0%)	0 (0.0%)
noulin Hos in Hospital Stay = /0/			
nsulin Use in Hospital Stay,n (%)	12 (75 00/)	12 (04 20/)	25 /70 40
No Yes	12 (75.0%) 4 (25.0%)	13 (81.3%) 3 (18.8%)	25 (78.1% 7 (21.9%
103	4 (20.070)	J (10.070)	1 (21.9%
Craniectomy,n (%)			
No	16 (100.0%)	14 (87.5%)	30 (93.8%
Yes	0 (0.0%)	2 (12.5%)	2 (6.3%)
Respiration Failure,n (%)			
No	15 (93.8%)	11 (68.8%)	26 (81.3%

Yes	1 (6.3%)	5 (31.3%)	6 (18.8%)
Circulation Failure, n (%)			
No	15 (93.8%)	14 (87.5%)	29 (90.6%)
Yes	1 (6.3%)	2 (12.5%)	3 (9.4%)

¹Chi-Square p-value;

	Center Order		
		17	
	Group		
	Methylprednisolone	Placebo	Total
	(N=21)	(N=20)	(N=41)
modified Rankin Scale score at 90 days,n (%)			
0	1 (4.8%)	2 (10.0%)	3 (7.3%)
1	3 (14.3%)	4 (20.0%)	7 (17.1%
2	4 (19.0%)	5 (25.0%)	9 (22.0%
3	1 (4.8%)	2 (10.0%)	3 (7.3%)
4	3 (14.3%)	0 (0.0%)	3 (7.3%)
5	0 (0.0%)	2 (10.0%)	2 (4.9%)
6	9 (42.9%)	5 (25.0%)	14 (34.1%
Missing	0	0	0
Symptomatic intracranial hemorrhage, n (%)			
No	18 (90.0%)	19 (95.0%)	37 (92.5%
Yes	2 (10.0%)	1 (5.0%)	3 (7.5%)
Missing	1	0	1
Pneumonia,n (%)			
No	15 (71.4%)	10 (50.0%)	25 (61.0%
Yes	6 (28.6%)	10 (50.0%)	16 (39.0%
103	0 (20.070)	10 (50.070)	10 (33.07
Jrinary tract infection,n (%)			
No	19 (90.5%)	18 (90.0%)	37 (90.2%
Yes	2 (9.5%)	2 (10.0%)	4 (9.8%
Other Infection,n (%)			
No	21 (100.0%)	20 (100.0%)	41 (100.0
Yes	0 (0.0%)	0 (0.0%)	0 (0.0%
Gastrointestinal bleeding within 7 days after EVT,n			
%)			
No	21 (100.0%)	19 (95.0%)	40 (97.6%

Yes	0 (0.0%)	1 (5.0%)	1 (2.4%)
Puncture site hematomancture site complication,n			
(%)			
Embolism in other locations	0 (0.0%)	0 (0.0%)	0 (0.0%)
No	21 (100.0%)	20 (100.0%)	41 (100.0%)
Pseudoaneurysm	0 (0.0%)	0 (0.0%)	0 (0.0%)
Puncture site hematoma	0 (0.0%)	0 (0.0%)	0 (0.0%)
Insulin Use in Hospital Stay,n (%)			
No	17 (81.0%)	20 (100.0%)	37 (90.2%)
Yes	4 (19.0%)	0 (0.0%)	4 (9.8%)
Craniectomy,n (%)			
No	20 (95.2%)	20 (100.0%)	40 (97.6%)
Yes	1 (4.8%)	0 (0.0%)	1 (2.4%)
Respiration Failure,n (%)			
No	16 (76.2%)	17 (85.0%)	33 (80.5%)
Yes	5 (23.8%)	3 (15.0%)	8 (19.5%)
Circulation Failure, n (%)			
No	16 (76.2%)	15 (75.0%)	31 (75.6%)
Yes	5 (23.8%)	5 (25.0%)	10 (24.4%)
1Chi Squara n value:	- ()	(==:::)	(=/

¹Chi-Square p-value;

	Ce	enter Order	
		18	
	Group		
	Methylprednisolone	Placebo	Total
	(N=15)	(N=15)	(N=30)
modified Rankin Scale score at 90 days,n (%)			
0	2 (14.3%)	1 (6.7%)	3 (10.3%)
1	3 (21.4%)	4 (26.7%)	7 (24.1%)
2	6 (42.9%)	2 (13.3%)	8 (27.6%)
3	1 (7.1%)	4 (26.7%)	5 (17.2%)
4	1 (7.1%)	1 (6.7%)	2 (6.9%)
5	0 (0.0%)	1 (6.7%)	1 (3.4%)
6	1 (7.1%)	2 (13.3%)	3 (10.3%)
Missing	1	0	1

Symptomatic intracranial hemorrhage, n (%)

No	14 (93.3%)	14 (93.3%)	28 (93.3%)
Yes	1 (6.7%)	1 (6.7%)	2 (6.7%)
Missing	0	0	0
Pneumonia,n (%)			
No	10 (66.7%)	9 (60.0%)	19 (63.3%)
Yes	5 (33.3%)	6 (40.0%)	11 (36.7%)
Urinary tract infection,n (%)			
No	15 (100.0%)	14 (93.3%)	29 (96.7%)
Yes	0 (0.0%)	1 (6.7%)	1 (3.3%)
Other Infection,n (%)			
No	15 (100.0%)	15 (100.0%)	30 (100.0%
Yes	0 (0.0%)	0 (0.0%)	0 (0.0%)
Gastrointestinal bleeding within 7 days after EVT,n			
(%)			
No	15 (100.0%)	13 (86.7%)	28 (93.3%
Yes	0 (0.0%)	2 (13.3%)	2 (6.7%)
Puncture site hematomancture site complication,n			
(%)			
Embolism in other locations	0 (0.0%)	0 (0.0%)	0 (0.0%)
No	15 (100.0%)	14 (93.3%)	29 (96.7%)
Pseudoaneurysm	0 (0.0%)	0 (0.0%)	0 (0.0%)
Puncture site hematoma	0 (0.0%)	1 (6.7%)	1 (3.3%)
Insulin Use in Hospital Stay,n (%)			
No	14 (93.3%)	15 (100.0%)	29 (96.7%)
Yes	1 (6.7%)	0 (0.0%)	1 (3.3%)
Craniectomy,n (%)			
No	15 (100.0%)	14 (93.3%)	29 (96.7%
Yes	0 (0.0%)	1 (6.7%)	1 (3.3%)
Respiration Failure,n (%)			
No	15 (100.0%)	13 (86.7%)	28 (93.3%)
Yes	0 (0.0%)	2 (13.3%)	2 (6.7%)
Circulation Failure, n (%)			
No	15 (100.0%)	15 (100.0%)	30 (100.0%
Yes	0 (0.0%)	0 (0.0%)	0 (0.0%)

¹Chi-Square p-value;

	С	enter Order	
	20		
	Group		
	Methylprednisolone	Placebo	Total
	(N=22)	(N=22)	(N=44)
modified Rankin Scale score at 90 days,n (%)			
0	1 (4.5%)	3 (14.3%)	4 (9.3%)
1	5 (22.7%)	3 (14.3%)	8 (18.6%)
2	3 (13.6%)	3 (14.3%)	6 (14.0%)
3	3 (13.6%)	1 (4.8%)	4 (9.3%)
4	1 (4.5%)	0 (0.0%)	1 (2.3%)
5	0 (0.0%)	0 (0.0%)	0 (0.0%)
6	9 (40.9%)	11 (52.4%)	20 (46.5%)
Missing	0	1	1
Symptomatic intracranial hemorrhage, n (%)			
No	19 (86.4%)	20 (100.0%)	39 (92.9%)
Yes	3 (13.6%)	0 (0.0%)	3 (7.1%)
Missing	0	2	2
Pneumonia,n (%)			
No	11 (50.0%)	8 (36.4%)	19 (43.2%)
Yes	11 (50.0%)	14 (63.6%)	25 (56.8%)
Urinary tract infection,n (%)			
No	18 (81.8%)	20 (90.9%)	38 (86.4%)
Yes	4 (18.2%)	2 (9.1%)	6 (13.6%)
163	4 (10.270)	2 (3.170)	0 (13.070)
Other Infection,n (%)			
No	22 (100.0%)	22 (100.0%)	44 (100.0%)
Yes	0 (0.0%)	0 (0.0%)	0 (0.0%)
	,	,	,
Gastrointestinal bleeding within 7 days after EVT,n			
(%)			
No	21 (95.5%)	22 (100.0%)	43 (97.7%)
Yes	1 (4.5%)	0 (0.0%)	1 (2.3%)
Puncture site hematomancture site complication,n			
(%)			
Embolism in other locations	0 (0.0%)	0 (0.0%)	0 (0.0%)
No	21 (95.5%)	22 (100.0%)	43 (97.7%)

Pseudoaneurysm	0 (0.0%)	0 (0.0%)	0 (0.0%)
Puncture site hematoma	1 (4.5%)	0 (0.0%)	1 (2.3%)
Insulin Use in Hospital Stay,n (%)			
No	19 (86.4%)	18 (81.8%)	37 (84.1%)
Yes	3 (13.6%)	4 (18.2%)	7 (15.9%)
Craniectomy,n (%)			
No	20 (90.9%)	20 (90.9%)	40 (90.9%)
Yes	2 (9.1%)	2 (9.1%)	4 (9.1%)
Respiration Failure,n (%)			
No	16 (72.7%)	16 (72.7%)	32 (72.7%)
Yes	6 (27.3%)	6 (27.3%)	12 (27.3%)
Circulation Failure, n (%)			
No	18 (81.8%)	16 (72.7%)	34 (77.3%)
Yes	4 (18.2%)	6 (27.3%)	10 (22.7%)

¹Chi-Square p-value;

	Ce	enter Order	
		22	
	Group		
	Methylprednisolone	Placebo	Total
	(N=6)	(N=8)	(N=14)
modified Rankin Scale score at 90 days,n (%)			
0	0 (0.0%)	2 (25.0%)	2 (14.3%
1	2 (33.3%)	1 (12.5%)	3 (21.4%
2	1 (16.7%)	2 (25.0%)	3 (21.4%
3	1 (16.7%)	0 (0.0%)	1 (7.1%)
4	1 (16.7%)	1 (12.5%)	2 (14.3%
5	0 (0.0%)	0 (0.0%)	0 (0.0%)
6	1 (16.7%)	2 (25.0%)	3 (21.4%
Missing	0	0	0
Symptomatic intracranial hemorrhage, n (%)			
No	6 (100.0%)	7 (87.5%)	13 (92.9%
Yes	0 (0.0%)	1 (12.5%)	1 (7.1%)
Missing	0	0	0
Pneumonia,n (%)			
No	4 (66.7%)	5 (62.5%)	9 (64.3%

Durinary tract infection,n (%)				
O(0.0%)	Yes	2 (33.3%)	3 (37.5%)	5 (35.7%
O (0.0%)	Urinary tract infection,n (%)			
No	No	6 (100.0%)	8 (100.0%)	14 (100.09
No 6 (100.0%) 8 (100.0%) 14 (100.7es 0 (0.0%) 0 (0.0%) 0 (0.0%) 14 (100.7es 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 14 (100.7es 0 (0.0%) 0	Yes	0 (0.0%)	0 (0.0%)	0 (0.0%)
Content	Other Infection,n (%)			
Castrointestinal bleeding within 7 days after EVT,n (%) No	No	6 (100.0%)	8 (100.0%)	14 (100.09
(%) No 6 (100.0%) 8 (100.0%) 14 (100. Yes 0 (0.0%) 0 (0.0%) 14 (100. Yes 0 (0.0%) 0 (0.0%) 0 (0.0%) 14 (100. Puncture site hematomancture site complication,n (%) Embolism in other locations 0 (0.0%) 0 (0.0%) 10 (0.0% No 6 (100.0%) 8 (100.0%) 14 (100. Pseudoaneurysm 0 (0.0%) 0 (0.0%) 0 (0.0%) 10 (0.0% Puncture site hematoma 0 (0.0%) 0 (0.0%) 10 (0.0% Insulin Use in Hospital Stay,n (%) No 5 (83.3%) 8 (100.0%) 13 (92.5% Yes 1 (16.7%) 0 (0.0%) 1 (7.15% Craniectomy,n (%) No 6 (100.0%) 8 (100.0%) 14 (100.0%) Yes 0 (0.0%) 0 (0.0%) 0 (0.0% Respiration Failure,n (%) No 4 (66.7%) 7 (87.5%) 11 (78.6%) Yes 2 (33.3%) 1 (12.5%) 3 (21.4% Circulation Failure, n (%) No 5 (83.3%) 6 (75.0%) 11 (78.6%) Yes 1 (16.7%) 2 (25.0%) 3 (21.4% Circulation Failure, n (%) No 5 (83.3%) 6 (75.0%) 11 (78.6% Yes 1 (16.7%) 2 (25.0%) 3 (21.4% Circulation Failure, n (%) No 5 (83.3%) 6 (75.0%) 11 (78.6% Circulation Failure, n (%) No 5 (83.3%) 6 (75.0%) 11 (78.6% Circulation Failure, n (%) Yes 1 (16.7%) 2 (25.0%) 3 (21.4% Circulation Failure, n (%) No 5 (83.3%) 6 (75.0%) 11 (78.6% Circulation Failure, n (%) Yes 1 (16.7%) 2 (25.0%) 3 (21.4% Circulation Failure, n (%)	Yes	0 (0.0%)	0 (0.0%)	0 (0.0%)
No 6 (100.0%) 8 (100.0%) 14 (100. Yes 0 (0.0%) 0 (0.0%) 0 (0.0%) 14 (100. Yes 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) Puncture site hematomancture site complication,n (%) Embolism in other locations 0 (0.0%) 0 (0.0%) 10 (0.0% No 6 (100.0%) 8 (100.0%) 14 (100. Pseudoaneurysm 0 (0.0%) 0 (0.0%) 0 (0.0% Puncture site hematoma 0 (0.0%) 0 (0.0%) 0 (0.0% Insulin Use in Hospital Stay,n (%) No 5 (83.3%) 8 (100.0%) 13 (92.9 (16.7%) 1 (16.7%) 0 (0.0%) 1 (7.19 (16.7%) 0 (0.0%) 1 (17.19 (16.7%) 0 (0.0%) 1 (17.19 (16.7%) 0 (0.0%) 1 (17.19 (16.7%) 1 (1	Gastrointestinal bleeding within 7 days after EVT,n			
Puncture site hematomancture site complication,n (%) Embolism in other locations 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 14 (100. Pseudoaneurysm 0 (0.0%) 0 (0.0%) 10 (0.0%) 10 (0.0%) 10 (0.0%) 10 (0.0%) 10 (0.0%) 10 (0.0%) 10 (0.0%) 10 (0.0%) 10 (0.0%) 10 (0.0%) 10 (0.0%) 10 (0.0%) 11 (16.7%) 12 (16.7%) 13 (16.7%) 14 (100. Craniectomy,n (%) No 6 (100.0%) 8 (100.0%) 14 (100. Yes 0 (0.0%) 14 (100. Yes 0 (0.0%) 14 (100. Yes 0 (0.0%) 14 (100. Yes 1 (16.7%) 1 (16.7%) 1 (12.5%) 1 (17.8.6 Circulation Failure, n (%) No 5 (83.3%) 6 (75.0%) 11 (78.6 Yes 1 (16.7%) 2 (25.0%) 3 (21.4 'Chi-Square p-value; Center Order 23 Group	(%)			
Puncture site hematomancture site complication,n (%) Embolism in other locations 0 (0.0%) 0 (0.0%) 0 (0.0%) 14 (100. Pseudoaneurysm 0 (0.0%) 0 (0.0%) 10 (0.0%) 10 (0.0%) 10 (0.0%) 10 (0.0%) 10 (0.0%) 10 (0.0%) 10 (0.0%) 10 (0.0%) 10 (0.0%) 10 (0.0%) 10 (0.0%) 10 (0.0%) 10 (0.0%) 11 (16.7%) 11 (16.7%) 12 (16.7%) 13 (92.5) 14 (100.0%) 15 (83.3%) 16 (100.0%) 17 (17.19 18 (100.0%) 19 (100.0%) 10 (100.0%) 10 (100.0%) 11 (100.0%) 11 (100.0%) 11 (100.0%) 11 (100.0%) 12 (23.3%) 13 (21.4) 14 (100.0%) 15 (83.3%) 16 (75.0%) 17 (78.5%) 17 (78.5%) 18 (100.0%) 19 (100.0%) 10 (100.0%) 10 (100.0%) 11 (78.6) 11 (78.6) 12 (25.0%) 13 (21.4) 14 (200.0%) 15 (83.3%) 16 (75.0%) 17 (78.5%) 18 (200.0%) 19 (200.0%) 10 (200.0%) 11 (78.6) 11 (78.6) 12 (25.0%) 12 (25.0%) 13 (21.4) 14 (200.0%) 15 (83.3%) 16 (75.0%) 17 (78.6) 17 (78.6) 18 (200.0%) 19 (200.0%) 10 (200.0%) 10 (200.0%) 10 (200.0%) 11 (78.6) 11 (78.6) 12 (200.0%) 13 (21.4) 14 (200.0%) 15 (200.0%) 16 (200.0%) 17 (200.0%) 18 (100.0%) 18 (100.0%) 19 (200.0%) 10 (200.	No			14 (100.09
Embolism in other locations 0 (0.0%) 0 (0.0%) 0 (0.0% 0 (0.0%) No 6 (100.0%) 8 (100.0%) 14 (100.0%) Pseudoaneurysm 0 (0.0%) 0 (0.0%) 0 (0.0% 0 (0.0%) 14 (100.0%) Puncture site hematoma 0 (0.0%) 0 (0.0%) 0 (0.0% 0 (0.0%) 10 (0.	Yes	0 (0.0%)	0 (0.0%)	0 (0.0%)
Embolism in other locations 0 (0.0%) 0 (0.0%) 0 (0.0%) No 6 (100.0%) 8 (100.0%) 14 (100. Pseudoaneurysm 0 (0.0%) 0 (0.0%) 0 (0.0%) Puncture site hematoma 0 (0.0%) 0 (0.0%) 0 (0.0% Insulin Use in Hospital Stay,n (%) No 5 (83.3%) 8 (100.0%) 13 (92.9 (92.9 (10.0 %)) 1 (7.1%) Craniectomy,n (%) No 6 (100.0%) 8 (100.0%) 14 (100.0 %) 14 (100.0 %) 14 (100.0 %) 14 (100.0 %) 14 (100.0 %) 14 (100.0 %) 14 (100.0 %) 14 (100.0 %) 14 (100.0 %) 15 (10.0 %)				
No 6 (100.0%) 8 (100.0%) 14 (100. Pseudoaneurysm 0 (0.0%) 0 (0.0%) 0 (0.0% Puncture site hematoma 0 (0.0%) 0 (0.0%) 0 (0.0% Insulin Use in Hospital Stay,n (%) No 5 (83.3%) 8 (100.0%) 13 (92.5 Yes 1 (16.7%) 0 (0.0%) 1 (7.19 Craniectomy,n (%) No 6 (100.0%) 8 (100.0%) 14 (100.0%) Yes 0 (0.0%) 0 (0.0%) 0 (0.0% Respiration Failure,n (%) No 4 (66.7%) 7 (87.5%) 11 (78.6 Yes 2 (33.3%) 1 (12.5%) 3 (21.4 Circulation Failure, n (%) No 5 (83.3%) 6 (75.0%) 11 (78.6 Yes 1 (16.7%) 2 (25.0%) 3 (21.4 Chi-Square p-value; Center Order 23 Group		0 (0 0%)	0 (0 0%)	0 (0 0%)
Pseudoaneurysm 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) Puncture site hematoma 0 (0.0%) 0 (0.0%) 0 (0.0%) Insulin Use in Hospital Stay,n (%) No 5 (83.3%) 8 (100.0%) 13 (92.5 (7.1%) Craniectomy,n (%) No 6 (100.0%) 8 (100.0%) 14 (100.0%) Yes 0 (0.0%) 0 (0.0%) 0 (0.0%) Respiration Failure,n (%) No 4 (66.7%) 7 (87.5%) 11 (78.6 (75.0%) 11 (78.6 (75.0%)) Yes 2 (33.3%) 1 (12.5%) 3 (21.4 (7.1%)) Circulation Failure, n (%) No 5 (83.3%) 6 (75.0%) 11 (78.6 (75.0%)) Yes 1 (16.7%) 2 (25.0%) 3 (21.4 (7.1%)) Chi-Square p-value; Center Order 23 Group		, ,		
Puncture site hematoma 0 (0.0%) 0 (0.0%) 0 (0.0%) Insulin Use in Hospital Stay,n (%) No 5 (83.3%) 8 (100.0%) 13 (92.5 Yes 1 (16.7%) 0 (0.0%) 1 (7.19 Craniectomy,n (%) No 6 (100.0%) 8 (100.0%) 14 (100.0%) Yes 0 (0.0%) 0 (0.0%) 0 (0.0%) Respiration Failure,n (%) No 4 (66.7%) 7 (87.5%) 11 (78.6 Yes 2 (33.3%) 1 (12.5%) 3 (21.4 Circulation Failure, n (%) No 5 (83.3%) 6 (75.0%) 11 (78.6 Yes 1 (16.7%) 2 (25.0%) 3 (21.4 'Chi-Square p-value; Center Order 23 Group				
Insulin Use in Hospital Stay,n (%) No 5 (83.3%) 8 (100.0%) 13 (92.5 1 (16.7%) 0 (0.0%) 1 (7.19 1 (16.7%) 0 (0.0%) 1 (7.19 1 (16.7%) 0 (0.0%) 1 (7.19 1 (16.7%) 0 (0.0%) 1 (7.19 1 (16.7%) 0 (0.0%) 1 (17.19 1 (16.7%) 0 (0.0%) 1 (10.0%) 1	•			
No 5 (83.3%) 8 (100.0%) 13 (92.5 Yes 1 (16.7%) 0 (0.0%) 1 (7.1%) Craniectomy,n (%) No 6 (100.0%) 8 (100.0%) 14 (100.0 Yes 0 (0.0%) 0 (0.0%) 0 (0.0%) Respiration Failure,n (%) No 4 (66.7%) 7 (87.5%) 11 (78.6 Yes 2 (33.3%) 1 (12.5%) 3 (21.4 Yes 1 (16.7%) 2 (25.0%) 3 (21.4 Yes 1 (16.7	Turicule site fichiateria	0 (0.070)	0 (0.070)	0 (0.070
Yes 1 (16.7%) 0 (0.0%) 1 (7.19) Craniectomy,n (%) 6 (100.0%) 8 (100.0%) 14 (100.0%) Yes 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) No 4 (66.7%) 7 (87.5%) 11 (78.6%) Yes 2 (33.3%) 1 (12.5%) 3 (21.4%) Circulation Failure, n (%) No 5 (83.3%) 6 (75.0%) 11 (78.6%) Yes 1 (16.7%) 2 (25.0%) 3 (21.4%) 1*Chi-Square p-value; Center Order 23 Group	Insulin Use in Hospital Stay,n (%)			
Craniectomy,n (%) No 6 (100.0%) 8 (100.0%) 14 (100.0%) Yes 0 (0.0%) 0 (0.0%) 0 (0.0%) Respiration Failure,n (%) No 4 (66.7%) 7 (87.5%) 11 (78.6%) Yes 2 (33.3%) 1 (12.5%) 3 (21.4%) Circulation Failure, n (%) No 5 (83.3%) 6 (75.0%) 11 (78.6%) Yes 1 (16.7%) 2 (25.0%) 3 (21.4%) **Chi-Square p-value; Center Order 23 Group	No	5 (83.3%)	8 (100.0%)	13 (92.9%
No 6 (100.0%) 8 (100.0%) 14 (100.0 Yes 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 14 (100.0 Yes 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 10 (0.0%) 11 (78.6 Yes 2 (33.3%) 1 (12.5%) 3 (21.4 Yes 2 (33.3%) 6 (75.0%) 11 (78.6 Yes 1 (16.7%) 2 (25.0%) 3 (21.4 Yes 1 (16.7%) 2 (25.0%) 3 (Yes	1 (16.7%)	0 (0.0%)	1 (7.1%)
Yes 0 (0.0%) 0 (0.0%) 0 (0.0%) Respiration Failure, n (%) Ves 2 (33.3%) 7 (87.5%) 11 (78.6%) Yes 2 (33.3%) 1 (12.5%) 3 (21.4%) Circulation Failure, n (%) Ves 1 (16.7%) 2 (25.0%) 3 (21.4%) Yes 1 (16.7%) 2 (25.0%) 3 (21.4%) 1*Chi-Square p-value; Center Order 23 Group	Craniectomy,n (%)			
Respiration Failure, n (%) No	No	6 (100.0%)	8 (100.0%)	14 (100.0
No 4 (66.7%) 7 (87.5%) 11 (78.69) Yes 2 (33.3%) 1 (12.5%) 3 (21.40) Circulation Failure, n (%) No 5 (83.3%) 6 (75.0%) 11 (78.69) Yes 1 (16.7%) 2 (25.0%) 3 (21.40) **Chi-Square p-value;** **Center Order 23 Group**	Yes	0 (0.0%)	0 (0.0%)	0 (0.0%)
Yes 2 (33.3%) 1 (12.5%) 3 (21.49) Circulation Failure, n (%) No 5 (83.3%) 6 (75.0%) 11 (78.69) Yes 1 (16.7%) 2 (25.0%) 3 (21.49) 1 Chi-Square p-value; Center Order 23 Group	Respiration Failure,n (%)			
Circulation Failure, n (%) No 5 (83.3%) 6 (75.0%) 11 (78.6 (75.0%)) 11 (78.6 (75.0%)) 3 (21.4 (75.0%))	No	4 (66.7%)	7 (87.5%)	11 (78.6%
No 5 (83.3%) 6 (75.0%) 11 (78.67) Yes 1 (16.7%) 2 (25.0%) 3 (21.47) **Chi-Square p-value;** Center Order	Yes	2 (33.3%)	1 (12.5%)	3 (21.4%
Yes 1 (16.7%) 2 (25.0%) 3 (21.4) 1 Chi-Square p-value; Center Order 23 Group	Circulation Failure, n (%)			
Center Order 23 Group		5 (83.3%)	6 (75.0%)	11 (78.6%
Center Order 23 Group	Yes	1 (16.7%)	2 (25.0%)	3 (21.4%
Group 23	¹Chi-Square p-value;			
Group 23				
Group				
Methylprednisolone Placebo Total		Group	-	
		Methylprednisolone	Placebo	Total

	(N=24)	(N=22)	(N=46)
modified Rankin Scale score at 90 days,n (%)			
0	5 (20.8%)	4 (18.2%)	9 (19.6%)
1	6 (25.0%)	5 (22.7%)	11 (23.9%)
2	5 (20.8%)	1 (4.5%)	6 (13.0%)
3	2 (8.3%)	1 (4.5%)	3 (6.5%)
4	3 (12.5%)	2 (9.1%)	5 (10.9%)
5	1 (4.2%)	2 (9.1%)	3 (6.5%)
6	2 (8.3%)	7 (31.8%)	9 (19.6%)
Missing	0	0	0
Symptomatic intracranial hemorrhage, n (%)			
No	22 (91.7%)	19 (86.4%)	41 (89.1%)
Yes	2 (8.3%)	3 (13.6%)	5 (10.9%)
Missing	0	0	0
, and the second			
Pneumonia,n (%)			
No	19 (79.2%)	16 (72.7%)	35 (76.1%)
Yes	5 (20.8%)	6 (27.3%)	11 (23.9%)
Urinary tract infection,n (%)			
No	22 (91.7%)	21 (95.5%)	43 (93.5%)
Yes	2 (8.3%)	1 (4.5%)	3 (6.5%)
Other Infection,n (%)			
No	24 (100.0%)	21 (95.5%)	45 (97.8%)
Yes	0 (0.0%)	1 (4.5%)	1 (2.2%)
165	0 (0.070)	1 (4.570)	1 (2.270)
Gastrointestinal bleeding within 7 days after EVT,n			
(%) No	24 (100.0%)	22 (100.0%)	46 (100.0%)
Yes	0 (0.0%)	0 (0.0%)	0 (0.0%)
	0 (0.070)	0 (0.070)	0 (0.070)
Puncture site hematomancture site complication,n (%)			
Embolism in other locations	0 (0.0%)	0 (0.0%)	0 (0.0%)
No	24 (100.0%)	20 (90.9%)	44 (95.7%)
Pseudoaneurysm	0 (0.0%)	1 (4.5%)	1 (2.2%)
Puncture site hematoma	0 (0.0%)	1 (4.5%)	1 (2.2%)
Insulin Use in Hospital Stay,n (%)	04 (07 50)	40 (00 40)	40 (07 00)
No	21 (87.5%)	19 (86.4%)	40 (87.0%)
Yes	3 (12.5%)	3 (13.6%)	6 (13.0%)

Craniectomy,n (%)			
No	24 (100.0%)	21 (95.5%)	45 (97.8%)
Yes	0 (0.0%)	1 (4.5%)	1 (2.2%)
Respiration Failure,n (%)			
No	20 (83.3%)	17 (77.3%)	37 (80.4%)
Yes	4 (16.7%)	5 (22.7%)	9 (19.6%)
Circulation Failure, n (%)			
No	23 (95.8%)	20 (90.9%)	43 (93.5%)
Yes	1 (4.2%)	2 (9.1%)	3 (6.5%)

¹Chi-Square p-value;

	Center Order		
	24		
	Group		
	Methylprednisolone	Placebo	Total
	(N=11)	(N=11)	(N=22)
modified Rankin Scale score at 90 days,n (%)			
0	1 (9.1%)	0 (0.0%)	1 (4.5%)
1	1 (9.1%)	3 (27.3%)	4 (18.2%
2	4 (36.4%)	2 (18.2%)	6 (27.3%
3	2 (18.2%)	1 (9.1%)	3 (13.6%
4	2 (18.2%)	1 (9.1%)	3 (13.6%
5	1 (9.1%)	0 (0.0%)	1 (4.5%)
6	0 (0.0%)	4 (36.4%)	4 (18.2%
Missing	0	0	0
Symptomatic intracranial hemorrhage, n (%)			
No	11 (100.0%)	8 (72.7%)	19 (86.4%
Yes	0 (0.0%)	3 (27.3%)	3 (13.6%
Missing	0	0	0
Pneumonia,n (%)			
No	4 (36.4%)	5 (45.5%)	9 (40.9%
Yes	7 (63.6%)	6 (54.5%)	13 (59.1%
Jrinary tract infection,n (%)			
No	8 (72.7%)	8 (72.7%)	16 (72.7%
Yes	3 (27.3%)	3 (27.3%)	6 (27.3%

No	11 (100.0%)	11 (100.0%)	22 (100.09
Yes	0 (0.0%)	0 (0.0%)	0 (0.0%
Sastrointestinal bleeding within 7 days after EVT,n			
%)			
No	10 (90.9%)	8 (72.7%)	18 (81.89
Yes	1 (9.1%)	3 (27.3%)	4 (18.2%
Puncture site hematomancture site complication,n			
%)			
Embolism in other locations	0 (0.0%)	0 (0.0%)	0 (0.0%
No	11 (100.0%)	11 (100.0%)	22 (100.0
Pseudoaneurysm	0 (0.0%)	0 (0.0%)	0 (0.0%
Puncture site hematoma	0 (0.0%)	0 (0.0%)	0 (0.0%
nsulin Use in Hospital Stay,n (%)			
No	9 (81.8%)	11 (100.0%)	20 (90.99
Yes	2 (18.2%)	0 (0.0%)	2 (9.1%
Craniectomy,n (%)			
No	11 (100.0%)	10 (90.9%)	21 (95.5%
Yes	0 (0.0%)	1 (9.1%)	1 (4.5%
	,	,	•
Respiration Failure,n (%)			
No	8 (72.7%)	7 (63.6%)	15 (68.29
Yes	3 (27.3%)	4 (36.4%)	7 (31.8%
Circulation Failure, n (%)			
No	10 (90.9%)	7 (63.6%)	17 (77.39
Yes	1 (9.1%)	4 (36.4%)	5 (22.7%

	Ce	enter Order		
		25		
	Group	Group		
	Methylprednisolone	Placebo	Total	
	(N=8)	(N=8)	(N=16)	
modified Rankin Scale score at 90 days,n (%)				
0	1 (12.5%)	1 (12.5%)	2 (12.5%)	
1	0 (0.0%)	3 (37.5%)	3 (18.8%)	
2	1 (12.5%)	1 (12.5%)	2 (12.5%)	

3	2 (25.0%)	0 (0.0%)	2 (12.5%)
4	2 (25.0%)	1 (12.5%)	3 (18.8%)
5	0 (0.0%)	1 (12.5%)	1 (6.3%)
6	2 (25.0%)	1 (12.5%)	3 (18.8%)
Missing	0	0	0
Symptomatic intracranial hemorrhage, n (%)			
No	7 (87.5%)	7 (87.5%)	14 (87.5%)
Yes	1 (12.5%)	1 (12.5%)	2 (12.5%)
Missing	0	0	0
Pneumonia,n (%)			
No	3 (37.5%)	5 (62.5%)	8 (50.0%)
Yes	5 (62.5%)	3 (37.5%)	8 (50.0%)
Urinary tract infection,n (%)			
No	6 (75.0%)	8 (100.0%)	14 (87.5%)
Yes	2 (25.0%)	0 (0.0%)	2 (12.5%)
Other Infection,n (%)			
No	8 (100.0%)	8 (100.0%)	16 (100.0%
Yes	0 (0.0%)	0 (0.0%)	0 (0.0%)
Gastrointestinal bleeding within 7 days after EVT,n			
(%)			
No	8 (100.0%)	8 (100.0%)	16 (100.0%
Yes	0 (0.0%)	0 (0.0%)	0 (0.0%)
Puncture site hematomancture site complication,n			
(%) Embolism in other locations	0 (0 00()	0 (0 00/)	0 (0 00()
	0 (0.0%)	0 (0.0%)	0 (0.0%) 16 (100.0%
No Decude on a constant	8 (100.0%)	8 (100.0%)	,
Pseudoaneurysm Puncture site hematoma	0 (0.0%)	0 (0.0%)	0 (0.0%)
Functure site nematoma	0 (0.0%)	0 (0.0%)	0 (0.0%)
Insulin Use in Hospital Stay,n (%)			
No	7 (87.5%)	6 (75.0%)	13 (81.3%
Yes	1 (12.5%)	2 (25.0%)	3 (18.8%)
	1 (12.570)	2 (20.070)	0 (10.070)
Craniectomy,n (%)			
No	7 (87.5%)	7 (87.5%)	14 (87.5%
	. (=:.0/0)	. (33/5)	
Yes	1 (12.5%)	1 (12.5%)	2 (12 5%)
Yes	1 (12.5%)	1 (12.5%)	2 (12.5%)

No	7 (87.5%)	8 (100.0%)	15 (93.8%)
Yes	1 (12.5%)	0 (0.0%)	1 (6.3%)
Circulation Failure, n (%)			
No	7 (87.5%)	8 (100.0%)	15 (93.8%)
Yes	1 (12.5%)	0 (0.0%)	1 (6.3%)

¹Chi-Square p-value;

	Center Order 26		
	Group		
	Methylprednisolone	Placebo	Total
	(N=40)	(N=38)	(N=78)
modified Rankin Scale score at 90 days,n (%)			
0	8 (20.0%)	10 (26.3%)	18 (23.1%
1	5 (12.5%)	11 (28.9%)	16 (20.5%
2	8 (20.0%)	8 (21.1%)	16 (20.5%
3	6 (15.0%)	4 (10.5%)	10 (12.8%
4	6 (15.0%)	1 (2.6%)	7 (9.0%)
5	0 (0.0%)	0 (0.0%)	0 (0.0%)
6	7 (17.5%)	4 (10.5%)	11 (14.1%
Missing	0	0	0
Symptomatic intracranial hemorrhage, n (%)			
No	37 (92.5%)	35 (94.6%)	72 (93.5%
Yes	3 (7.5%)	2 (5.4%)	5 (6.5%)
Missing	0	1	1
Pneumonia,n (%)			
No	33 (82.5%)	25 (65.8%)	58 (74.4%
Yes	7 (17.5%)	13 (34.2%)	20 (25.6%
165	7 (17.5%)	13 (34.270)	20 (23.07
Urinary tract infection,n (%)			
No	40 (100.0%)	37 (97.4%)	77 (98.7%
Yes	0 (0.0%)	1 (2.6%)	1 (1.3%)
Other Infection,n (%)	40 (400 00()	00 (400 00()	70 (400 0
No	40 (100.0%)	38 (100.0%)	78 (100.09
Yes	0 (0.0%)	0 (0.0%)	0 (0.0%)
Gastrointestinal bleeding within 7 days after EVT,n			
%)			

No	40 (100.0%)	38 (100.0%)	78 (100.0%)
Yes	0 (0.0%)	0 (0.0%)	0 (0.0%)
Puncture site hematomancture site complication,n			
(%)			
Embolism in other locations	0 (0.0%)	0 (0.0%)	0 (0.0%)
No	39 (97.5%)	35 (92.1%)	74 (94.9%)
Pseudoaneurysm	1 (2.5%)	3 (7.9%)	4 (5.1%)
Puncture site hematoma	0 (0.0%)	0 (0.0%)	0 (0.0%)
Insulin Use in Hospital Stay,n (%)			
No	38 (95.0%)	37 (97.4%)	75 (96.2%)
Yes	2 (5.0%)	1 (2.6%)	3 (3.8%)
Craniectomy,n (%)			
No	40 (100.0%)	38 (100.0%)	78 (100.0%)
Yes	0 (0.0%)	0 (0.0%)	0 (0.0%)
Respiration Failure,n (%)			
No	35 (87.5%)	33 (86.8%)	68 (87.2%)
Yes	5 (12.5%)	5 (13.2%)	10 (12.8%)
Circulation Failure, n (%)			
No	38 (95.0%)	31 (81.6%)	69 (88.5%)
			9 (11.5%)

¹Chi-Square p-value;

	Center Order		
		27	
	Group		
	Methylprednisolone	Placebo	Total
	(N=4)	(N=4)	(N=8)
modified Rankin Scale score at 90 days,n (%)			
0	1 (25.0%)	0 (0.0%)	1 (12.5%)
1	0 (0.0%)	0 (0.0%)	0 (0.0%)
2	1 (25.0%)	0 (0.0%)	1 (12.5%)
3	0 (0.0%)	1 (25.0%)	1 (12.5%)
4	0 (0.0%)	0 (0.0%)	0 (0.0%)
5	0 (0.0%)	1 (25.0%)	1 (12.5%)
6	2 (50.0%)	2 (50.0%)	4 (50.0%)
Missing	0	0	0

Symptomatic intracranial hemorrhage, n (%)			
No	3 (75.0%)	4 (100.0%)	7 (87.5%)
Yes	1 (25.0%)	0 (0.0%)	1 (12.5%)
Missing	0	0	0
Pneumonia,n (%)			
No	2 (75 00/)	2 (50 0%)	E (62 E0/)
	3 (75.0%)	2 (50.0%)	5 (62.5%)
Yes	1 (25.0%)	2 (50.0%)	3 (37.5%)
Urinary tract infection,n (%)			
No	4 (100.0%)	3 (75.0%)	7 (87.5%)
Yes	0 (0.0%)	1 (25.0%)	1 (12.5%)
Other Infection in (0/)			
Other Infection,n (%) No	4 (100.0%)	4 (100 0%)	9 (100 0%)
	· · · ·	4 (100.0%)	8 (100.0%)
Yes	0 (0.0%)	0 (0.0%)	0 (0.0%)
Gastrointestinal bleeding within 7 days after EVT,n			
(%)			
No	4 (100.0%)	4 (100.0%)	8 (100.0%)
Yes	0 (0.0%)	0 (0.0%)	0 (0.0%)
Puncture site hematomancture site complication,n			
Embolism in other locations	0 (0.0%)	0 (0.0%)	0 (0.0%)
No	4 (100.0%)	4 (100.0%)	8 (100.0%)
Pseudoaneurysm	0 (0.0%)	0 (0.0%)	0 (0.0%)
Puncture site hematoma	0 (0.0%)	0 (0.0%)	0 (0.0%)
described the in the middle Oderson (0/)			
Insulin Use in Hospital Stay,n (%) No	2 (50 0%)	2 (75 0%)	5 (62 E%)
	2 (50.0%)	3 (75.0%)	5 (62.5%)
Yes	2 (50.0%)	1 (25.0%)	3 (37.5%)
Craniectomy,n (%)			
No	4 (100.0%)	4 (100.0%)	8 (100.0%)
Yes	0 (0.0%)	0 (0.0%)	0 (0.0%)
Respiration Failure,n (%)			
No	2 (50.0%)	2 (50.0%)	4 (50.0%)
Yes	2 (50.0%)	2 (50.0%)	4 (50.0%)
Circulation Failure, n (%)			
No	2 (50.0%)	4 (100.0%)	6 (75.0%)
Yes	2 (50.0%)	0 (0.0%)	2 (25.0%)

¹Chi-Square p-value;

	Center Order		
	28		
	Group		
	Methylprednisolone	Placebo	Total
	(N=10)	(N=10)	(N=20)
modified Rankin Scale score at 90 days,n (%)			
0	0 (0.0%)	2 (20.0%)	2 (10.0%
1	3 (30.0%)	1 (10.0%)	4 (20.0%
2	2 (20.0%)	2 (20.0%)	4 (20.0%
3	1 (10.0%)	4 (40.0%)	5 (25.0%
4	1 (10.0%)	0 (0.0%)	1 (5.0%)
5	0 (0.0%)	0 (0.0%)	0 (0.0%)
6	3 (30.0%)	1 (10.0%)	4 (20.0%
Missing	0	0	0
Symptomatic intracranial hemorrhage, n (%)			
No	9 (100.0%)	9 (90.0%)	18 (94.7%
Yes	0 (0.0%)	1 (10.0%)	1 (5.3%)
Missing	1	0	1
Pneumonia,n (%)			
No	5 (50.0%)	5 (50.0%)	10 (50.0%
Yes	5 (50.0%)	5 (50.0%)	10 (50.0%
	,	- ()	. (
Jrinary tract infection,n (%)			
No	8 (80.0%)	10 (100.0%)	18 (90.0%
Yes	2 (20.0%)	0 (0.0%)	2 (10.0%
Other Infection,n (%)			
No	10 (100.0%)	9 (90.0%)	19 (95.0%
Yes	0 (0.0%)	1 (10.0%)	1 (5.0%)
	,	,	
Sastrointestinal bleeding within 7 days after EVT,n			
%)			
No	10 (100.0%)	9 (90.0%)	19 (95.0%
Yes	0 (0.0%)	1 (10.0%)	1 (5.0%)
Puncture site hematomancture site complication,n			
%)			

No	10 (100.0%)	10 (100.0%)	20 (100.0%)
Pseudoaneurysm	0 (0.0%)	0 (0.0%)	0 (0.0%)
Puncture site hematoma	0 (0.0%)	0 (0.0%)	0 (0.0%)
Insulin Use in Hospital Stay,n (%)			
No	9 (90.0%)	9 (90.0%)	18 (90.0%)
Yes	1 (10.0%)	1 (10.0%)	2 (10.0%)
Craniectomy,n (%)			
No	10 (100.0%)	10 (100.0%)	20 (100.0%)
Yes	0 (0.0%)	0 (0.0%)	0 (0.0%)
Respiration Failure,n (%)			
No	7 (70.0%)	10 (100.0%)	17 (85.0%)
Yes	3 (30.0%)	0 (0.0%)	3 (15.0%)
Circulation Failure, n (%)			
No	8 (80.0%)	8 (80.0%)	16 (80.0%)
Yes	2 (20.0%)	2 (20.0%)	4 (20.0%)

1Chi-Sc	mare	n-va	lue.

	Center Order		
	29		
	Group		
	Methylprednisolone	Placebo	Total
	(N=63)	(N=63)	(N=126)
modified Rankin Scale score at 90 days,n (%)			
0	9 (14.3%)	4 (6.3%)	13 (10.3%)
1	15 (23.8%)	13 (20.6%)	28 (22.2%)
2	11 (17.5%)	11 (17.5%)	22 (17.5%)
3	6 (9.5%)	9 (14.3%)	15 (11.9%
4	6 (9.5%)	7 (11.1%)	13 (10.3%)
5	5 (7.9%)	6 (9.5%)	11 (8.7%)
6	11 (17.5%)	13 (20.6%)	24 (19.0%)
Missing	0	0	0
Symptomatic intracranial hemorrhage, n (%)			
No	57 (91.9%)	59 (95.2%)	116 (93.5%
Yes	5 (8.1%)	3 (4.8%)	8 (6.5%)
Missing	1	1	2

No	23 (36.5%)	17 (27.0%)	40 (31.7%
Yes	40 (63.5%)	46 (73.0%)	86 (68.3%
Urinary tract infection,n (%)			
No	60 (95.2%)	54 (85.7%)	114 (90.59
Yes	3 (4.8%)	9 (14.3%)	12 (9.5%
Other Infection in (0/)			
Other Infection,n (%)	00 (05 00/)	04 (00 00()	404 (00 0)
No	60 (95.2%)	61 (96.8%)	121 (96.09
Yes	3 (4.8%)	2 (3.2%)	5 (4.0%)
Gastrointestinal bleeding within 7 days after EVT,n			
(%)			
No	60 (95.2%)	57 (90.5%)	117 (92.99
Yes	3 (4.8%)	6 (9.5%)	9 (7.1%)
Puncture site hematomancture site complication,n			
(%)			
Embolism in other locations	0 (0.0%)	0 (0.0%)	0 (0.0%
Na	62 (400 00/)	62 (400 00/)	126
No	63 (100.0%)	63 (100.0%)	(100.0%
Pseudoaneurysm	0 (0.0%)	0 (0.0%)	0 (0.0%
Puncture site hematoma	0 (0.0%)	0 (0.0%)	0 (0.0%
Insulin Use in Hospital Stay,n (%)			
No	49 (77.8%)	49 (77.8%)	98 (77.8%
Yes	14 (22.2%)	14 (22.2%)	28 (22.2%
105	14 (22.270)	14 (22.270)	20 (22.27
Craniectomy,n (%)			
No	58 (92.1%)	57 (90.5%)	115 (91.3
Yes	5 (7.9%)	6 (9.5%)	11 (8.7%
Respiration Failure,n (%)			
No	51 (81.0%)	44 (69.8%)	95 (75.4%
Yes	12 (19.0%)	19 (30.2%)	31 (24.6%
Circulation Failure, n (%)			
No	48 (76.2%)	47 (74.6%)	95 (75.4%
Yes	15 (23.8%)	16 (25.4%)	31 (24.6%
¹Chi-Square p-value;	· · · · · · · · · · · · · · · · · · ·	, , ,	,
		Center Order	
		32	

	Group		_	
	Methylprednisolone	Placebo	Total	
	(N=2)	(N=2)	(N=4)	
modified Rankin Scale score at 90 days,n (%)				
0	0 (0.0%)	0 (0.0%)	0 (0.0%	
1	1 (50.0%)	0 (0.0%)	1 (25.0%	
2	0 (0.0%)	0 (0.0%)	0 (0.0%	
3	1 (50.0%)	1 (50.0%)	2 (50.0%	
4	0 (0.0%)	1 (50.0%)	1 (25.0%	
5	0 (0.0%)	0 (0.0%)	0 (0.0%	
6	0 (0.0%)	0 (0.0%)	0 (0.0%	
Missing	0	0	0	
Symptomatic intracranial hemorrhage, n (%)				
No	2 (100.0%)	2 (100.0%)	4 (100.09	
Yes	0 (0.0%)	0 (0.0%)	0 (0.0%	
Missing	0	0	0	
Dunasania n. (0/)				
Pneumonia,n (%) No	1 (50.0%)	0 (0.0%)	1 (25.0%	
Yes	1 (50.0%)	2 (100.0%)	3 (75.0%	
ies	1 (30.076)	2 (100.076)	3 (75.07)	
Urinary tract infection,n (%)				
No	2 (100.0%)	2 (100.0%)	4 (100.09	
Yes	0 (0.0%)	0 (0.0%)	0 (0.0%)	
Other Infection,n (%)				
No	2 (100.0%)	2 (100.0%)	4 (100.0%	
Yes	0 (0.0%)	0 (0.0%)	0 (0.0%	
Gastrointestinal bleeding within 7 days after EVT,n				
No	2 (100.0%)	2 (100.0%)	4 (100.0%	
Yes	0 (0.0%)	0 (0.0%)	0 (0.0%	
Puncture site hematomancture site complication,n				
(%)				
Embolism in other locations	0 (0.0%)	0 (0.0%)	0 (0.0%	
No	2 (100.0%)	2 (100.0%)	4 (100.0%	
Pseudoaneurysm	0 (0.0%)	0 (0.0%)	0 (0.0%	
Puncture site hematoma	0 (0.0%)	0 (0.0%)	0 (0.0%	
Inculin Lice in Hespital Stay 5 (9/)				
Insulin Use in Hospital Stay,n (%)				

No	2 (100.0%)	1 (50.0%)	3 (75.0%)
Yes	0 (0.0%)	1 (50.0%)	1 (25.0%)
Craniectomy,n (%)			
No	2 (100.0%)	2 (100.0%)	4 (100.0%)
Yes	0 (0.0%)	0 (0.0%)	0 (0.0%)
Respiration Failure,n (%)			
No	2 (100.0%)	2 (100.0%)	4 (100.0%)
Yes	0 (0.0%)	0 (0.0%)	0 (0.0%)
Circulation Failure, n (%)			
No	2 (100.0%)	2 (100.0%)	4 (100.0%)
Yes	0 (0.0%)	0 (0.0%)	0 (0.0%)

¹Chi-Square p-value;

	Center Order		
	33		
	Group		
	Methylprednisolone	Placebo	Total
	(N=15)	(N=16)	(N=31)
modified Rankin Scale score at 90 days,n (%)			
0	1 (6.7%)	2 (12.5%)	3 (9.7%
1	4 (26.7%)	1 (6.3%)	5 (16.1%
2	3 (20.0%)	3 (18.8%)	6 (19.4%
3	1 (6.7%)	2 (12.5%)	3 (9.7%
4	2 (13.3%)	2 (12.5%)	4 (12.9%
5	1 (6.7%)	0 (0.0%)	1 (3.2%
6	3 (20.0%)	6 (37.5%)	9 (29.0%
Missing	0	0	0
Symptomatic intracranial hemorrhage, n (%)			
No	14 (93.3%)	13 (81.3%)	27 (87.19
Yes	1 (6.7%)	3 (18.8%)	4 (12.9%
Missing	0	0	0
Pneumonia,n (%)			
No	10 (66.7%)	6 (37.5%)	16 (51.69
Yes	5 (33.3%)	10 (62.5%)	15 (48.49
Urinary tract infection,n (%)			
No	15 (100.0%)	16 (100.0%)	31 (100.0

	Group Methylprednisolone	Placebo	Total
	C	enter Order 34	
Chi-Square p-value;			
Yes	1 (6.7%)	3 (18.8%)	4 (12.9%
No	14 (93.3%)	13 (81.3%)	27 (87.1%
Circulation Failure, n (%)			
	,	, ,	,
Yes	0 (0.0%)	3 (18.8%)	3 (9.7%)
Respiration Failure,n (%) No	15 (100.0%)	13 (81.3%)	28 (90.3%
Provinction Failure v (01)			
Yes	0 (0.0%)	1 (6.3%)	1 (3.2%)
No	15 (100.0%)	15 (93.8%)	30 (96.8%
Craniectomy,n (%)			
Yes	1 (6.7%)	4 (25.0%)	5 (16.1%
No	14 (93.3%)	12 (75.0%)	26 (83.9%
nsulin Use in Hospital Stay,n (%)			
Pulicture site nematoma	0 (0.0%)	0 (0.0%)	0 (0.0%)
Pseudoaneurysm Puncture site hematoma	0 (0.0%)	0 (0.0%)	0 (0.0%)
No Decorded to the control of the co	15 (100.0%)	16 (100.0%)	31 (100.09
Embolism in other locations	0 (0.0%)	0 (0.0%)	0 (0.0%)
Puncture site hematomancture site complication,n %)			
Yes	1 (6.7%)	1 (6.3%)	2 (6.5%)
No	14 (93.3%)	15 (93.8%)	29 (93.5%
Gastrointestinal bleeding within 7 days after EVT,n %)			
Yes	0 (0.0%)	0 (0.0%)	0 (0.0%)
No	15 (100.0%)	16 (100.0%)	31 (100.09
Other Infection,n (%)			

1 (1,5,9%) 5 (33,3%) 6 (18,8%) 2 4 (23,5%) 1 (6,7%) 5 (15,6%) 3 4 (23,5%) 0 (0,0%) 4 (12,5%) 4 2 (11,8%) 4 (26,7%) 6 (18,8%) 5 1 (5,9%) 1 (6,7%) 2 (6,3%) 5 1 (5,9%) 1 (6,7%) 2 (6,3%) 6 3 (17,6%) 4 (26,7%) 7 (21,9%) Missing 0 1 1 Symptomatic intracranial hemorrhage, n (%) No 14 (82,4%) 15 (93,8%) 29 (87,9%) Yes 3 (17,6%) 1 (6,3%) 4 (12,1%) Missing 0 0 1 1 1 Symptomatic intracranial hemorrhage, n (%) No 14 (82,4%) 15 (93,8%) 29 (87,9%) Yes 3 (17,6%) 1 (6,3%) 4 (12,1%) Missing 0 0 0 0 Pneumonia,n (%) No 9 (52,9%) 7 (43,8%) 16 (48,5%) Yes 8 (47,1%) 9 (56,3%) 17 (51,5%) Urinary tract infection,n (%) No 17 (100,0%) 16 (100,0%) 33 (100,0%) Yes 0 (0,0%) 0 (0,0%) 0 (0,0%) Other infection,n (%) No 17 (100,0%) 16 (100,0%) 33 (100,0%) Yes 0 (0,0%) 0 (0,0%) 0 (0,0%) Other infection,n (%) No 17 (100,0%) 16 (100,0%) 33 (100,0%) Yes 0 (0,0%) 0 (0,0%) 0 (0,0%) Puncture site hematomancture site complication,n (%) Puncture site hematomancture site complication,n (%) No 17 (100,0%) 16 (100,0%) 30 (0,0%) Pescudoaneurysm 0 (0,0%) 0 (0,0%) 0 (0,0%) Puncture site hematoman 0 (0,0%) 0 (0,0%) 0 (0,0%) Insulin Use in Hospital Stay,n (%) No 14 (82,4%) 16 (100,0%) 30 (9,0%) Yes 3 (17,6%) 16 (100,0%) 30 (9,0%) Yes 3 (11,6%) 16 (100,0%) 30 (9,0%) Yes 3				
3	1	1 (5.9%)	5 (33.3%)	6 (18.8%)
4 2 (11.8%) 4 (26.7%) 6 (18.8%) 5 1 (5.9%) 1 (6.7%) 2 (6.3%) 6 3 (17.6%) 4 (26.7%) 7 (21.9%) Missing 0 1 1 Symptomatic intracranial hemorrhage, n (%) No 14 (82.4%) 15 (93.8%) 29 (87.9%) Yes 3 (17.6%) 1 (6.3%) 4 (12.1%) Missing 0 0 0 0 Pneumonia.n (%) Mo 9 (52.9%) 7 (43.8%) 16 (48.5%) Yes 8 (47.1%) 9 (56.3%) 17 (51.5%) Urinary tract infection, n (%) No 17 (100.0%) 16 (100.0%) 33 (100.0% Yes 0 (0.0%) 0 (0.0%) 0 (0.0%) Other infection.n (%) No 17 (100.0%) 16 (100.0%) 33 (100.0% Yes 0 (0.0%) 0 (0.0%) 0 (0.0%) Other infection of (%) No 17 (100.0%) 16 (100.0%) 33 (100.0% Yes 0 (0.0%) 0 (0.0%) 0 (0.0%) Definition of the foliation of (%) Sastrointestinal bleeding within 7 days after EVT.n (%) No 17 (100.0%) 16 (100.0%) 33 (100.0% Yes 0 (0.0%) 0 (0.0%) 0 (0.0%) Puncture site hematomancture site complication.n (%) Puncture site hematomancture site complication.n (%) No 17 (100.0%) 16 (100.0%) 33 (100.0% Yes 0 (0.0%) 0 (0.0%) 0 (0.0%) Puncture site hematomancture site complication.n (%) Impulse in hospital Stay.n (%) No 14 (82.4%) 16 (100.0%) 30 (90.9%) Yes 3 (17.6%) 0 (0.0%) 30 (90.9%) Yes 3 (17.6%) 0 (0.0%) 30 (90.9%) Yes 3 (17.6%) 0 (0.0%) 30 (90.9%) Yes 3 (17.6%) 16 (100.0%) 31 (93.9%) Yes 3 (17.6%) 16 (100.0%) 31 (93.9%)	2	4 (23.5%)	1 (6.7%)	5 (15.6%)
1 (5.9%) 1 (6.7%) 2 (6.3%) 6	3	4 (23.5%)	0 (0.0%)	4 (12.5%)
Symptomatic intracranial hemorrhage, n (%) 14 (82.4%) 15 (93.8%) 29 (87.9%) 7 (21.9%) 7 (2	4	2 (11.8%)	4 (26.7%)	6 (18.8%)
Missing	5	1 (5.9%)	1 (6.7%)	2 (6.3%)
Symptomatic intracranial hemorrhage, n (%) 14 (82.4%) 15 (93.8%) 29 (87.9%) Yes 3 (17.6%) 1 (6.3%) 4 (12.1%) Missing 0 0 0 0 O O O O O O	6	3 (17.6%)	4 (26.7%)	7 (21.9%)
No 14 (82.4%) 15 (93.8%) 29 (87.9%) Yes 3 (17.6%) 1 (6.3%) 4 (12.1%) Missing 0 0 0 0 Preumonia,n (%) No 9 (52.9%) 7 (43.8%) 16 (48.5%) Yes 8 (47.1%) 9 (56.3%) 17 (51.5%) Drinary tract infection,n (%) No 17 (100.0%) 16 (100.0%) 33 (100.0% Yes 0 (0.0%) 0 (0.0%) 0 (0.0%) Other Infection,n (%) No 17 (100.0%) 16 (100.0%) 33 (100.0% Yes 0 (0.0%) 0 (0.0%) 0 (0.0%) Other Infection,n (%) No 17 (100.0%) 16 (100.0%) 33 (100.0% Yes 0 (0.0%) 0 (0.0%) 0 (0.0%) Drinary tract infection,n (%) No 17 (100.0%) 16 (100.0%) 33 (100.0% Yes 0 (0.0%) 0 (0.0%) 0 (0.0%) Drinary tract infection,n (%) No 17 (100.0%) 16 (100.0%) 33 (100.0% Yes 0 (0.0%) 0 (0.0%) 0 (0.0%) Puncture site hematomancture site complication,n %) Embolism in other locations 0 (0.0%) 0 (0.0%) 0 (0.0%) No 17 (100.0%) 16 (100.0%) 33 (100.0% Pseudoaneurysm 0 (0.0%) 0 (0.0%) 0 (0.0%) Puncture site hematoma 0 (0.0%) 0 (0.0%) 0 (0.0%) Puncture site hematoma 0 (0.0%) 0 (0.0%) 0 (0.0%) nsulin Use in Hospital Stay,n (%) No 14 (82.4%) 16 (100.0%) 3 (90.9%) Yes 3 (17.6%) 0 (0.0%) 3 (91.9%) Yes 3 (17.6%) 0 (0.0%) 3 (91.9%) Yes 3 (17.6%) 15 (88.2%) 16 (100.0%) 31 (93.9%)	Missing	0	1	1
Yes 3 (17.6%) 1 (6.3%) 4 (12.1%) Missing 0 0 0 Persumonia,n (%) No 9 (52.9%) 7 (43.8%) 16 (48.5%) Yes 8 (47.1%) 9 (56.3%) 17 (51.5%) Juniary tract infection,n (%) No 17 (100.0%) 16 (100.0%) 33 (100.0%) Yes 0 (0.0%) 0 (0.0%) 0 (0.0%) Other Infection,n (%) 17 (100.0%) 16 (100.0%) 33 (100.0%) Yes 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) Persure infection,n (%) No 17 (100.0%) 16 (100.0%) 33 (100.0%) Yes 0 (0.0%) 0 (0.0%) 0 (0.0%) Puncture site hematomancture site complication,n (%) 16 (100.0%) 33 (100.0%) Puncture site hematomancture site complication,n (%) 0 (0.0%) 0 (0.0%) 0 (0.0%) Pseudoaneurysm 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.	Symptomatic intracranial hemorrhage, n (%)			
Preumonia,n (%) No 9 (52.9%) 7 (43.8%) 16 (48.5%) Yes 8 (47.1%) 9 (56.3%) 17 (51.5%) Prinary tract infection,n (%) No 17 (100.0%) 16 (100.0%) 33 (100.0%, 100.0%) No 17 (100.0%) 16 (100.0%) 33 (100.0%, 100.0%) Poter Infection,n (%) No 17 (100.0%) 16 (100.0%) 33 (100.0%, 100.0%) Poter Infection,n (%) No 17 (100.0%) 16 (100.0%) 33 (100.0%, 100.0%) Poter Infection,n (%) No 17 (100.0%) 16 (100.0%) 33 (100.0%, 100.0%) Poter Infection,n (%) No 17 (100.0%) 16 (100.0%) 33 (100.0%, 100.0%) Poter Infection,n (%) No 17 (100.0%) 16 (100.0%) 33 (100.0%, 100.0%) Poter Infection,n (%) No 17 (100.0%) 16 (100.0%) 33 (100.0%, 100.0%) Poter Infection,n (%) No 17 (100.0%) 16 (100.0%) 33 (100.0%, 100.0%) Poter Infection,n (%) No 17 (100.0%) 16 (100.0%) 30 (00.0%) No 17 (100.0%) 16 (100.0%) 30 (00.0%) Poter Infection,n (%) No 14 (82.4%) 16 (100.0%) 30 (90.9%) Yes 3 (17.6%) 0 (0.0%) 3 (9.1%) Poter Infection,n (%) No 14 (82.4%) 16 (100.0%) 30 (90.9%) Yes 3 (17.6%) 0 (0.0%) 3 (9.1%) Poter Infection,n (%) No 14 (82.4%) 16 (100.0%) 30 (90.9%) Yes 3 (17.6%) 0 (0.0%) 3 (9.1%) Poter Infection,n (%) No 15 (88.2%) 16 (100.0%) 31 (93.9%)	No	14 (82.4%)	15 (93.8%)	29 (87.9%)
Preumonia,n (%) No 9 (52.9%) 7 (43.8%) 16 (48.5%) Yes 8 (47.1%) 9 (56.3%) 17 (51.5%) Urinary tract infection,n (%) No 17 (100.0%) 16 (100.0%) 33 (100.0%, Yes 0 (0.0%) 0 (0.0%) 0 (0.0%) Other Infection,n (%) No 17 (100.0%) 16 (100.0%) 33 (100.0%, Yes 0 (0.0%) 0 (0.0%) 0 (0.0%) Sastrointestinal bleeding within 7 days after EVT,n %) No 17 (100.0%) 16 (100.0%) 33 (100.0%, Yes 0 (0.0%) 0 (0.0%) 0 (0.0%) Puncture site hematomancture site complication,n %) Embolism in other locations 0 (0.0%) 0 (0.0%) 0 (0.0%) Pseudoaneurysm 0 (0.0%) 0 (0.0%) 0 (0.0%) Puncture site hematoma 0 (0.0%) 0 (0.0%) 0 (0.0%) Puncture site hematoma 0 (0.0%) 0 (0.0%) 0 (0.0%) No 17 (100.0%) 16 (100.0%) 33 (100.0% Pseudoaneurysm 0 (0.0%) 0 (0.0%) 0 (0.0%) Puncture site hematoma 0 (0.0%) 0 (0.0%) 0 (0.0%) No 14 (82.4%) 16 (100.0%) 30 (90.9%) No 14 (82.4%) 16 (100.0%) 30 (90.9%) Yes 3 (17.6%) 0 (0.0%) 31 (93.9%) Craniectomy,n (%)	Yes	3 (17.6%)	1 (6.3%)	4 (12.1%)
No	Missing	0	0	0
No				
Yes	neumonia,n (%)			
Urinary tract infection,n (%) No 17 (100.0%) 16 (100.0%) 33 (100.0%) Yes 0 (0.0%) 0 (0.0%) 0 (0.0%) Other Infection,n (%) No 17 (100.0%) 16 (100.0%) 33 (100.0%) Yes 0 (0.0%) 0 (0.0%) 0 (0.0%) Sastrointestinal bleeding within 7 days after EVT.n Who 17 (100.0%) 16 (100.0%) 33 (100.0%) Yes 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) Pouncture site hematomancture site complication,n Who 17 (100.0%) 16 (100.0%) 33 (100.0%) Pouncture site hematomancture site complication,n Who 17 (100.0%) 16 (100.0%) 33 (100.0%) No 17 (100.0%) 16 (100.0%) 33 (100.0%) Pseudoaneurysm 0 (0.0%) 0 (0.0%) 0 (0.0%) Puncture site hematoma 0 (0.0%) 0 (0.0%) 0 (0.0%) Puncture site hematoma 0 (0.0%) 0 (0.0%) 30 (00.0%) Pseudoaneurysm 0 (0.0%) 0 (0.0%) 0 (0.0%) Puncture site hematoma 0 (0.0%) 0 (0.0%) 0 (0.0%) President in Hospital Stay,n (%) No 14 (82.4%) 16 (100.0%) 30 (90.9%) Yes 3 (17.6%) 0 (0.0%) 3 (93.9%) Formiectomy,n (%)	No	9 (52.9%)	7 (43.8%)	16 (48.5%)
No 17 (100.0%) 16 (100.0%) 33 (100.0%) Yes 0 (0.0%) 0 (0.0%) 0 (0.0%) No 17 (100.0%) 16 (100.0%) 33 (100.0%) Yes 0 (0.0%) 0 (0.0%) 33 (100.0%) Yes 0 (0.0%) 0 (0.0%) 0 (0.0%) Sastrointestinal bleeding within 7 days after EVT,n %) No 17 (100.0%) 16 (100.0%) 33 (100.0%) Yes 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) Puncture site hematomancture site complication,n %) Embolism in other locations 0 (0.0%) 0 (0.0%) 0 (0.0%) No 17 (100.0%) 16 (100.0%) 33 (100.0%) Pseudoaneurysm 0 (0.0%) 0 (0.0%) 0 (0.0%) Puncture site hematoma 0 (0.0%) 0 (0.0%) 0 (0.0%) Puncture site hematoma 0 (0.0%) 0 (0.0%) 0 (0.0%) Puncture site hematoma 14 (82.4%) 16 (100.0%) 30 (90.9%) Yes 3 (17.6%) 0 (0.0%) 3 (91.9%) Yes 3 (17.6%) 16 (100.0%) 31 (93.9%) Craniectomy,n (%)	Yes	8 (47.1%)	9 (56.3%)	17 (51.5%)
No				
Other Infection,n (%) 0 (0.0%) 0 (0.0%) 0 (0.0%) No 17 (100.0%) 16 (100.0%) 33 (100.0%) Yes 0 (0.0%) 0 (0.0%) 0 (0.0%) Sastrointestinal bleeding within 7 days after EVT,n %) Sastrointestinal bleeding within 7 days after EVT,n %) 17 (100.0%) 16 (100.0%) 33 (100.0%) Yes 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) Puncture site hematomancture site complication,n 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) No 17 (100.0%) 16 (100.0%) 33 (100.0%) Pseudoaneurysm 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) Puncture site hematoma 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) nsulin Use in Hospital Stay,n (%) No 14 (82.4%) 16 (100.0%) 30 (90.9%) Yes 3 (17.6%) 0 (0.0%) 3 (91.%) Craniectomy,n (%) 15 (88.2%) 16 (100.0%) 31 (93.9%)	Jrinary tract infection,n (%)			
Deter Infection,n (%) No 17 (100.0%) 16 (100.0%) 33 (100.0%) Yes 0 (0.0%) 0 (0.0%) 0 (0.0%) Bastrointestinal bleeding within 7 days after EVT,n Who 17 (100.0%) 16 (100.0%) 33 (100.0%) Yes 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) Puncture site hematomancture site complication,n Who 17 (100.0%) 16 (100.0%) 33 (100.0%) No 17 (100.0%) 16 (100.0%) 33 (100.0%) Pseudoaneurysm 0 (0.0%) 0 (0.0%) 0 (0.0%) Puncture site hematoma 0 (0.0%) 0 (0.0%) 0 (0.0%) Puncture site hematoma 0 (0.0%) 0 (0.0%) 30 (0.0%) Pseudoaneurysm 0 (0.0%) 0 (0.0%) 0 (0.0%) Puncture site hematoma 14 (82.4%) 16 (100.0%) 30 (90.9%) Puncture site hematoma 15 (88.2%) 16 (100.0%) 31 (93.9%) Praniectomy,n (%)	No	17 (100.0%)	16 (100.0%)	33 (100.0%)
No	Yes	0 (0.0%)	0 (0.0%)	0 (0.0%)
No				
Puncture site hematomancture site complication,n No 17 (100.0%) 16 (100.0%) 33 (100.0%) Embolism in other locations 0 (0.0%) 0 (0.0%) 0 (0.0%) Pseudoaneurysm 0 (0.0%) 0 (0.0%) 0 (0.0%) Puncture site hematomancture site complication,n No 17 (100.0%) 16 (100.0%) 33 (100.0%) Pseudoaneurysm 0 (0.0%) 0 (0.0%) 0 (0.0%) Puncture site hematoma 0 (0.0%) 0 (0.0%) 0 (0.0%) Puncture site hematoma 1 (0.0%) 0 (0.0%) 0 (0.0%) Pseudoaneurysm 0 (0.0%) 0 (0.0%) 0 (0.0%) Puncture site hematoma 1 (0.0%) 0 (0.0%) 0 (0.0%) Parallel Use in Hospital Stay,n (%) No 14 (82.4%) 16 (100.0%) 30 (90.9%) Yes 3 (17.6%) 0 (0.0%) 3 (91.9%) Craniectomy,n (%)				
Sastrointestinal bleeding within 7 days after EVT,n %) No 17 (100.0%) 16 (100.0%) 33 (100.0%) Yes 0 (0.0%) 0 (0.0%) 0 (0.0%) Puncture site hematomancture site complication,n %) Embolism in other locations 0 (0.0%) 0 (0.0%) 0 (0.0%) No 17 (100.0%) 16 (100.0%) 33 (100.0%) Pseudoaneurysm 0 (0.0%) 0 (0.0%) 0 (0.0%) Puncture site hematoma 0 (0.0%) 0 (0.0%) 0 (0.0%) nsulin Use in Hospital Stay,n (%) No 14 (82.4%) 16 (100.0%) 30 (90.9%) Yes 3 (17.6%) 0 (0.0%) 3 (9.1%) Craniectomy,n (%) No 15 (88.2%) 16 (100.0%) 31 (93.9%)				
No 17 (100.0%) 16 (100.0%) 33 (100.0%) Yes 0 (0.0%) 0 (0.0%) 0 (0.0%) Functure site hematomancture site complication,n %) Embolism in other locations 0 (0.0%) 0 (0.0%) 0 (0.0%) No 17 (100.0%) 16 (100.0%) 33 (100.0%) Pseudoaneurysm 0 (0.0%) 0 (0.0%) 0 (0.0%) Puncture site hematoma 0 (0.0%) 0 (0.0%) 0 (0.0%) Puncture site hematoma 0 (0.0%) 0 (0.0%) 0 (0.0%) Puncture site hematoma 14 (82.4%) 16 (100.0%) 30 (90.9%) Assulin Use in Hospital Stay,n (%) No 14 (82.4%) 16 (100.0%) 30 (90.9%) Yes 3 (17.6%) 0 (0.0%) 3 (91.9%) Craniectomy,n (%)	Yes	0 (0.0%)	0 (0.0%)	0 (0.0%)
No 17 (100.0%) 16 (100.0%) 33 (100.0%) Yes 0 (0.0%) 0 (0.0%) 0 (0.0%) Puncture site hematomancture site complication,n %) Embolism in other locations 0 (0.0%) 0 (0.0%) 0 (0.0%) No 17 (100.0%) 16 (100.0%) 33 (100.0%) Pseudoaneurysm 0 (0.0%) 0 (0.0%) 0 (0.0%) Puncture site hematoma 0 (0.0%) 0 (0.0%) 0 (0.0%) Puncture site hematoma 0 (0.0%) 0 (0.0%) 0 (0.0%) Puncture site hematoma 14 (82.4%) 16 (100.0%) 30 (90.9%) President Use in Hospital Stay,n (%) No 14 (82.4%) 16 (100.0%) 30 (90.9%) President Use in Hospital Stay,n (%) President Use in Hospital Stay,n (%) No 14 (82.4%) 16 (100.0%) 30 (90.9%) President Use in Hospital Stay,n (%) President Use in Hospital Stay,n (%) No 15 (88.2%) 16 (100.0%) 31 (93.9%)	Destroint estimately a discountable 7 days after FNT o			
No 17 (100.0%) 16 (100.0%) 33 (100.0%) Yes 0 (0.0%) 0 (0.0%) 0 (0.0%) Puncture site hematomancture site complication,n %) Embolism in other locations 0 (0.0%) 0 (0.0%) 0 (0.0%) No 17 (100.0%) 16 (100.0%) 33 (100.0%) Pseudoaneurysm 0 (0.0%) 0 (0.0%) 0 (0.0%) Puncture site hematoma 0 (0.0%) 0 (0.0%) 0 (0.0%) nsulin Use in Hospital Stay,n (%) No 14 (82.4%) 16 (100.0%) 30 (90.9%) Yes 3 (17.6%) 0 (0.0%) 3 (91.9%) Craniectomy,n (%) No 15 (88.2%) 16 (100.0%) 31 (93.9%)				
Puncture site hematomancture site complication,n %) Embolism in other locations 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 16 (100.0%) 33 (100.0%) Pseudoaneurysm 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 14 (82.4%) 16 (100.0%) 30 (90.9%) Yes 3 (17.6%) 0 (0.0%) 3 (91.9%) Craniectomy,n (%) No 15 (88.2%) 16 (100.0%) 3 (93.9%)		17 (100 00/)	16 (100 09/)	22 (400 00/)
Puncture site hematomancture site complication,n %) Embolism in other locations 0 (0.0%) 0 (0.0%) 0 (0.0%) No 17 (100.0%) 16 (100.0%) 33 (100.0%) Pseudoaneurysm 0 (0.0%) 0 (0.0%) 0 (0.0%) Puncture site hematoma 0 (0.0%) 0 (0.0%) 0 (0.0%) nsulin Use in Hospital Stay,n (%) No 14 (82.4%) 16 (100.0%) 30 (90.9%) Yes 3 (17.6%) 0 (0.0%) 3 (91.9%) Craniectomy,n (%) No 15 (88.2%) 16 (100.0%) 31 (93.9%)				
Embolism in other locations 0 (0.0%) 0 (0.0%) 0 (0.0%) No 17 (100.0%) 16 (100.0%) 33 (100.0%) Pseudoaneurysm 0 (0.0%) 0 (0.0%) 0 (0.0%) Puncture site hematoma 0 (0.0%) 0 (0.0%) 0 (0.0%) No 14 (82.4%) 16 (100.0%) 30 (90.9%) Yes 3 (17.6%) 0 (0.0%) 3 (91.9%) Craniectomy,n (%) No 15 (88.2%) 16 (100.0%) 31 (93.9%)	165	0 (0.0%)	0 (0.078)	0 (0.076)
Embolism in other locations 0 (0.0%) 0 (0.0%) 0 (0.0%) No 17 (100.0%) 16 (100.0%) 33 (100.0%) Pseudoaneurysm 0 (0.0%) 0 (0.0%) 0 (0.0%) Puncture site hematoma 0 (0.0%) 0 (0.0%) 0 (0.0%) No 14 (82.4%) 16 (100.0%) 30 (90.9%) Yes 3 (17.6%) 0 (0.0%) 3 (91.9%) Craniectomy,n (%) No 15 (88.2%) 16 (100.0%) 31 (93.9%)	Puncture site hematomancture site complication.n			
Embolism in other locations 0 (0.0%) 0 (0.0%) 0 (0.0%) No 17 (100.0%) 16 (100.0%) 33 (100.0%) Pseudoaneurysm 0 (0.0%) 0 (0.0%) 0 (0.0%) Puncture site hematoma 0 (0.0%) 0 (0.0%) 0 (0.0%) Insulin Use in Hospital Stay,n (%) 14 (82.4%) 16 (100.0%) 30 (90.9%) Yes 3 (17.6%) 0 (0.0%) 3 (91.1%) Craniectomy,n (%) 15 (88.2%) 16 (100.0%) 31 (93.9%)				
No 17 (100.0%) 16 (100.0%) 33 (100.0%) Pseudoaneurysm 0 (0.0%) 0 (0.0%) 0 (0.0%) Puncture site hematoma 0 (0.0%) 0 (0.0%) 0 (0.0%) No 14 (82.4%) 16 (100.0%) 30 (90.9%) Yes 3 (17.6%) 0 (0.0%) 3 (9.1%) Craniectomy,n (%) No 15 (88.2%) 16 (100.0%) 31 (93.9%)		0 (0.0%)	0 (0.0%)	0 (0.0%)
Pseudoaneurysm 0 (0.0%) 0 (0.0%) 0 (0.0%) Puncture site hematoma 0 (0.0%) 0 (0.0%) 0 (0.0%) Insulin Use in Hospital Stay,n (%) No 14 (82.4%) 16 (100.0%) 30 (90.9%) Yes 3 (17.6%) 0 (0.0%) 3 (9.1%) Craniectomy,n (%) No 15 (88.2%) 16 (100.0%) 31 (93.9%)	No		, ,	
Puncture site hematoma 0 (0.0%) 0 (0.0%) 0 (0.0%) nsulin Use in Hospital Stay,n (%) No 14 (82.4%) 16 (100.0%) 30 (90.9%) Yes 3 (17.6%) 0 (0.0%) 3 (9.1%) Craniectomy,n (%) No 15 (88.2%) 16 (100.0%) 31 (93.9%)	Pseudoaneurysm			
No 14 (82.4%) 16 (100.0%) 30 (90.9%) Yes 3 (17.6%) 0 (0.0%) 3 (9.1%) Craniectomy,n (%) No 15 (88.2%) 16 (100.0%) 31 (93.9%)				
No 14 (82.4%) 16 (100.0%) 30 (90.9%) Yes 3 (17.6%) 0 (0.0%) 3 (9.1%) Craniectomy,n (%) No 15 (88.2%) 16 (100.0%) 31 (93.9%)				
Yes 3 (17.6%) 0 (0.0%) 3 (9.1%) Craniectomy,n (%) No 15 (88.2%) 16 (100.0%) 31 (93.9%)	nsulin Use in Hospital Stay,n (%)			
Craniectomy,n (%) No 15 (88.2%) 16 (100.0%) 31 (93.9%)	No	14 (82.4%)	16 (100.0%)	30 (90.9%)
No 15 (88.2%) 16 (100.0%) 31 (93.9%)	Yes	3 (17.6%)	0 (0.0%)	3 (9.1%)
No 15 (88.2%) 16 (100.0%) 31 (93.9%)	Craniectomy,n (%)			
		15 (88.2%)	16 (100.0%)	31 (93.9%)
	Yes			

Respiration Failure,n (%)			
No	13 (76.5%)	15 (93.8%)	28 (84.8%)
Yes	4 (23.5%)	1 (6.3%)	5 (15.2%)
Circulation Failure, n (%)			
No	12 (70.6%)	15 (93.8%)	27 (81.8%)
Yes	5 (29.4%)	1 (6.3%)	6 (18.2%)

¹Chi-Square p-value;

	Center Order 35		
	Group		
	Methylprednisolone	Placebo	Total
	(N=2)	(N=2)	(N=4)
nodified Rankin Scale score at 90 days,n (%)			
0	0 (0.0%)	0 (0.0%)	0 (0.0%)
1	0 (0.0%)	0 (0.0%)	0 (0.0%)
2	0 (0.0%)	0 (0.0%)	0 (0.0%)
3	1 (50.0%)	1 (50.0%)	2 (50.0%
4	0 (0.0%)	0 (0.0%)	0 (0.0%)
5	0 (0.0%)	0 (0.0%)	0 (0.0%)
6	1 (50.0%)	1 (50.0%)	2 (50.0%
Missing	0	0	0
Symptomatic intracranial hemorrhage, n (%)			
No	2 (100.0%)	2 (100.0%)	4 (100.0%
Yes	0 (0.0%)	0 (0.0%)	0 (0.0%)
Missing	0	0	0
Pneumonia,n (%)			
No	0 (0.0%)	0 (0.0%)	0 (0.0%)
Yes	2 (100.0%)	2 (100.0%)	4 (100.0%
Jrinary tract infection,n (%)			
No	2 (100.0%)	2 (100.0%)	4 (100.0%
Yes	0 (0.0%)	0 (0.0%)	0 (0.0%)
Other Infection,n (%)			
No	2 (100.0%)	2 (100.0%)	4 (100.0%
Yes	0 (0.0%)	0 (0.0%)	0 (0.0%)

Gastrointestinal bleeding within 7 days after EVT,n			
(%)			
No	2 (100.0%)	1 (50.0%)	3 (75.0%
Yes	0 (0.0%)	1 (50.0%)	1 (25.0%
Puncture site hematomancture site complication,n			
%)			
Embolism in other locations	0 (0.0%)	0 (0.0%)	0 (0.0%
No	2 (100.0%)	2 (100.0%)	4 (100.09
Pseudoaneurysm	0 (0.0%)	0 (0.0%)	0 (0.0%
Puncture site hematoma	0 (0.0%)	0 (0.0%)	0 (0.0%
r unclui e site nematoma	0 (0.070)	0 (0.070)	0 (0.070
nsulin Use in Hospital Stay,n (%)			
No	2 (100.0%)	2 (100.0%)	4 (100.09
Yes	0 (0.0%)	0 (0.0%)	0 (0.0%
100	0 (0.070)	0 (0.070)	0 (0.0%
Craniectomy,n (%)			
No	1 (50.0%)	2 (100.0%)	3 (75.0%
Yes	1 (50.0%)	0 (0.0%)	1 (25.0%
163	1 (30.070)	0 (0.070)	1 (23.07)
Respiration Failure,n (%)			
No	0 (0.0%)	1 (50.0%)	1 (25.0%
Yes	2 (100.0%)	1 (50.0%)	3 (75.0%
Circulation Failure, n (%)			
No	2 (100.0%)	2 (100.0%)	4 (100.09
Yes	0 (0.0%)	0 (0.0%)	0 (0.0%
Yes Chi-Square p-value;		0 (0.0%)	0 (0.0%
		36	
	Group		
	Methylprednisolone	Placebo	Total
	(N=4)	(N=4)	(N=8)
nodified Rankin Scale score at 90 days,n (%)			
0	2 (50.0%)	1 (25.0%)	3 (37.5%
1	0 (0.0%)	0 (0.0%)	0 (0.0%
2	0 (0.0%)	2 (50.0%)	2 (25.0%
3	0 (0.0%)	0 (0.0%)	0 (0.0%
4	0 (0.0%)	0 (0.0%)	0 (0.0%
5	0 (0.0%)	0 (0.0%)	0 (0.0%
	- ()	(/	- (2.2.2)

2 (50.0%)

1 (25.0%)

3 (37.5%)

6

Symptomatic intracranial hemorrhage, n (%) No	0	0
No		
Yes 1 (25. Missing 0 Pneumonia,n (%) 4 (100. Yes 0 (0.5. Urinary tract infection,n (%) 4 (100. Yes 0 (0.5. Other Infection,n (%) 4 (100. Yes 0 (0.5. Gastrointestinal bleeding within 7 days after EVT,n (%) No 4 (100. Yes 0 (0.5. Puncture site hematomancture site complication,n (%) Embolism in other locations 0 (0.5. No 4 (100. Pseudoaneurysm 0 (0.5. Puncture site hematoma 0 (0.5. Insulin Use in Hospital Stay,n (%) No 4 (100. Yes 0 (0.5. Craniectomy,n (%) 0 (0.5. No 4 (100. Yes 0 (0.5.		
Missing	5.0%) 4 (100.0%)	7 (87.5%)
Pneumonia,n (%) No	5.0%) 0 (0.0%)	1 (12.5%)
No	0	0
Ves 0 (0.9) Urinary tract infection,n (%) 4 (100) Yes 0 (0.9) Other Infection,n (%) 4 (100) No 4 (100) Yes 0 (0.9) On 4 (100) Yes 0 (0.9) Puncture site hematomancture site complication,n (%) Embolism in other locations 0 (0.9) No 4 (100) Pseudoaneurysm 0 (0.9) Puncture site hematoma 0 (0.9) Insulin Use in Hospital Stay,n (%) No 4 (100) Yes 0 (0.9) Craniectomy,n (%) 0 (0.9) Yes 0 (0.9)		
Urinary tract infection,n (%) No	0.0%) 3 (75.0%)	7 (87.5%)
No	.0%) 1 (25.0%)	1 (12.5%)
Yes 0 (0.9) Other Infection,n (%) 4 (100) Yes 0 (0.9) Gastrointestinal bleeding within 7 days after EVT,n (%) No 4 (100) Yes 0 (0.9) Puncture site hematomancture site complication,n (%) Embolism in other locations 0 (0.9) No 4 (100) Pseudoaneurysm 0 (0.9) Puncture site hematoma 0 (0.9) Insulin Use in Hospital Stay,n (%) No Yes 0 (0.9) Craniectomy,n (%) A (100) No 4 (100) Yes 0 (0.9)		
Other Infection,n (%) No 4 (100 Yes 0 (0.9) Gastrointestinal bleeding within 7 days after EVT,n (%) No 4 (100 Yes 0 (0.9) Puncture site hematomancture site complication,n (%) Embolism in other locations 0 (0.9) No 4 (100 Pseudoaneurysm 0 (0.9) Puncture site hematoma 0 (0.9) Insulin Use in Hospital Stay,n (%) No Yes 0 (0.9) Craniectomy,n (%) 4 (100 No 4 (100 Yes 0 (0.9)	0.0%) 3 (75.0%)	7 (87.5%)
No 4 (100 Yes) Quantities 0 (0.9) Gastrointestinal bleeding within 7 days after EVT,n (%) No 4 (100 Yes) Puncture site hematomancture site complication,n (%) Embolism in other locations 0 (0.9) No 4 (100 Pseudoaneurysm) Puncture site hematoma 0 (0.9) Insulin Use in Hospital Stay,n (%) No 4 (100 Yes) Craniectomy,n (%) No 4 (100 Yes) O (0.9)	.0%) 1 (25.0%)	1 (12.5%)
Yes 0 (0.9) Gastrointestinal bleeding within 7 days after EVT,n (%) No 4 (100 yes) Yes 0 (0.9) Puncture site hematomancture site complication,n (%) Embolism in other locations 0 (0.9) No 4 (100 yes) Pseudoaneurysm 0 (0.9) Puncture site hematoma 0 (0.9) Insulin Use in Hospital Stay,n (%) 4 (100 yes) Yes 0 (0.9) Craniectomy,n (%) 4 (100 yes) Yes 0 (0.9)		
Gastrointestinal bleeding within 7 days after EVT,n (%) No 4 (100 Yes 0 (0.0 Puncture site hematomancture site complication,n (%) Embolism in other locations 0 (0.0 No 4 (100 Pseudoaneurysm 0 (0.0 Puncture site hematoma 0 (0.0 Insulin Use in Hospital Stay,n (%) No 4 (100 Yes 0 (0.0 Craniectomy,n (%) No 4 (100 Yes 0 (0.0 Output Craniectomy,n (%) No 4 (100 Yes 0 (0.0 Output Craniectomy,n (%) No 4 (100 Yes 0 (0.0 Output Craniectomy,n (%) No 4 (100 Yes 0 (0.0 Output Craniectomy,n (%)	0.0%) 4 (100.0%)	8 (100.0%
(%) No 4 (100 Yes 0 (0.4) Puncture site hematomancture site complication,n (%) Embolism in other locations 0 (0.4) No 4 (100 Pseudoaneurysm 0 (0.4) Puncture site hematoma 0 (0.4) Insulin Use in Hospital Stay,n (%) 4 (100 Yes 0 (0.4) Craniectomy,n (%) 4 (100 Yes 0 (0.4)	.0%) 0 (0.0%)	0 (0.0%)
No 4 (100 Mes) Yes 0 (0.0 Mes) Puncture site hematomancture site complication, n (%) Embolism in other locations 0 (0.0 Mes) No 4 (100 Mes) Pseudoaneurysm 0 (0.0 Mes) Puncture site hematoma 0 (0.0 Mes) Insulin Use in Hospital Stay,n (%) 4 (100 Mes) Yes 0 (0.0 Mes) Craniectomy,n (%) 4 (100 Mes) Yes 0 (0.0 Mes)		
Yes 0 (0.9) Puncture site hematomancture site complication,n (%) Embolism in other locations 0 (0.9) No 4 (100) Pseudoaneurysm 0 (0.9) Puncture site hematoma 0 (0.9) Insulin Use in Hospital Stay,n (%) Ves No 4 (100) Yes 0 (0.9) Craniectomy,n (%) Ves No 4 (100) Yes 0 (0.9)		
Puncture site hematomancture site complication,n (%) Embolism in other locations 0 (0.0 No 4 (100 Pseudoaneurysm 0 (0.1 Puncture site hematoma 0 (0.1 Insulin Use in Hospital Stay,n (%) No 4 (100 Yes 0 (0.1 Craniectomy,n (%) 4 (100 Yes 0 (0.1	0.0%) 4 (100.0%)	8 (100.0%
(%) Embolism in other locations 0 (0.4) No 4 (100) Pseudoaneurysm 0 (0.4) Puncture site hematoma 0 (0.4) Insulin Use in Hospital Stay,n (%) No 4 (100) Yes 0 (0.4) Craniectomy,n (%) No 4 (100) Yes 0 (0.4)	.0%) 0 (0.0%)	0 (0.0%)
Embolism in other locations 0 (0.4) No 4 (100) Pseudoaneurysm 0 (0.4) Puncture site hematoma 0 (0.4) Insulin Use in Hospital Stay,n (%) Ves No 4 (100) Yes 0 (0.4) Craniectomy,n (%) Ves No 4 (100) Yes 0 (0.4)		
No 4 (100) Pseudoaneurysm 0 (0.4) Puncture site hematoma 0 (0.4) Insulin Use in Hospital Stay,n (%) 4 (100) Yes 0 (0.4) Craniectomy,n (%) 4 (100) Yes 0 (0.4)		
Pseudoaneurysm 0 (0.4 Puncture site hematoma 0 (0.4 Insulin Use in Hospital Stay,n (%) 4 (100 Yes 0 (0.4 Craniectomy,n (%) 4 (100 Yes 0 (0.4	.0%) 0 (0.0%)	0 (0.0%)
Puncture site hematoma 0 (0.4) Insulin Use in Hospital Stay,n (%) No 4 (100 Yes 0 (0.4) Craniectomy,n (%) No 4 (100 Yes 0 (0.4)	0.0%) 4 (100.0%)) 8 (100.0%
Insulin Use in Hospital Stay,n (%) No	.0%) 0 (0.0%)	0 (0.0%)
No 4 (100 Yes 0 (0.1) Craniectomy,n (%) No 4 (100 Yes 0 (0.1)	.0%) 0 (0.0%)	0 (0.0%)
Yes 0 (0.0 Craniectomy,n (%) No 4 (100 Yes 0 (0.0 Craniectomy)		
Craniectomy,n (%) No 4 (100 Yes 0 (0.0	0.0%) 4 (100.0%)) 8 (100.0%
No 4 (100 Yes 0 (0.0	.0%) 0 (0.0%)	0 (0.0%)
Yes 0 (0.0		
	0.0%) 4 (100.0%)) 8 (100.0%
Respiration Failure,n (%)	.0%) 0 (0.0%)	0 (0.0%)
No 3 (75	5.0%) 4 (100.0%)) 7 (87.5%)
Yes 1 (25	5.0%) 0 (0.0%)	1 (12.5%)
Circulation Failure, n (%)		

No	4 (100.0%)	4 (100.0%)	8 (100.0%)
Yes	0 (0.0%)	0 (0.0%)	0 (0.0%)

¹Chi-Square p-value;

	Co	enter Order	
		37	
	Group		
	Methylprednisolone	Placebo	Total
	(N=4)	(N=4)	(N=8)
modified Rankin Scale score at 90 days,n (%)			
0	2 (50.0%)	1 (25.0%)	3 (37.5%
1	0 (0.0%)	0 (0.0%)	0 (0.0%
2	0 (0.0%)	0 (0.0%)	0 (0.0%
3	0 (0.0%)	0 (0.0%)	0 (0.0%
4	0 (0.0%)	1 (25.0%)	1 (12.5%
5	1 (25.0%)	1 (25.0%)	2 (25.0%
6	1 (25.0%)	1 (25.0%)	2 (25.0%
Missing	0	0	0
Symptomatic intracranial hemorrhage, n (%)			
No	4 (100.0%)	3 (75.0%)	7 (87.5%
Yes	0 (0.0%)	1 (25.0%)	1 (12.5%
Missing	0	0	0
Pneumonia,n (%)			
No	3 (75.0%)	0 (0.0%)	3 (37.5%
Yes	1 (25.0%)	4 (100.0%)	5 (62.5%
Jrinary tract infection,n (%)			
No	4 (100.0%)	4 (100.0%)	8 (100.0%
Yes	0 (0.0%)	0 (0.0%)	0 (0.0%
Other Infection,n (%)			
No	4 (100.0%)	4 (100.0%)	8 (100.0%
Yes	0 (0.0%)	0 (0.0%)	0 (0.0%
Gastrointestinal bleeding within 7 days after EVT,n			
%)			
No	4 (100.0%)	4 (100.0%)	8 (100.0%
Yes	0 (0.0%)	0 (0.0%)	0 (0.0%

Puncture site hematomancture site complication	on ,n		
%)			
Embolism in other locations	0 (0.0%)	0 (0.0%)	0 (0.0%)
No	4 (100.0%)	3 (75.0%)	7 (87.5%
Pseudoaneurysm	0 (0.0%)	0 (0.0%)	0 (0.0%)
Puncture site hematoma	0 (0.0%)	1 (25.0%)	1 (12.5%
Insulin Use in Hospital Stay,n (%)			
No	2 (50.0%)	4 (100.0%)	6 (75.0%
Yes	2 (50.0%)	0 (0.0%)	2 (25.0%
Craniectomy,n (%)			
No	3 (75.0%)	4 (100.0%)	7 (87.5%
Yes	1 (25.0%)	0 (0.0%)	1 (12.5%
Respiration Failure,n (%)			
No	3 (75.0%)	3 (75.0%)	6 (75.0%
Yes	1 (25.0%)	1 (25.0%)	2 (25.0%
Circulation Failure, n (%)			
No	4 (100.0%)	3 (75.0%)	7 (87.5%
Yes	0 (0.0%)	1 (25.0%)	1 (12.5%

¹Chi-Square p-value;

	Ce	enter Order	
	38		
	Group		
	Methylprednisolone	Methylprednisolone Placebo	Total
	(N=12)	(N=12)	(N=24)
modified Rankin Scale score at 90 days,n (%)			
0	1 (8.3%)	1 (8.3%)	2 (8.3%)
1	1 (8.3%)	3 (25.0%)	4 (16.7%)
2	2 (16.7%)	1 (8.3%)	3 (12.5%)
3	3 (25.0%)	3 (25.0%)	6 (25.0%)
4	2 (16.7%)	2 (16.7%)	4 (16.7%)
5	1 (8.3%)	0 (0.0%)	1 (4.2%)
6	2 (16.7%)	2 (16.7%)	4 (16.7%)
Missing	0	0	0
Symptomatic intracranial hemorrhage, n (%)			
No	10 (83.3%)	11 (91.7%)	21 (87.5%)
Yes	2 (16.7%)	1 (8.3%)	3 (12.5%)

Missing	0	0	0
Pneumonia,n (%)			
No No	8 (66.7%)	5 (41.7%)	13 (54.2%)
Yes	4 (33.3%)	7 (58.3%)	11 (45.8%)
Urinary tract infection,n (%)			
No	12 (100.0%)	10 (83.3%)	22 (91.7%)
Yes	0 (0.0%)	2 (16.7%)	2 (8.3%)
Other Infection,n (%)			
No	12 (100.0%)	11 (91.7%)	23 (95.8%)
Yes	0 (0.0%)	1 (8.3%)	1 (4.2%)
Gastrointestinal bleeding within 7 days after EVT,n (%)			
No	12 (100.0%)	12 (100.0%)	24 (100.0%
Yes	0 (0.0%)	0 (0.0%)	0 (0.0%)
Puncture site hematomancture site complication,n			
(%)	0 (0 00()	0 (0 00()	0 (0 00()
Embolism in other locations	0 (0.0%)	0 (0.0%)	0 (0.0%)
No Pagudeangun om	9 (75.0%) 1 (8.3%)	12 (100.0%)	21 (87.5%)
Pseudoaneurysm		0 (0.0%)	1 (4.2%)
Puncture site hematoma	2 (16.7%)	0 (0.0%)	2 (8.3%)
Insulin Use in Hospital Stay,n (%)			
No	10 (83.3%)	11 (91.7%)	21 (87.5%
Yes	2 (16.7%)	1 (8.3%)	3 (12.5%)
Cronicatomy n (9/)			
Craniectomy,n (%) No	11 (91.7%)	12 (100.0%)	23 (95.8%
Yes	1 (8.3%)	0 (0.0%)	1 (4.2%)
100	1 (0.070)	0 (0.070)	1 (4.270)
Respiration Failure,n (%)			
No	9 (75.0%)	10 (83.3%)	19 (79.2%
Yes	3 (25.0%)	2 (16.7%)	5 (20.8%)
Circulation Failure, n (%)			
No	10 (83.3%)	11 (91.7%)	21 (87.5%
Yes	2 (16.7%)	1 (8.3%)	3 (12.5%)

	Center Order			
	39			
	Group			
	Methylprednisolone	Placebo	Total	
	(N=18)	(N=18)	(N=36)	
modified Rankin Scale score at 90 days,n (%)				
0	1 (5.6%)	2 (11.1%)	3 (8.3%)	
1	4 (22.2%)	3 (16.7%)	7 (19.4%)	
2	1 (5.6%)	3 (16.7%)	4 (11.1%)	
3	4 (22.2%)	1 (5.6%)	5 (13.9%)	
4	2 (11.1%)	3 (16.7%)	5 (13.9%)	
5	1 (5.6%)	1 (5.6%)	2 (5.6%)	
6	5 (27.8%)	5 (27.8%)	10 (27.8%)	
Missing	0	0	0	
Symptomatic intracranial hemorrhage, n (%)				
No	17 (94.4%)	15 (83.3%)	32 (88.9%)	
Yes	1 (5.6%)	3 (16.7%)	4 (11.1%)	
Missing	0	0	0	
Pneumonia,n (%)				
No	12 (66.7%)	10 (55.6%)	22 (61.1%)	
Yes	6 (33.3%)	8 (44.4%)	14 (38.9%	
Urinary tract infection,n (%)				
No	18 (100.0%)	17 (94.4%)	35 (97.2%	
Yes	0 (0.0%)	1 (5.6%)	1 (2.8%)	
1.50	0 (0.070)	1 (0.070)	1 (2.070)	
Other Infection,n (%)				
No	18 (100.0%)	18 (100.0%)	36 (100.0%	
Yes	0 (0.0%)	0 (0.0%)	0 (0.0%)	
Gastrointestinal bleeding within 7 days after EVT,n				
(%)				
No	18 (100.0%)	16 (88.9%)	34 (94.4%	
Yes	0 (0.0%)	2 (11.1%)	2 (5.6%)	
Puncture site hematomancture site complication,n				
(%)				
Embolism in other locations	0 (0.0%)	0 (0.0%)	0 (0.0%)	
No No	18 (100.0%)	18 (100.0%)	36 (100.0%	
Pseudoaneurysm	0 (0.0%)	0 (0.0%)	0 (0.0%)	
Puncture site hematoma	0 (0.0%)	0 (0.0%)	0 (0.0%)	
r undule site nematoma	0 (0.0%)	0 (0.0%)	0 (0.0%)	

Insulin Use in Hospital Stay,n (%)			
No	14 (77.8%)	17 (94.4%)	31 (86.1%)
Yes	4 (22.2%)	1 (5.6%)	5 (13.9%)
Craniectomy,n (%)			
No	18 (100.0%)	18 (100.0%)	36 (100.0%)
Yes	0 (0.0%)	0 (0.0%)	0 (0.0%)
Respiration Failure,n (%)			
No	15 (83.3%)	11 (61.1%)	26 (72.2%)
Yes	3 (16.7%)	7 (38.9%)	10 (27.8%)
Circulation Failure, n (%)			
No	17 (94.4%)	14 (77.8%)	31 (86.1%)
Yes	1 (5.6%)	4 (22.2%)	5 (13.9%)

¹Chi-Square p-value;

	Center Order 40		
	Group		
	Methylprednisolone	Placebo	Total
	(N=4)	(N=4)	(N=8)
nodified Rankin Scale score at 90 days,n (%)			
0	0 (0.0%)	1 (25.0%)	1 (12.5%
1	0 (0.0%)	1 (25.0%)	1 (12.5%
2	0 (0.0%)	1 (25.0%)	1 (12.5%
3	0 (0.0%)	1 (25.0%)	1 (12.5%
4	1 (25.0%)	0 (0.0%)	1 (12.5%
5	0 (0.0%)	0 (0.0%)	0 (0.0%
6	3 (75.0%)	0 (0.0%)	3 (37.5%
Missing	0	0	0
symptomatic intracranial hemorrhage, n (%)			
No	3 (75.0%)	4 (100.0%)	7 (87.5%
Yes	1 (25.0%)	0 (0.0%)	1 (12.5%
Missing	0	0	0
neumonia,n (%)			
No	2 (50.0%)	2 (50.0%)	4 (50.0%
Yes	2 (50.0%)	2 (50.0%)	4 (50.0%

Jrinary tract infection,n (%) No			
INU	4 (100.0%)	4 (100.0%)	8 (100.09
V		, ,	· ·
Yes	0 (0.0%)	0 (0.0%)	0 (0.0%
Other Infection,n (%)			
No	4 (100.0%)	4 (100.0%)	8 (100.09
Yes	0 (0.0%)	0 (0.0%)	0 (0.0%
Gastrointestinal bleeding within 7 days after EVT,n			
(%)			
No	4 (100.0%)	3 (75.0%)	7 (87.5%
Yes	0 (0.0%)	1 (25.0%)	1 (12.5%
	, ,	, ,	,
Puncture site hematomancture site complication,n			
(%)			
Embolism in other locations	0 (0.0%)	0 (0.0%)	0 (0.0%
No	4 (100.0%)	3 (75.0%)	7 (87.5%
Pseudoaneurysm	0 (0.0%)	1 (25.0%)	1 (12.5%
Puncture site hematoma	0 (0.0%)	0 (0.0%)	0 (0.0%
Insulin Use in Hospital Stay,n (%)			
No	4 (100.0%)	4 (100.0%)	8 (100.09
Yes	0 (0.0%)	0 (0.0%)	0 (0.0%
Craniectomy,n (%)			
No	4 (100.0%)	4 (100.0%)	8 (100.09
Yes	0 (0.0%)	0 (0.0%)	0 (0.0%
Respiration Failure,n (%)			
	2 (50.0%)	3 (75.0%)	5 (62.5%
No			
No Yes	2 (50.0%)	1 (25.0%)	3 (37.5%
Yes	2 (50.0%)	1 (25.0%)	3 (37.5%
	2 (50.0%) 4 (100.0%)	1 (25.0%) 3 (75.0%)	3 (37.5% 7 (87.5%

modified Rankin Scale score at 90 days,n (%)			
0	0 (0.0%)	1 (5.0%)	1 (2.6%)
1	2 (10.5%)	1 (5.0%)	3 (7.7%)
2	2 (10.5%)	2 (10.0%)	4 (10.3%)
3	6 (31.6%)	4 (20.0%)	10 (25.6%)
4	4 (21.1%)	4 (20.0%)	8 (20.5%)
5	0 (0.0%)	1 (5.0%)	1 (2.6%)
6	5 (26.3%)	7 (35.0%)	12 (30.8%)
Missing	1	0	1
Symptomatic intracranial hemorrhage, n (%)			
No	18 (90.0%)	17 (85.0%)	35 (87.5%)
Yes	2 (10.0%)	3 (15.0%)	5 (12.5%)
Missing	0	0	0
Pneumonia,n (%)			
No	6 (30.0%)	7 (35.0%)	13 (32.5%)
Yes	14 (70.0%)	13 (65.0%)	27 (67.5%)
Urinary tract infection,n (%)			
No	15 (75.0%)	15 (75.0%)	30 (75.0%)
Yes	5 (25.0%)	5 (25.0%)	10 (25.0%)
1.50	0 (20.070)	0 (20.070)	10 (20.070)
Other Infection,n (%)			
No	20 (100.0%)	20 (100.0%)	40 (100.0%)
Yes	0 (0.0%)	0 (0.0%)	0 (0.0%)
Gastrointestinal bleeding within 7 days after EVT,n			
(%) No	20 (100.0%)	20 (100.0%)	40 (100.0%)
Yes	0 (0.0%)	0 (0.0%)	0 (0.0%)
100	0 (0.070)	0 (0.070)	0 (0.070)
Puncture site hematomancture site complication,n			
(%)			
Embolism in other locations	0 (0.0%)	0 (0.0%)	0 (0.0%)
No	18 (90.0%)	20 (100.0%)	38 (95.0%)
Pseudoaneurysm	2 (10.0%)	0 (0.0%)	2 (5.0%)
Puncture site hematoma	0 (0.0%)	0 (0.0%)	0 (0.0%)
Insulin Use in Hospital Stay,n (%)			
No	18 (90.0%)	20 (100.0%)	38 (95.0%)
Yes	2 (10.0%)	0 (0.0%)	2 (5.0%)

Craniectomy,n (%)			
No	19 (95.0%)	19 (95.0%)	38 (95.0%)
Yes	1 (5.0%)	1 (5.0%)	2 (5.0%)
Respiration Failure,n (%)			
No	18 (90.0%)	15 (75.0%)	33 (82.5%)
Yes	2 (10.0%)	5 (25.0%)	7 (17.5%)
Circulation Failure, n (%)			
No	20 (100.0%)	18 (90.0%)	38 (95.0%)
Yes	0 (0.0%)	2 (10.0%)	2 (5.0%)

	Center Order 42		
	42 Group		
	Methylprednisolone	Placebo	Total
	(N=66)	(N=67)	(N=133)
nodified Rankin Scale score at 90 days,n (%)	(/		(22)
0	4 (6.1%)	7 (10.4%)	11 (8.3%)
1	12 (18.2%)	11 (16.4%)	23 (17.3%
2	7 (10.6%)	9 (13.4%)	16 (12.0%
3	9 (13.6%)	8 (11.9%)	17 (12.8%
4	8 (12.1%)	12 (17.9%)	20 (15.0%
5	9 (13.6%)	6 (9.0%)	15 (11.3%
6	17 (25.8%)	14 (20.9%)	31 (23.3%
Missing	0	0	0
ymptomatic intracranial hemorrhage, n (%)			
No	58 (89.2%)	59 (90.8%)	117 (90.09
Yes	7 (10.8%)	6 (9.2%)	13 (10.0%
Missing	1	2	3
neumonia,n (%)			
No	36 (54.5%)	47 (70.1%)	83 (62.4%
Yes	30 (45.5%)	20 (29.9%)	50 (37.6%
rinary tract infection,n (%)			
No	65 (98.5%)	65 (97.0%)	130 (97.79
Yes	1 (1.5%)	2 (3.0%)	3 (2.3%)

			133	
No	66 (100.0%)	67 (100.0%)	(100.0%)	
Yes	0 (0.0%)	0 (0.0%)	0 (0.0%)	
Gastrointestinal bleeding within 7 days after EVT,n %)				
No.	64 (97.0%)	66 (98.5%)	130 (97.79	
Yes	2 (3.0%)	1 (1.5%)	3 (2.3%	
	(/	(-)		
Puncture site hematomancture site complication,n				
(%)				
Embolism in other locations	0 (0.0%)	0 (0.0%)	0 (0.0%	
No	65 (98.5%)	66 (98.5%)	131 (98.5	
Pseudoaneurysm	1 (1.5%)	1 (1.5%)	2 (1.5%	
Puncture site hematoma	0 (0.0%)	0 (0.0%)	0 (0.0%	
Insulin Use in Hospital Stay,n (%)				
No	60 (90.9%)	62 (92.5%)	122 (91.7	
Yes	6 (9.1%)	5 (7.5%)	11 (8.3%	
Cronicatomy p. (0/)				
Craniectomy,n (%)	62 (93.9%)	64 (95.5%)	126 (94.7	
Yes	4 (6.1%)	3 (4.5%)	7 (5.3%	
1.00	1 (0.170)	0 (1.070)	1 (0.070	
Respiration Failure,n (%)				
No	50 (75.8%)	53 (79.1%)	103 (77.49	
Yes	16 (24.2%)	14 (20.9%)	30 (22.6%	
Circulation Failure, n (%)				
No	55 (83.3%)	62 (92.5%)	117 (88.0	
Yes	11 (16.7%)	5 (7.5%)	16 (12.0%	
¹ Chi-Square p-value;				
	Center Order			
	43			
	Group	Group		
	Methylprednisolone	Placebo	Total	
	(N=10)	(N=9)	(N=19)	
modified Rankin Scale score at 90 days,n (%)				
0	0 (0.0%)	0 (0.0%)	0 (0.0%	
1	1 (10.0%)	2 (22.2%)	3 (15.8%	

1 (11.1%)

3 (30.0%)

4 (21.1%)

3	4 (40.0%)	3 (33.3%)	7 (36.8%)
4	0 (0.0%)	1 (11.1%)	1 (5.3%)
5	0 (0.0%)	0 (0.0%)	0 (0.0%)
6	2 (20.0%)	2 (22.2%)	4 (21.1%)
Missing	0	0	0
symptomatic intracranial hemorrhage, n (%)			
No	10 (100.0%)	8 (88.9%)	18 (94.7%
Yes	0 (0.0%)	1 (11.1%)	1 (5.3%)
Missing	0	0	0
Pneumonia,n (%)			
No	4 (40.0%)	3 (33.3%)	7 (36.8%
Yes	6 (60.0%)	6 (66.7%)	12 (63.2%
Irinary tract infection,n (%)			
No	10 (100.0%)	9 (100.0%)	19 (100.09
Yes	0 (0.0%)	0 (0.0%)	0 (0.0%)
Other Infection,n (%)			
No	10 (100.0%)	9 (100.0%)	19 (100.09
Yes	0 (0.0%)	0 (0.0%)	0 (0.0%)
Sastrointestinal bleeding within 7 days after EVT,n			
%)			
No	10 (100.0%)	8 (88.9%)	18 (94.7%
Yes	0 (0.0%)	1 (11.1%)	1 (5.3%)
Puncture site hematomancture site complication,n			
%) 	- //	- //	- //
Embolism in other locations	0 (0.0%)	0 (0.0%)	0 (0.0%)
No	10 (100.0%)	9 (100.0%)	19 (100.09
Pseudoaneurysm	0 (0.0%)	0 (0.0%)	0 (0.0%)
Puncture site hematoma	0 (0.0%)	0 (0.0%)	0 (0.0%)
F. H H			
nsulin Use in Hospital Stay,n (%)	0 (00 00/)	7 (77 00/)	46 (04 00
No	9 (90.0%)	7 (77.8%)	16 (84.2%
Vaa	1 (10.0%)	2 (22.2%)	3 (15.8%
Yes			
Yes Craniectomy,n (%)			
	10 (100.0%)	9 (100.0%)	19 (100.09
Craniectomy,n (%)	10 (100.0%) 0 (0.0%)	9 (100.0%) 0 (0.0%)	19 (100.09 0 (0.0%)

No	9 (90.0%)	8 (88.9%)	17 (89.5%)
Yes	1 (10.0%)	1 (11.1%)	2 (10.5%)
Circulation Failure, n (%)			
No	10 (100.0%)	7 (77.8%)	17 (89.5%)
Yes	0 (0.0%)	2 (22.2%)	2 (10.5%)

¹Chi-Square p-value;

	Ce	enter Order	
	44		
	Group		
	Methylprednisolone	Placebo (N=4)	Total (N=8)
	(N=4)		
modified Rankin Scale score at 90 days,n (%)			
0	0 (0.0%)	1 (25.0%)	1 (12.5%
1	1 (25.0%)	0 (0.0%)	1 (12.5%
2	1 (25.0%)	0 (0.0%)	1 (12.5%
3	0 (0.0%)	0 (0.0%)	0 (0.0%
4	0 (0.0%)	0 (0.0%)	0 (0.0%)
5	0 (0.0%)	0 (0.0%)	0 (0.0%
6	2 (50.0%)	3 (75.0%)	5 (62.5%
Missing	0	0	0
Symptomatic intracranial hemorrhage, n (%)			
No	4 (100.0%)	2 (100.0%)	6 (100.0%
Yes	0 (0.0%)	0 (0.0%)	0 (0.0%)
Missing	0	2	2
- (0/)			
Pneumonia,n (%)	0 (75 00())	4 (400 00()	7 (07 50)
No	3 (75.0%)	4 (100.0%)	7 (87.5%
Yes	1 (25.0%)	0 (0.0%)	1 (12.5%
Urinary tract infection,n (%)			
No	4 (100.0%)	4 (100.0%)	8 (100.0%
Yes	0 (0.0%)	0 (0.0%)	0 (0.0%
Other Infection,n (%)			
No	4 (100.0%)	4 (100.0%)	8 (100.0%
Yes	0 (0.0%)	0 (0.0%)	0 (0.0%
Gastrointestinal bleeding within 7 days after EVT,n (%)			

No	4 (100.0%)	4 (100.0%)	8 (100.0%)
Yes	0 (0.0%)	0 (0.0%)	0 (0.0%)
Puncture site hematomancture site complication,n			
(%)			
Embolism in other locations	0 (0.0%)	0 (0.0%)	0 (0.0%)
No	4 (100.0%)	4 (100.0%)	8 (100.0%)
Pseudoaneurysm	0 (0.0%)	0 (0.0%)	0 (0.0%)
Puncture site hematoma	0 (0.0%)	0 (0.0%)	0 (0.0%)
Insulin Use in Hospital Stay,n (%)			
No	2 (50.0%)	4 (100.0%)	6 (75.0%)
Yes	2 (50.0%)	0 (0.0%)	2 (25.0%)
Craniectomy,n (%)			
No	4 (100.0%)	4 (100.0%)	8 (100.0%)
Yes	0 (0.0%)	0 (0.0%)	0 (0.0%)
Respiration Failure,n (%)			
No	4 (100.0%)	3 (75.0%)	7 (87.5%)
Yes	0 (0.0%)	1 (25.0%)	1 (12.5%)
Circulation Failure, n (%)			
No	4 (100.0%)	3 (75.0%)	7 (87.5%)
Yes	0 (0.0%)	1 (25.0%)	1 (12.5%)

¹Chi-Square p-value;

	Center Order		
	45		
	Group		
	Methylprednisolone	nylprednisolone Placebo	Total
	(N=9)	(N=10)	(N=19)
modified Rankin Scale score at 90 days,n (%)			
0	0 (0.0%)	2 (22.2%)	2 (11.8%)
1	2 (25.0%)	2 (22.2%)	4 (23.5%)
2	2 (25.0%)	1 (11.1%)	3 (17.6%)
3	0 (0.0%)	1 (11.1%)	1 (5.9%)
4	2 (25.0%)	0 (0.0%)	2 (11.8%)
5	0 (0.0%)	0 (0.0%)	0 (0.0%)
6	2 (25.0%)	3 (33.3%)	5 (29.4%)
Missing	1	1	2

Symptomatic intracranial hemorrhage, n (%)			
No	9 (100.0%)	10 (100.0%)	19 (100.0%
Yes	0 (0.0%)	0 (0.0%)	0 (0.0%)
Missing	0	0	0
Pneumonia,n (%)			
No	5 (55.6%)	8 (80.0%)	13 (68.4%)
Yes	4 (44.4%)	2 (20.0%)	6 (31.6%)
Urinary tract infection,n (%)			
No	6 (66.7%)	8 (80.0%)	14 (73.7%
Yes	3 (33.3%)	2 (20.0%)	5 (26.3%)
Other Infection,n (%)			
No	8 (88.9%)	9 (90.0%)	17 (89.5%
Yes	1 (11.1%)	1 (10.0%)	2 (10.5%)
Gastrointestinal bleeding within 7 days after EVT,n %)			
No No	9 (100.0%)	9 (90.0%)	18 (94.7%
Yes	0 (0.0%)	1 (10.0%)	1 (5.3%)
Puncture site hematomancture site complication,n (%)			
Embolism in other locations	0 (0.0%)	0 (0.0%)	0 (0.0%)
No	9 (100.0%)	10 (100.0%)	19 (100.0%
Pseudoaneurysm	0 (0.0%)	0 (0.0%)	0 (0.0%)
Puncture site hematoma	0 (0.0%)	0 (0.0%)	0 (0.0%)
Insulin Use in Hospital Stay,n (%)			
No	8 (88.9%)	7 (70.0%)	15 (78.9%
Yes	1 (11.1%)	3 (30.0%)	4 (21.1%)
Craniectomy,n (%)			
No	8 (88.9%)	10 (100.0%)	18 (94.7%
Yes	1 (11.1%)	0 (0.0%)	1 (5.3%)
Respiration Failure,n (%)			
No	8 (88.9%)	8 (80.0%)	16 (84.2%
Yes	1 (11.1%)	2 (20.0%)	3 (15.8%)
Circulation Failure p (%)			
Circulation Failure, n (%) No	6 (66.7%)	8 (80.0%)	14 (73.7%
Yes	3 (33.3%)	2 (20.0%)	5 (26.3%)
100	0 (00.070)	2 (20.070)	0 (20.070)

	Center Order		
	46		
	Group		
	Methylprednisolone	Placebo	Total
	(N=8)	(N=8)	(N=16)
modified Rankin Scale score at 90 days,n (%)			
0	0 (0.0%)	1 (12.5%)	1 (6.3%)
1	1 (12.5%)	1 (12.5%)	2 (12.5%)
2	4 (50.0%)	2 (25.0%)	6 (37.5%)
3	0 (0.0%)	1 (12.5%)	1 (6.3%)
4	0 (0.0%)	0 (0.0%)	0 (0.0%)
5	0 (0.0%)	0 (0.0%)	0 (0.0%)
6	3 (37.5%)	3 (37.5%)	6 (37.5%)
Missing	0	0	0
Symptomatic intracranial hemorrhage, n (%)			
No	7 (87.5%)	8 (100.0%)	15 (93.8%)
Yes	1 (12.5%)	0 (0.0%)	1 (6.3%)
Missing	0	0	0
Pneumonia,n (%)			
No	4 (50.0%)	4 (50.0%)	8 (50.0%)
Yes	4 (50.0%)	4 (50.0%)	8 (50.0%)
	1 (001070)	. (00.070)	0 (00.070)
Urinary tract infection,n (%)			
No	8 (100.0%)	7 (87.5%)	15 (93.8%)
Yes	0 (0.0%)	1 (12.5%)	1 (6.3%)
	,	,	, ,
Other Infection,n (%)			
No	8 (100.0%)	7 (87.5%)	15 (93.8%)
Yes	0 (0.0%)	1 (12.5%)	1 (6.3%)
Gastrointestinal bleeding within 7 days after EVT,n			
(%)			
No	8 (100.0%)	8 (100.0%)	16 (100.0%
Yes	0 (0.0%)	0 (0.0%)	0 (0.0%)
Puncture site hematomancture site complication,n			
(%)			

No	8 (100.0%)	8 (100.0%)	16 (100.0%)
Pseudoaneurysm	0 (0.0%)	0 (0.0%)	0 (0.0%)
Puncture site hematoma	0 (0.0%)	0 (0.0%)	0 (0.0%)
Insulin Use in Hospital Stay,n (%)			
No	6 (75.0%)	7 (87.5%)	13 (81.3%)
Yes	2 (25.0%)	1 (12.5%)	3 (18.8%)
Craniectomy,n (%)			
No	7 (87.5%)	7 (87.5%)	14 (87.5%)
Yes	1 (12.5%)	1 (12.5%)	2 (12.5%)
Respiration Failure,n (%)			
No	6 (75.0%)	6 (75.0%)	12 (75.0%)
Yes	2 (25.0%)	2 (25.0%)	4 (25.0%)
Circulation Failure, n (%)			
No	6 (75.0%)	5 (62.5%)	11 (68.8%)
Yes	2 (25.0%)	3 (37.5%)	5 (31.3%)
101:0			

1Chi-Sc	mare	n-va	lue.

	Center Order 48		
	Group		
	Methylprednisolone	Placebo	Total
	(N=12)	(N=12)	(N=24)
modified Rankin Scale score at 90 days,n (%)			
0	0 (0.0%)	0 (0.0%)	0 (0.0%)
1	0 (0.0%)	1 (8.3%)	1 (4.2%)
2	0 (0.0%)	0 (0.0%)	0 (0.0%)
3	5 (41.7%)	3 (25.0%)	8 (33.3%
4	2 (16.7%)	0 (0.0%)	2 (8.3%)
5	0 (0.0%)	0 (0.0%)	0 (0.0%)
6	5 (41.7%)	8 (66.7%)	13 (54.2%
Missing	0	0	0
Symptomatic intracranial hemorrhage, n (%)			
No	8 (80.0%)	11 (91.7%)	19 (86.4%
Yes	2 (20.0%)	1 (8.3%)	3 (13.6%
Missing	2	0	2

		Center Order	
¹Chi-Square p-value;	, , ,	, , ,	(1 1 1
Yes	4 (33.3%)	3 (25.0%)	7 (29.2%)
Circulation Failure, n (%)	8 (66.7%)	9 (75.0%)	17 (70.8%
Oinculation Failure or (0/)			
Yes	6 (50.0%)	5 (41.7%)	11 (45.8%
No	6 (50.0%)	7 (58.3%)	13 (54.2%
Respiration Failure,n (%)			
	, , ,	()	()
Yes	0 (0.0%)	0 (0.0%)	0 (0.0%)
No	12 (100.0%)	12 (100.0%)	24 (100.09
Craniectomy,n (%)			
Yes	5 (41.7%)	2 (16.7%)	7 (29.2%
No	7 (58.3%)	10 (83.3%)	17 (70.8%
Insulin Use in Hospital Stay,n (%)			
Puncture site hematoma	0 (0.0%)	0 (0.0%)	0 (0.0%)
Pseudoaneurysm	0 (0.0%)	0 (0.0%)	0 (0.0%)
No	12 (100.0%)	12 (100.0%)	24 (100.0
Embolism in other locations	0 (0.0%)	0 (0.0%)	0 (0.0%)
Puncture site hematomancture site complication,n (%)			
Yes	1 (8.3%)	1 (8.3%)	2 (8.3%)
No	11 (91.7%)	11 (91.7%)	22 (91.7%
Gastrointestinal bleeding within 7 days after EVT,n			
Yes	0 (0.0%)	1 (8.3%)	1 (4.2%)
No	12 (100.0%)	11 (91.7%)	23 (95.8%
Other Infection,n (%)			
Yes	0 (0.0%)	0 (0.0%)	0 (0.0%)
No	12 (100.0%)	12 (100.0%)	24 (100.09
Urinary tract infection,n (%)			
Yes	9 (75.0%)	8 (66.7%)	17 (70.8%
No	3 (25.0%)	4 (33.3%)	7 (29.2%

49

Group

	Methylprednisolone	Placebo	Total
	(N=6)	(N=7)	(N=13)
modified Rankin Scale score at 90 days,n (%)			
0	0 (0.0%)	1 (14.3%)	1 (7.7%)
1	2 (33.3%)	1 (14.3%)	3 (23.1%)
2	2 (33.3%)	1 (14.3%)	3 (23.1%)
3	0 (0.0%)	1 (14.3%)	1 (7.7%)
4	0 (0.0%)	1 (14.3%)	1 (7.7%)
5	0 (0.0%)	0 (0.0%)	0 (0.0%)
6	2 (33.3%)	2 (28.6%)	4 (30.8%)
Missing	0	0	0
0			
Symptomatic intracranial hemorrhage, n (%)			
No	5 (100.0%)	5 (71.4%)	10 (83.3%
Yes	0 (0.0%)	2 (28.6%)	2 (16.7%
Missing	1	0	1
Pneumonia,n (%)			
No	6 (100.0%)	2 (28.6%)	8 (61.5%
Yes	0 (0.0%)	5 (71.4%)	5 (38.5%
Urinary tract infection,n (%)			
No	5 (83.3%)	7 (100.0%)	12 (92.3%
Yes	1 (16.7%)	0 (0.0%)	1 (7.7%)
Other Infection v (0/)			
Other Infection,n (%)	F (02.20/)	7 (400 00()	40 (00 00
No	5 (83.3%)	7 (100.0%)	12 (92.3%
Yes	1 (16.7%)	0 (0.0%)	1 (7.7%)
Gastrointestinal bleeding within 7 days after EVT,n			
(%)			
No	6 (100.0%)	7 (100.0%)	13 (100.09
Yes	0 (0.0%)	0 (0.0%)	0 (0.0%)
Puncture site hematomancture site complication,n			
(%)			
Embolism in other locations	0 (0.0%)	0 (0.0%)	0 (0.0%)
No	6 (100.0%)	7 (100.0%)	13 (100.09
Pseudoaneurysm	0 (0.0%)	0 (0.0%)	0 (0.0%)
Puncture site hematoma	0 (0.0%)	0 (0.0%)	0 (0.0%)
neulin Hoe in Hoonital Ster = /9/			
Insulin Use in Hospital Stay,n (%)	6 (100.0%)	5 (71.4%)	11 (84.6%
INO	0 (100.070)	J (11.470)	11 (04.07

Yes	0 (0.0%)	2 (28.6%)	2 (15.4%)
Craniectomy,n (%)			
No	5 (83.3%)	6 (85.7%)	11 (84.6%)
Yes	1 (16.7%)	1 (14.3%)	2 (15.4%)
Respiration Failure,n (%)			
No	5 (83.3%)	5 (71.4%)	10 (76.9%)
Yes	1 (16.7%)	2 (28.6%)	3 (23.1%)
Circulation Failure, n (%)			
No	5 (83.3%)	6 (85.7%)	11 (84.6%)
Yes	1 (16.7%)	1 (14.3%)	2 (15.4%)

¹Chi-Square p-value;

	Center Order		
	51		
	Group		
	Methylprednisolone	Placebo	Total
	(N=8)	(N=8)	(N=16)
modified Rankin Scale score at 90 days,n (%)			
0	0 (0.0%)	0 (0.0%)	0 (0.0%)
1	1 (12.5%)	0 (0.0%)	1 (6.3%)
2	4 (50.0%)	0 (0.0%)	4 (25.0%
3	0 (0.0%)	0 (0.0%)	0 (0.0%)
4	0 (0.0%)	1 (12.5%)	1 (6.3%)
5	2 (25.0%)	1 (12.5%)	3 (18.8%
6	1 (12.5%)	6 (75.0%)	7 (43.8%
Missing	0	0	0
Symptomatic intracranial hemorrhage, n (%)			
No	6 (75.0%)	7 (87.5%)	13 (81.3%
Yes	2 (25.0%)	1 (12.5%)	3 (18.8%
Missing	0	0	0
Pneumonia,n (%)			
No	3 (37.5%)	2 (25.0%)	5 (31.3%
Yes	5 (62.5%)	6 (75.0%)	11 (68.8%
Jrinary tract infection,n (%)			
No	7 (87.5%)	6 (75.0%)	13 (81.3%
Yes	1 (12.5%)	2 (25.0%)	3 (18.8%

No	7 (87.5%)	7 (87.5%)	14 (87.5%
Yes	1 (12.5%)	1 (12.5%)	2 (12.5%
Gastrointestinal bleeding within 7 days after EVT,n			
%)			
No	8 (100.0%)	8 (100.0%)	16 (100.0
Yes	0 (0.0%)	0 (0.0%)	0 (0.0%
Puncture site hematomancture site complication,n			
%)			
Embolism in other locations	0 (0.0%)	0 (0.0%)	0 (0.0%
No	8 (100.0%)	8 (100.0%)	16 (100.0
Pseudoaneurysm	0 (0.0%)	0 (0.0%)	0 (0.0%
Puncture site hematoma	0 (0.0%)	0 (0.0%)	0 (0.0%
nsulin Use in Hospital Stay,n (%)			
No	7 (87.5%)	5 (62.5%)	12 (75.09
Yes	1 (12.5%)	3 (37.5%)	4 (25.0%
Craniectomy,n (%)			
No	6 (75.0%)	7 (87.5%)	13 (81.39
Yes	2 (25.0%)		
res	2 (23.0%)	1 (12.5%)	3 (18.8%
Respiration Failure,n (%)			
No	5 (62.5%)	4 (50.0%)	9 (56.3%
Yes	3 (37.5%)	4 (50.0%)	7 (43.8%
Circulation Failure, n (%)		- /	
No	5 (62.5%)	6 (75.0%)	11 (68.89
Yes	3 (37.5%)	2 (25.0%)	5 (31.3%

	Ce	Center Order		
		52		
	Group			
	Methylprednisolone	Placebo	Total	
	(N=10)	(N=10)	(N=20)	
modified Rankin Scale score at 90 days,n (%)				
0	1 (10.0%)	1 (10.0%)	2 (10.0%)	
1	6 (60.0%)	2 (20.0%)	8 (40.0%)	

2	1 (10.0%)	0 (0.0%)	1 (5.0%)
3	1 (10.0%)	3 (30.0%)	4 (20.0%)
4	0 (0.0%)	0 (0.0%)	0 (0.0%)
5	0 (0.0%)	1 (10.0%)	1 (5.0%)
6	1 (10.0%)	3 (30.0%)	4 (20.0%)
Missing	0	0	0
Symptomatic intracranial hemorrhage, n (%)			
No	10 (100.0%)	8 (88.9%)	18 (94.7%)
Yes	0 (0.0%)	1 (11.1%)	1 (5.3%)
Missing	0	1	1
Pneumonia,n (%)			
No	8 (80.0%)	5 (50.0%)	13 (65.0%)
Yes	2 (20.0%)	5 (50.0%)	7 (35.0%)
Urinary tract infection,n (%)			
No	9 (90.0%)	7 (70.0%)	16 (80.0%)
Yes	1 (10.0%)	3 (30.0%)	4 (20.0%)
Other Infection,n (%)			
No	9 (90.0%)	10 (100.0%)	19 (95.0%)
Yes	1 (10.0%)	0 (0.0%)	1 (5.0%)
Gastrointestinal bleeding within 7 days after EVT,n			
(%)			
No	10 (100.0%)	10 (100.0%)	20 (100.0%)
Yes	0 (0.0%)	0 (0.0%)	0 (0.0%)
Puncture site hematomancture site complication,n			
(%)			
Embolism in other locations	0 (0.0%)	0 (0.0%)	0 (0.0%)
No	10 (100.0%)	9 (90.0%)	19 (95.0%)
Pseudoaneurysm	0 (0.0%)	0 (0.0%)	0 (0.0%)
Puncture site hematoma	0 (0.0%)	1 (10.0%)	1 (5.0%)
Insulin Use in Hospital Stay,n (%)			
No	9 (90.0%)	6 (60.0%)	15 (75.0%)
Yes	1 (10.0%)	4 (40.0%)	5 (25.0%)
Craniectomy,n (%)			
No	10 (100.0%)	10 (100.0%)	20 (100.0%)
Yes	0 (0.0%)	0 (0.0%)	0 (0.0%)

Respiration Failure,n (%)			
No	10 (100.0%)	8 (80.0%)	18 (90.0%)
Yes	0 (0.0%)	2 (20.0%)	2 (10.0%)
Circulation Failure, n (%)			
No	10 (100.0%)	9 (90.0%)	19 (95.0%)
Yes	0 (0.0%)	1 (10.0%)	1 (5.0%)

	Center Order		
		53	
	Group		
	Methylprednisolone	Placebo	Total
	(N=24)	(N=24)	(N=48)
modified Rankin Scale score at 90 days,n (%)			
0	1 (4.2%)	1 (4.2%)	2 (4.2%)
1	5 (20.8%)	1 (4.2%)	6 (12.5%
2	4 (16.7%)	4 (16.7%)	8 (16.7%
3	6 (25.0%)	3 (12.5%)	9 (18.8%
4	2 (8.3%)	6 (25.0%)	8 (16.7%
5	0 (0.0%)	2 (8.3%)	2 (4.2%)
6	6 (25.0%)	7 (29.2%)	13 (27.1%
Missing	0	0	0
D			
Symptomatic intracranial hemorrhage, n (%)			
No	18 (78.3%)	20 (83.3%)	38 (80.9%
Yes	5 (21.7%)	4 (16.7%)	9 (19.1%
Missing	1	0	1
Pneumonia,n (%)			
No	7 (29.2%)	6 (25.0%)	13 (27.1%
Yes	17 (70.8%)	18 (75.0%)	35 (72.9%
Urinary tract infection,n (%)			
No	20 (83.3%)	22 (91.7%)	42 (87.5%
Yes	4 (16.7%)	2 (8.3%)	6 (12.5%
Other Infection,n (%)			
No	21 (87.5%)	22 (91.7%)	43 (89.6%
Yes	3 (12.5%)	2 (8.3%)	5 (10.4%

Gastrointestinal bleeding within 7 days after EVT,n			
(%)			
No	20 (83.3%)	20 (83.3%)	40 (83.3%
Yes	4 (16.7%)	4 (16.7%)	8 (16.7%
Puncture site hematomancture site complication,n			
(%)			
Embolism in other locations	0 (0.0%)	0 (0.0%)	0 (0.0%)
No	24 (100.0%)	24 (100.0%)	48 (100.09
Pseudoaneurysm	0 (0.0%)	0 (0.0%)	0 (0.0%)
Puncture site hematoma	0 (0.0%)	0 (0.0%)	0 (0.0%)
Insulin Use in Hospital Stay,n (%)			
No	18 (75.0%)	19 (79.2%)	37 (77.1%
Yes	6 (25.0%)	5 (20.8%)	11 (22.9%
	· (==::)	(_0.0.1)	(,
Craniectomy,n (%)			
No	23 (95.8%)	22 (91.7%)	45 (93.8%
Yes	1 (4.2%)	2 (8.3%)	3 (6.3%)
Respiration Failure,n (%)			
No	17 (70.8%)	16 (66.7%)	33 (68.8%
Yes	7 (29.2%)	8 (33.3%)	15 (31.3%
Circulation Failure, n (%)			
No	22 (91.7%)	20 (83.3%)	42 (87.5%
Yes	2 (8.3%)	4 (16.7%)	6 (12.5%
¹Chi-Square p-value;			
	С	enter Order	
		55	
	Group	1	
	Methylprednisolone	Placebo	Total
	(N=4)	(N=4)	(N=8)
modified Rankin Scale score at 90 days,n (%)			
0	1 (25.0%)	1 (25.0%)	2 (25.0%
1	1 (25.0%)	0 (0.0%)	1 (12.5%
2	1 (25.0%)	0 (0.0%)	1 (12.5%

0 (0.0%)

1 (25.0%)

0 (0.0%)

0 (0.0%)

1 (25.0%)

1 (25.0%)

0 (0.0%)

1 (25.0%)

1 (12.5%)

2 (25.0%)

0 (0.0%)

1 (12.5%)

3

4

5

6

No 3 (75.0%) 4 (100.0%) 7 (87.5%) Yes 1 (25.0%) 0 (0.0%) 1 (12.5%) Missing 0 0 0 0 Pneumonia,n (%) No 4 (100.0%) 2 (50.0%) 6 (75.0%) Yes 0 (0.0%) 2 (50.0%) 2 (25.0%) Urinary tract infection,n (%) No 4 (100.0%) 4 (100.0%) 8 (100.0% Yes 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) Other Infection,n (%) No 4 (100.0%) 4 (100.0%) 8 (100.0% Yes 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) Other Infection,n (%) No 4 (100.0%) 4 (100.0%) 8 (100.0% Yes 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) Gastrointestinal bleeding within 7 days after EVT.n (%) No 4 (100.0%) 4 (100.0%) 8 (100.0% Yes 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) Puncture site hematomancture site complication.n (%) Embolism in other locations 0 (0.0%) 0 (0.0%) 0 (0.0%) No 4 (100.0%) 4 (100.0%) 8 (100.0% Pseudoaneurysm 0 (0.0%) 0 (0.0%) 0 (0.0%) Puncture site hematoma 0 (0.0%) 0 (0.0%) 0 (0.0%) Puncture site hematoma 0 (0.0%) 0 (0.0%) 0 (0.0%) No 3 (75.0%) 2 (50.0%) 3 (75.0%) Yes 1 (25.0%) 3 (75.0%) 6 (75.0%) Yes 1 (25.0%) 3 (75.0%) 6 (75.0%) No 3 (75.0%) 3 (75.0%) 6 (75.0%)	Missing	0	0	0	
No 3 (75.0%) 4 (100.0%) 7 (87.5%) Yes 1 (25.0%) 0 (0.0%) 1 (12.5%) Missing 0 0 0 0 Pneumonia.n (%) No 4 (100.0%) 2 (50.0%) 6 (75.0%) Yes 0 (0.0%) 2 (50.0%) 6 (75.0%) Yes 0 (0.0%) 2 (50.0%) 8 (100.0% Yes 0 (0.0%) 4 (100.0%) 8 (100.0% Yes 0 (0.0%) 0 (0.0%) 0 (0.0%) Other Infection,n (%) No 4 (100.0%) 4 (100.0%) 8 (100.0% Yes 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) Other Infection,n (%) No 4 (100.0%) 4 (100.0%) 8 (100.0% Yes 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) Pures 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) Pureture site hematomancture site complication,n (%) Pureture site hematomancture site complication,n (%) Pureture site hematomancture site complication,n (%) No 4 (100.0%) 4 (100.0%) 8 (100.0%) Pureture site hematomancture site complication,n (%) No 4 (100.0%) 4 (100.0%) 8 (100.0%) Pureture site hematoman (0.0%) 0 (0.0%) 0 (0.0%) No 4 (100.0%) 4 (100.0%) 8 (100.0%) Pureture site hematoma 0 (0.0%) 0 (0.0%) 0 (0.0%) Insulin Use in Hospital Stay.n (%) No 3 (75.0%) 2 (50.0%) 5 (62.5%) Yes 1 (25.0%) 1 (25.0%) 2 (25.0%) Respiration Failure,n (%) No 3 (75.0%) 3 (75.0%) 6 (75.0%) Yes 1 (25.0%) 1 (25.0%) 6 (75.0%) Yes 1 (25.0%) 1 (25.0%) 6 (75.0%)					
Yes	Symptomatic intracranial hemorrhage, n (%)				
Missing 0 0 0 0 0 0 0 0 0	No	3 (75.0%)	4 (100.0%)	7 (87.5%)	
Pneumonia,n (%) No	Yes	1 (25.0%)	0 (0.0%)	1 (12.5%)	
No 4 (100.0%) 2 (50.0%) 6 (75.0%) Yes 0 (0.0%) 2 (50.0%) 2 (25.0%) Yes 0 (0.0%) 2 (50.0%) 2 (25.0%) Urinary tract infection,n (%) No 4 (100.0%) 4 (100.0%) 8 (100.0% Yes 0 (0.0%) 0 (0.0%) 0 (0.0%) Other Infection,n (%) No 4 (100.0%) 4 (100.0%) 8 (100.0% Yes 0 (0.0%) 0 (0.0%) 0 (0.0%) Gastrointestinal bleeding within 7 days after EVT.n (%) No 4 (100.0%) 4 (100.0%) 8 (100.0% Yes 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) Puncture site hematomancture site complication,n (%) Embolism in other locations 0 (0.0%) 0 (0.0%) 0 (0.0%) No 4 (100.0%) 4 (100.0%) 3 (100.0% Pseudoaneurysm 0 (0.0%) 0 (0.0%) 0 (0.0%) 10 (0.0%) Puncture site hematoma 0 (0.0%) 0 (0.0%) 0 (0.0%) Insulin Use in Hospital Stay,n (%) No 3 (75.0%) 2 (50.0%) 3 (75.0%) 1 (25.0%) 2 (25.0%) Craniectomy,n (%) No 3 (75.0%) 3 (75.0%) 2 (25.0%) Respiration Failure,n (%) No 3 (75.0%) 3 (75.0%) 6 (75.0%) Yes 1 (25.0%) 1 (25.0%) 2 (25.0%)	Missing	0	0	0	
Ves 0 (0.0%) 2 (50.0%) 2 (25.0%) Urinary tract infection,n (%) No 4 (100.0%) 4 (100.0%) 8 (100.0%) Yes 0 (0.0%) 0 (0.0%) 0 (0.0%) Other Infection,n (%) 4 (100.0%) 4 (100.0%) 8 (100.0%) Yes 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) Gastrointestinal bleeding within 7 days after EVT.n Ves Ves 0 (0.0%)	Pneumonia,n (%)				
Urinary tract infection,n (%) No 4 (100.0%) 4 (100.0%) 8 (100.0%) Yes 0 (0.0%) 0 (0.0%) 0 (0.0%) Other Infection,n (%) No 4 (100.0%) 4 (100.0%) 8 (100.0%) Yes 0 (0.0%) 0 (0.0%) 0 (0.0%) Gastrointestinal bleeding within 7 days after EVT,n (%) No 4 (100.0%) 4 (100.0%) 8 (100.0%) Yes 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) Puncture site hematomancture site complication,n (%) Embolism in other locations 0 (0.0%) 0 (0.0%) 0 (0.0%) No 4 (100.0%) 4 (100.0%) 8 (100.0%) Puncture site hematomancture site complication,n (%) Embolism in other locations 0 (0.0%) 0 (0.0%) 0 (0.0%) Puncture site hematoman 0 (0.0%) 0 (0.0%) 0 (0.0%) No 4 (100.0%) 4 (100.0%) 8 (100.0%) Puncture site hematoma 0 (0.0%) 0 (0.0%) 0 (0.0%) Puncture site hematoma 0 (0.0%) 0 (0.0%) 0 (0.0%) Poseudoaneurysm 0 (0.0%) 0 (0.0%) 0 (0.0%) Puncture site hematoma 0 (0.0%) 0 (0.0%) 0 (0.0%) Poseudoaneurysm 0 (0.0%) 0 (0.0%) 0 (0.0%) Poseudoaneurysm 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) Puncture site hematoma 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) Poseudoaneurysm 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) Poseudoaneurysm 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) Poseudoaneurysm 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) Poseudoaneurysm 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) Poseudoaneurysm 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) Poseudoaneurysm 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) Poseudoaneurysm 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) Poseudoaneurysm 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) Poseudoaneurysm 0 (0.0%) 0 (No	4 (100.0%)	2 (50.0%)	6 (75.0%)	
No 4 (100.0%) 4 (100.0%) 8 (100.0%) Yes 0 (0.0%) 0 (0.0%) 0 (0.0%) Other Infection,n (%) No 4 (100.0%) 4 (100.0%) 8 (100.0%) Yes 0 (0.0%) 0 (0.0%) 0 (0.0%) 8 (100.0%) Gastrointestinal bleeding within 7 days after EVT,n (%) No 4 (100.0%) 4 (100.0%) 8 (100.0%) Yes 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) Puncture site hematomancture site complication,n (%) Embolism in other locations 0 (0.0%) 0 (0.0%) 0 (0.0%) No 4 (100.0%) 4 (100.0%) 8 (100.0%) Pseudoaneurysm 0 (0.0%) 0 (0.0%) 0 (0.0%) Puncture site hematoma 0 (0.0%) 0 (0.0%) 0 (0.0%) Insulin Use in Hospital Stay,n (%) No 3 (75.0%) 2 (50.0%) 3 (37.5%) Craniectomy,n (%) No 3 (75.0%) 3 (75.0%) 6 (75.0%) Yes 1 (25.0%) 1 (25.0%) 2 (25.0%) Respiration Failure,n (%) No 3 (75.0%) 3 (75.0%) 6 (75.0%) Yes 1 (25.0%) 1 (25.0%) 2 (25.0%)	Yes	0 (0.0%)	2 (50.0%)	2 (25.0%)	
Yes 0 (0.0%) 0 (0.0%) 0 (0.0%) Other Infection,n (%) 4 (100.0%) 4 (100.0%) 8 (100.0%) Yes 0 (0.0%) 0 (0.0%) 0 (0.0%) Gastrointestinal bleeding within 7 days after EVT,n (%) 4 (100.0%) 4 (100.0%) 8 (100.0%) No 4 (100.0%) 4 (100.0%) 8 (100.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) Puncture site hematomancture site complication,n (%) 5 (0.0%) 0 (0.0%)	Urinary tract infection,n (%)				
Other Infection,n (%) No 4 (100.0%) 4 (100.0%) 8 (100.0%) Yes 0 (0.0%) 0 (0.0%) 0 (0.0%) Gastrointestinal bleeding within 7 days after EVT,n (%) No 4 (100.0%) 4 (100.0%) 8 (100.0%) Yes 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) Puncture site hematomancture site complication,n (%) Embolism in other locations 0 (0.0%) 0 (0.0%) 0 (0.0%) No 4 (100.0%) 4 (100.0%) 8 (100.0%) Pseudoaneurysm 0 (0.0%) 0 (0.0%) 0 (0.0%) Puncture site hematoma 0 (0.0%) 0 (0.0%) 0 (0.0%) Puncture site hematoma 0 (0.0%) 0 (0.0%) 0 (0.0%) Puncture site hematoma 0 (0.0%) 0 (0.0%) 0 (0.0%) Craniectomy,n (%) No 3 (75.0%) 2 (50.0%) 5 (62.5%) Yes 1 (25.0%) 3 (75.0%) 6 (75.0%) Yes 1 (25.0%) 3 (75.0%) 2 (25.0%) Respiration Failure,n (%) No 3 (75.0%) 3 (75.0%) 6 (75.0%) Yes 1 (25.0%) 1 (25.0%) 6 (75.0%)	No	4 (100.0%)	4 (100.0%)	8 (100.0%)	
No 4 (100.0%) 4 (100.0%) 8 (100.0%) Yes 0 (0.0%) 0 (0.0%) 0 (0.0%) Gastrointestinal bleeding within 7 days after EVT.n (%) No 4 (100.0%) 4 (100.0%) 8 (100.0%) Yes 0 (0.0%) 0 (0.0%) 0 (0.0%) 8 (100.0%) Puncture site hematomancture site complication,n (%) Embolism in other locations 0 (0.0%) 0 (0.0%) 8 (100.0%) No 4 (100.0%) 4 (100.0%) 8 (100.0%) Pseudoaneurysm 0 (0.0%) 0 (0.0%) 0 (0.0%) Puncture site hematoma 0 (0.0%) 0 (0.0%) 0 (0.0%) Puncture site hematoma 0 (0.0%) 0 (0.0%) 0 (0.0%) Consideration Stay,n (%) No 3 (75.0%) 2 (50.0%) 3 (37.5%) Craniectomy,n (%) No 3 (75.0%) 3 (75.0%) 6 (75.0%) Yes 1 (25.0%) 3 (75.0%) 6 (75.0%) Respiration Failure,n (%) No 3 (75.0%) 3 (75.0%) 6 (75.0%) Yes 1 (25.0%) 1 (25.0%) 2 (25.0%)	Yes	0 (0.0%)	0 (0.0%)	0 (0.0%)	
Yes 0 (0.0%) <th cols<="" td=""><td>Other Infection,n (%)</td><td></td><td></td><td></td></th>	<td>Other Infection,n (%)</td> <td></td> <td></td> <td></td>	Other Infection,n (%)			
Gastrointestinal bleeding within 7 days after EVT,n (%) No	No	4 (100.0%)	4 (100.0%)	8 (100.0%)	
(%) No 4 (100.0%) 4 (100.0%) 8 (100.0%) Yes 0 (0.0%) 0 (0.0%) 0 (0.0%) Puncture site hematomancture site complication,n (%) Embolism in other locations 0 (0.0%) 0 (0.0%) 0 (0.0%) No 4 (100.0%) 4 (100.0%) 8 (100.0%) Pseudoaneurysm 0 (0.0%) 0 (0.0%) 0 (0.0%) Puncture site hematoma 0 (0.0%) 0 (0.0%) 0 (0.0%) Insulin Use in Hospital Stay,n (%) No 3 (75.0%) 2 (50.0%) 5 (62.5%) Yes 1 (25.0%) 2 (50.0%) 3 (37.5%) Craniectomy,n (%) No 3 (75.0%) 3 (75.0%) 6 (75.0%) Yes 1 (25.0%) 3 (75.0%) 6 (75.0%) Respiration Failure,n (%) No 3 (75.0%) 3 (75.0%) 6 (75.0%) Yes 1 (25.0%) 1 (25.0%) 6 (75.0%)	Yes	0 (0.0%)	0 (0.0%)	0 (0.0%)	
No 4 (100.0%) 4 (100.0%) 8 (100.0%) Yes 0 (0.0%) 0 (0.0%) 0 (0.0%) Puncture site hematomancture site complication,n (%) Embolism in other locations 0 (0.0%) 0 (0.0%) 0 (0.0%) No 4 (100.0%) 4 (100.0%) 8 (100.0%) Pseudoaneurysm 0 (0.0%) 0 (0.0%) 0 (0.0%) Puncture site hematoma 0 (0.0%) 0 (0.0%) 0 (0.0%) Insulin Use in Hospital Stay,n (%) No 3 (75.0%) 2 (50.0%) 5 (62.5%) Yes 1 (25.0%) 2 (50.0%) 3 (37.5%) Craniectomy,n (%) No 3 (75.0%) 3 (75.0%) 6 (75.0%) Yes 1 (25.0%) 3 (75.0%) 6 (75.0%) Respiration Failure,n (%) No 3 (75.0%) 3 (75.0%) 6 (75.0%) Yes 1 (25.0%) 1 (25.0%) 6 (75.0%)	Gastrointestinal bleeding within 7 days after EVT,n				
Yes 0 (0.0%) <th cols<="" td=""><td>(%)</td><td></td><td></td><td></td></th>	<td>(%)</td> <td></td> <td></td> <td></td>	(%)			
Puncture site hematomancture site complication,n (%) Embolism in other locations 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 8 (100.0%) Pseudoaneurysm 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 10 (0.0%)	No	4 (100.0%)	4 (100.0%)	8 (100.0%)	
(%) Embolism in other locations 0 (0.0%) 0 (0.0%) 0 (0.0%) No 4 (100.0%) 4 (100.0%) 8 (100.0%) Pseudoaneurysm 0 (0.0%) 0 (0.0%) 0 (0.0%) Puncture site hematoma 0 (0.0%) 0 (0.0%) 0 (0.0%) Insulin Use in Hospital Stay,n (%) No 3 (75.0%) 2 (50.0%) 5 (62.5%) Yes 1 (25.0%) 2 (50.0%) 3 (37.5%) Craniectomy,n (%) No 3 (75.0%) 3 (75.0%) 6 (75.0%) Yes 1 (25.0%) 1 (25.0%) 2 (25.0%) Respiration Failure,n (%) No 3 (75.0%) 3 (75.0%) 6 (75.0%) Yes 1 (25.0%) 1 (25.0%) 6 (75.0%) Yes 1 (25.0%) 1 (25.0%) 2 (25.0%)	Yes	0 (0.0%)	0 (0.0%)	0 (0.0%)	
Embolism in other locations 0 (0.0%) 0 (0.0%) 0 (0.0%) No 4 (100.0%) 4 (100.0%) 8 (100.0%) Pseudoaneurysm 0 (0.0%) 0 (0.0%) 0 (0.0%) Puncture site hematoma 0 (0.0%) 0 (0.0%) 0 (0.0%) Insulin Use in Hospital Stay,n (%) Ves 2 (50.0%) 5 (62.5%) Yes 1 (25.0%) 2 (50.0%) 3 (37.5%) Craniectomy,n (%) 3 (75.0%) 3 (75.0%) 6 (75.0%) Yes 1 (25.0%) 1 (25.0%) 2 (25.0%) Respiration Failure,n (%) 3 (75.0%) 3 (75.0%) 6 (75.0%) Yes 1 (25.0%) 1 (25.0%) 2 (25.0%)	Puncture site hematomancture site complication,n				
No 4 (100.0%) 4 (100.0%) 8 (100.0% Pseudoaneurysm 0 (0.0%) 0 (0.0%) 0 (0.0%) Puncture site hematoma 0 (0.0%) 0 (0.0%) 0 (0.0%) Insulin Use in Hospital Stay,n (%) No 3 (75.0%) 2 (50.0%) 5 (62.5%) Yes 1 (25.0%) 2 (50.0%) 3 (37.5%) Craniectomy,n (%) No 3 (75.0%) 3 (75.0%) 6 (75.0%) Yes 1 (25.0%) 1 (25.0%) 2 (25.0%) Respiration Failure,n (%) No 3 (75.0%) 3 (75.0%) 6 (75.0%) Yes 1 (25.0%) 1 (25.0%) 2 (25.0%)	(%)				
Pseudoaneurysm 0 (0.0%) 0 (0.0%) 0 (0.0%) Puncture site hematoma 0 (0.0%) 0 (0.0%) Insulin Use in Hospital Stay,n (%) No 3 (75.0%) 2 (50.0%) 5 (62.5%) Yes 1 (25.0%) 2 (50.0%) 3 (37.5%) Craniectomy,n (%) No 3 (75.0%) 3 (75.0%) 6 (75.0%) Yes 1 (25.0%) 1 (25.0%) 2 (25.0%) Respiration Failure,n (%) No 3 (75.0%) 3 (75.0%) 6 (75.0%) Yes 1 (25.0%) 1 (25.0%) 2 (25.0%)	Embolism in other locations	0 (0.0%)	0 (0.0%)	0 (0.0%)	
Puncture site hematoma 0 (0.0%) 0 (0.0%) 0 (0.0%) Insulin Use in Hospital Stay,n (%) No 3 (75.0%) 2 (50.0%) 5 (62.5%) Yes 1 (25.0%) 2 (50.0%) 3 (37.5%) Craniectomy,n (%) No 3 (75.0%) 3 (75.0%) 6 (75.0%) Yes 1 (25.0%) 1 (25.0%) 2 (25.0%) Respiration Failure,n (%) No 3 (75.0%) 3 (75.0%) 6 (75.0%) Yes 1 (25.0%) 1 (25.0%) 2 (25.0%)	No	4 (100.0%)	4 (100.0%)	8 (100.0%)	
Insulin Use in Hospital Stay,n (%) No 3 (75.0%) 2 (50.0%) 5 (62.5%) Yes 1 (25.0%) 2 (50.0%) 3 (37.5%) Craniectomy,n (%) No 3 (75.0%) 3 (75.0%) 6 (75.0%) Yes 1 (25.0%) 1 (25.0%) 2 (25.0%) Respiration Failure,n (%) No 3 (75.0%) 3 (75.0%) 6 (75.0%) Yes 1 (25.0%) 1 (25.0%) 2 (25.0%)	Pseudoaneurysm	0 (0.0%)	0 (0.0%)	0 (0.0%)	
No 3 (75.0%) 2 (50.0%) 5 (62.5%) Yes 1 (25.0%) 2 (50.0%) 3 (37.5%) Craniectomy,n (%) No 3 (75.0%) 3 (75.0%) 6 (75.0%) Yes 1 (25.0%) 1 (25.0%) 2 (25.0%) Respiration Failure,n (%) No 3 (75.0%) 3 (75.0%) 6 (75.0%) Yes 1 (25.0%) 1 (25.0%) 2 (25.0%)	Puncture site hematoma	0 (0.0%)	0 (0.0%)	0 (0.0%)	
Yes 1 (25.0%) 2 (50.0%) 3 (37.5%) Craniectomy,n (%) Section 1 (25.0%) 3 (75.0%) 6 (75.0%) Yes 1 (25.0%) 1 (25.0%) 2 (25.0%) Respiration Failure,n (%) Section 2 (25.0%) 3 (75.0%) 3 (75.0%) 6 (75.0%) Yes 1 (25.0%) 1 (25.0%) 2 (25.0%)	Insulin Use in Hospital Stay,n (%)				
Craniectomy,n (%) No 3 (75.0%) 3 (75.0%) 6 (75.0%) Yes 1 (25.0%) 1 (25.0%) 2 (25.0%) Respiration Failure,n (%) No 3 (75.0%) 3 (75.0%) 6 (75.0%) Yes 1 (25.0%) 1 (25.0%) 2 (25.0%)	No	3 (75.0%)	2 (50.0%)	5 (62.5%)	
No 3 (75.0%) 3 (75.0%) 6 (75.0%) Yes 1 (25.0%) 1 (25.0%) 2 (25.0%) Respiration Failure,n (%) No 3 (75.0%) 3 (75.0%) 6 (75.0%) Yes 1 (25.0%) 1 (25.0%) 2 (25.0%)	Yes	1 (25.0%)	2 (50.0%)	3 (37.5%)	
Yes 1 (25.0%) 1 (25.0%) 2 (25.0%) Respiration Failure,n (%) 3 (75.0%) 3 (75.0%) 6 (75.0%) Yes 1 (25.0%) 1 (25.0%) 2 (25.0%)	Craniectomy,n (%)				
Respiration Failure,n (%) No 3 (75.0%) 3 (75.0%) 6 (75.0%) Yes 1 (25.0%) 1 (25.0%) 2 (25.0%)	No	3 (75.0%)	3 (75.0%)	6 (75.0%)	
No 3 (75.0%) 3 (75.0%) 6 (75.0%) Yes 1 (25.0%) 1 (25.0%) 2 (25.0%)	Yes	1 (25.0%)	1 (25.0%)	2 (25.0%)	
Yes 1 (25.0%) 1 (25.0%) 2 (25.0%)	Respiration Failure,n (%)				
	No	3 (75.0%)	3 (75.0%)	6 (75.0%)	
Circulation Failure, n (%)	Yes	1 (25.0%)	1 (25.0%)	2 (25.0%)	
	Circulation Failure, n (%)				

No	3 (75.0%)	4 (100.0%)	7 (87.5%)
Yes	1 (25.0%)	0 (0.0%)	1 (12.5%)

	Center Order		
		56	
	Group		
	Methylprednisolone	Placebo	Total
	(N=10)	(N=10)	(N=20)
modified Rankin Scale score at 90 days,n (%)			
0	2 (20.0%)	0 (0.0%)	2 (10.0%
1	4 (40.0%)	2 (20.0%)	6 (30.0%
2	0 (0.0%)	0 (0.0%)	0 (0.0%)
3	0 (0.0%)	3 (30.0%)	3 (15.0%
4	1 (10.0%)	2 (20.0%)	3 (15.0%
5	0 (0.0%)	0 (0.0%)	0 (0.0%)
6	3 (30.0%)	3 (30.0%)	6 (30.0%
Missing	0	0	0
Symptomatic intracranial hemorrhage, n (%)			
No	8 (88.9%)	9 (90.0%)	17 (89.5%
Yes	1 (11.1%)	1 (10.0%)	2 (10.5%
Missing	1	0	1
Pneumonia,n (%)			
No	6 (60.0%)	4 (40.0%)	10 (50.0%
Yes	4 (40.0%)	6 (60.0%)	10 (50.0%
Jrinary tract infection,n (%)			
No	10 (100.0%)	10 (100.0%)	20 (100.09
Yes	0 (0.0%)	0 (0.0%)	0 (0.0%)
Other Infection,n (%)			
No	10 (100.0%)	10 (100.0%)	20 (100.0
Yes	0 (0.0%)	0 (0.0%)	0 (0.0%)
Gastrointestinal bleeding within 7 days after EVT,n			
%)			
No	10 (100.0%)	9 (90.0%)	19 (95.0%
Yes	0 (0.0%)	1 (10.0%)	1 (5.0%)

%)			
Embolism in other locations	0 (0.0%)	0 (0.0%)	0 (0.0%
No	10 (100.0%)	10 (100.0%)	20 (100.0
Pseudoaneurysm	0 (0.0%)	0 (0.0%)	0 (0.0%)
Puncture site hematoma	0 (0.0%)	0 (0.0%)	0 (0.0%)
nsulin Use in Hospital Stay,n (%)			
No	8 (80.0%)	8 (80.0%)	16 (80.0%
Yes	2 (20.0%)	2 (20.0%)	4 (20.0%
Craniectomy,n (%)			
No	9 (90.0%)	9 (90.0%)	18 (90.0%
Yes	1 (10.0%)	1 (10.0%)	2 (10.0%
Respiration Failure,n (%)			
No	7 (70.0%)	6 (60.0%)	13 (65.0%
Yes	3 (30.0%)	4 (40.0%)	7 (35.0%
Circulation Failure, n (%)			
No	7 (70.0%)	4 (40.0%)	11 (55.0%
Yes	3 (30.0%)	6 (60.0%)	9 (45.0%

'Chi-Square	p-val	lue;

	Ce	enter Order		
		58 Group		
	Group			
	Methylprednisolone	Placebo	Total	
	(N=17)	(N=18)	(N=35)	
modified Rankin Scale score at 90 days,n (%)				
0	1 (5.9%)	0 (0.0%)	1 (2.9%)	
1	2 (11.8%)	3 (16.7%)	5 (14.3%)	
2	2 (11.8%)	0 (0.0%)	2 (5.7%)	
3	6 (35.3%)	2 (11.1%)	8 (22.9%)	
4	2 (11.8%)	1 (5.6%)	3 (8.6%)	
5	0 (0.0%)	0 (0.0%)	0 (0.0%)	
6	4 (23.5%)	12 (66.7%)	16 (45.7%)	
Missing	0	0	0	
Symptomatic intracranial hemorrhage, n (%)				
No	15 (93.8%)	15 (83.3%)	30 (88.2%)	
Yes	1 (6.3%)	3 (16.7%)	4 (11.8%)	

Missing	1	0	1
Pneumonia,n (%)			
No	8 (47.1%)	4 (22.2%)	12 (34.3%
Yes	9 (52.9%)	14 (77.8%)	23 (65.7%
Jrinary tract infection,n (%)			
No	13 (76.5%)	18 (100.0%)	31 (88.6%
Yes	4 (23.5%)	0 (0.0%)	4 (11.4%
Other Infection,n (%)			
No	16 (94.1%)	17 (94.4%)	33 (94.3%
Yes	1 (5.9%)	1 (5.6%)	2 (5.7%
Gastrointestinal bleeding within 7 days after EVT,n %)			
No No	16 (94.1%)	17 (94.4%)	33 (94.39
Yes	1 (5.9%)	1 (5.6%)	2 (5.7%
Puncture site hematomancture site complication,n			
Embolism in other locations	0 (0.0%)	0 (0.0%)	0 (0.0%
No	17 (100.0%)	18 (100.0%)	35 (100.0
Pseudoaneurysm	0 (0.0%)	0 (0.0%)	0 (0.0%
Puncture site hematoma	0 (0.0%)	0 (0.0%)	0 (0.0%
Insulin Use in Hospital Stay,n (%)			
No	12 (70.6%)	16 (88.9%)	28 (80.09
Yes	5 (29.4%)	2 (11.1%)	7 (20.0%
Craniectomy,n (%)			
No	16 (94.1%)	16 (88.9%)	32 (91.49
Yes	1 (5.9%)	2 (11.1%)	3 (8.6%
Respiration Failure,n (%)			
No	13 (76.5%)	8 (44.4%)	21 (60.09
Yes	4 (23.5%)	10 (55.6%)	14 (40.0%
Circulation Failure, n (%)			
No	13 (76.5%)	9 (50.0%)	22 (62.9%
Yes	4 (23.5%)	9 (50.0%)	13 (37.1%

	C	enter Order	
		59	
	Group		
	Methylprednisolone	Placebo	Total
	(N=2)	(N=2)	(N=4)
modified Rankin Scale score at 90 days,n (%)			
0	0 (0.0%)	0 (0.0%)	0 (0.0%)
1	0 (0.0%)	0 (0.0%)	0 (0.0%)
2	0 (0.0%)	0 (0.0%)	0 (0.0%)
3	2 (100.0%)	0 (0.0%)	2 (50.0%)
4	0 (0.0%)	0 (0.0%)	0 (0.0%)
5	0 (0.0%)	1 (50.0%)	1 (25.0%)
6	0 (0.0%)	1 (50.0%)	1 (25.0%)
Missing	0	0	0
Symptomatic intracranial hemorrhage, n (%)			
No	2 (100.0%)	1 (50.0%)	3 (75.0%)
Yes	0 (0.0%)	1 (50.0%)	1 (25.0%)
Missing	0	0	0
Procure and a result of the second			
Pneumonia,n (%)	0 (0 00()	0 (0 00()	0 (0 00()
	0 (0.0%)	0 (0.0%)	0 (0.0%)
Yes	2 (100.0%)	2 (100.0%)	4 (100.0%)
Urinary tract infection,n (%)			
No	2 (100.0%)	2 (100.0%)	4 (100.0%)
Yes	0 (0.0%)	0 (0.0%)	0 (0.0%)
Other Infection,n (%)	0 (400 00()	0 (400 00()	4 (400 00)
No	2 (100.0%)	2 (100.0%)	4 (100.0%)
Yes	0 (0.0%)	0 (0.0%)	0 (0.0%)
Gastrointestinal bleeding within 7 days after EVT,n			
(%)			
No	2 (100.0%)	1 (50.0%)	3 (75.0%)
Yes	0 (0.0%)	1 (50.0%)	1 (25.0%)
Puncture site hematomancture site complication,n			
(%) Embolism in other locations	0 (0.0%)	0 (0.0%)	0 (0.0%)
No			
	2 (100.0%) 0 (0.0%)	2 (100.0%) 0 (0.0%)	4 (100.0%)
Pseudoaneurysm			0 (0.0%)
Puncture site hematoma	0 (0.0%)	0 (0.0%)	0 (0.0%)

Insulin Use in Hospital Stay,n (%)			
No	2 (100.0%)	2 (100.0%)	4 (100.0%)
Yes	0 (0.0%)	0 (0.0%)	0 (0.0%)
Craniectomy,n (%)			
No	2 (100.0%)	1 (50.0%)	3 (75.0%)
Yes	0 (0.0%)	1 (50.0%)	1 (25.0%)
Respiration Failure,n (%)			
No	2 (100.0%)	0 (0.0%)	2 (50.0%)
Yes	0 (0.0%)	2 (100.0%)	2 (50.0%)
Circulation Failure, n (%)			
No	2 (100.0%)	0 (0.0%)	2 (50.0%)
Yes	0 (0.0%)	2 (100.0%)	2 (50.0%)

¹Chi-Square p-value;

	C	enter Order	
		60	
	Group		
	Methylprednisolone	Placebo	Total
	(N=12)	(N=12)	(N=24)
nodified Rankin Scale score at 90 days,n (%)			
0	0 (0.0%)	0 (0.0%)	0 (0.0%)
1	3 (25.0%)	4 (33.3%)	7 (29.2%)
2	4 (33.3%)	0 (0.0%)	4 (16.7%
3	1 (8.3%)	3 (25.0%)	4 (16.7%
4	2 (16.7%)	3 (25.0%)	5 (20.8%
5	0 (0.0%)	1 (8.3%)	1 (4.2%)
6	2 (16.7%)	1 (8.3%)	3 (12.5%
Missing	0	0	0
ymptomatic intracranial hemorrhage, n (%)			
No	11 (100.0%)	12 (100.0%)	23 (100.09
Yes	0 (0.0%)	0 (0.0%)	0 (0.0%)
Missing	1	0	1
neumonia,n (%)			
No No	4 (33.3%)	5 (41.7%)	9 (37.5%
Yes	8 (66.7%)	7 (58.3%)	15 (62.5%

Urinary tract infection,n (%)			
No	12 (100.0%)	12 (100.0%)	24 (100.09
Yes	0 (0.0%)	0 (0.0%)	0 (0.0%)
165	0 (0.0%)	0 (0.0%)	0 (0.078)
Other Infection,n (%)			
No	11 (91.7%)	12 (100.0%)	23 (95.8%
Yes	1 (8.3%)	0 (0.0%)	1 (4.2%)
Gastrointestinal bleeding within 7 days after EVT,n			
(%)			
No	12 (100.0%)	12 (100.0%)	24 (100.09
Yes	0 (0.0%)	0 (0.0%)	0 (0.0%)
Puncture site hematomancture site complication,n			
(%)			
Embolism in other locations	0 (0.0%)	0 (0.0%)	0 (0.0%)
No	12 (100.0%)	12 (100.0%)	24 (100.0
Pseudoaneurysm	0 (0.0%)	0 (0.0%)	0 (0.0%)
Puncture site hematoma	0 (0.0%)	0 (0.0%)	0 (0.0%)
Insulin Use in Hospital Stay,n (%)			
No	10 (83.3%)	11 (91.7%)	21 (87.5%
Yes	2 (16.7%)	1 (8.3%)	3 (12.5%
Craniectomy,n (%)			
No	12 (100.0%)	11 (91.7%)	23 (95.8%
Yes	0 (0.0%)	1 (8.3%)	1 (4.2%)
103	0 (0.070)	1 (0.070)	1 (4.270)
Respiration Failure,n (%)			
No	10 (83.3%)	9 (75.0%)	19 (79.2%
Yes	2 (16.7%)	3 (25.0%)	5 (20.8%
	2 (16.7%)	3 (25.0%)	5 (20.8%
Yes Circulation Failure, n (%) No	2 (16.7%)	3 (25.0%)	5 (20.8% 23 (95.8%

nodified Rankin Scale score at 90 days,n (%)			
0	0 (0.0%)	0 (0.0%)	0 (0.0%
1	0 (0.0%)	1 (25.0%)	1 (12.5%
2	2 (50.0%)	0 (0.0%)	2 (25.0%
3	0 (0.0%)	0 (0.0%)	0 (0.0%
4	1 (25.0%)	1 (25.0%)	2 (25.0%
5	0 (0.0%)	0 (0.0%)	0 (0.0%
6	1 (25.0%)	2 (50.0%)	3 (37.5%
Missing	0	0	0
Symptomatic intracranial hemorrhage, n (%)			
No	3 (100.0%)	4 (100.0%)	7 (100.0
Yes	0 (0.0%)	0 (0.0%)	0 (0.0%
Missing	1	0	1
Pneumonia,n (%)			
No	2 (50.0%)	3 (75.0%)	5 (62.5%
Yes	2 (50.0%)	1 (25.0%)	3 (37.5%
Jrinary tract infection,n (%)			
No	4 (100.0%)	4 (100.0%)	8 (100.0
Yes	0 (0.0%)	0 (0.0%)	0 (0.0%
Other Infection,n (%)	4 (400 00()	4 (400 00()	0 (400 0
No	4 (100.0%)	4 (100.0%)	8 (100.0
Yes	0 (0.0%)	0 (0.0%)	0 (0.0%
Gastrointestinal bleeding within 7 days after EVT,n			
%)			
No	4 (100.0%)	4 (100.0%)	8 (100.0
Yes	0 (0.0%)	0 (0.0%)	0 (0.0%
Puncture site hematomancture site complication,n			
%)			
Embolism in other locations	0 (0.0%)	0 (0.0%)	0 (0.0%
No	4 (100.0%)	4 (100.0%)	8 (100.0
Pseudoaneurysm	0 (0.0%)	0 (0.0%)	0 (0.0%
Puncture site hematoma	0 (0.0%)	0 (0.0%)	0 (0.0%
nsulin Use in Hospital Stay,n (%)			
No	4 (100.0%)	3 (75.0%)	7 (87.5%
Yes	0 (0.0%)	1 (25.0%)	1 (12.5%

Craniectomy,n (%)			
No	3 (75.0%)	4 (100.0%)	7 (87.5%)
Yes	1 (25.0%)	0 (0.0%)	1 (12.5%)
Respiration Failure,n (%)			
No	3 (75.0%)	3 (75.0%)	6 (75.0%)
Yes	1 (25.0%)	1 (25.0%)	2 (25.0%)
Circulation Failure, n (%)			
No	3 (75.0%)	4 (100.0%)	7 (87.5%)
Yes	1 (25.0%)	0 (0.0%)	1 (12.5%)
¹Chi-Square p-value:			

¹Chi-Square p-value;

		Ce	enter Order	
Methylprednisolone Placebo Total (N=2) (N=2) (N=4) (N=4) (N=4)			62	
No		Group		
1 (50.0%)		Methylprednisolone	Placebo	Total
1 (50.0%) 0 (0.0%) 1 (25.0%) 1 (0.0%) 1 (50.0%) 1 (25.0%) 1 (0.0%) 1 (50.0%) 1 (25.0%) 2 (0 (0.0%) 0 (0.0%) 0 (0.0%) 3 (0 (0.0%) 0 (0.0%) 0 (0.0%) 4 (0 (0.0%) 0 (0.0%) 0 (0.0%) 5 (0 (0.0%) 0 (0.0%) 0 (0.0%) 6 (1 (50.0%) 1 (50.0%) 2 (50.0%) Missing 0 0 0 0 Symptomatic intracranial hemorrhage, n (%) No 2 (100.0%) 2 (100.0%) 4 (100.0%) Yes 0 (0.0%) 0 (0.0%) 0 (0.0%) Missing 0 0 0 0 Preumonia,n (%) No 1 (50.0%) 1 (50.0%) 2 (50.0% Yes 1 (50.0%) 1 (50.0%) 2 (50.0%		(N=2)	(N=2)	(N=4)
1 0 (0.0%) 1 (50.0%) 1 (25.0%) 2 0 (0.0%) 0 (0.0%) 0 (0.0%) 3 0 (0.0%) 0 (0.0%) 0 (0.0%) 4 0 (0.0%) 0 (0.0%) 0 (0.0%) 5 0 (0.0%) 0 (0.0%) 0 (0.0%) 6 1 (50.0%) 1 (50.0%) 2 (50.0%) Missing 0 0 0 0 Symptomatic intracranial hemorrhage, n (%) No 2 (100.0%) 2 (100.0%) 4 (100.0%) Yes 0 (0.0%) 0 (0.0%) 0 (0.0%) Missing 0 0 0 0 Pneumonia,n (%) No 1 (50.0%) 1 (50.0%) 2 (50.0%) Yes 1 (50.0%) 1 (50.0%) 2 (50.0%) Yes 1 (50.0%) 1 (50.0%) 2 (50.0%) Yes 1 (50.0%) 1 (50.0%) 2 (50.0%) Urinary tract infection,n (%)	modified Rankin Scale score at 90 days,n (%)			
2 0 (0.0%) 0 (0.0%) 0 (0.0%) 3 0 (0.0%) 0 (0.0%) 0 (0.0%) 4 0 (0.0%) 0 (0.0%) 0 (0.0%) 5 0 (0.0%) 0 (0.0%) 0 (0.0%) 6 1 (50.0%) 1 (50.0%) 2 (50.0% Missing 0 0 0 0 Symptomatic intracranial hemorrhage, n (%) No 2 (100.0%) 2 (100.0%) 4 (100.0%) Yes 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0% Missing 0 0 0 0 Pneumonia,n (%) No 1 (50.0%) 1 (50.0%) 2 (50.0% Yes 1 (50.0%) 1 (50.0%) 2 (50.0% Yes 1 (50.0%) 1 (50.0%) 2 (50.0% Yes 1 (50.0%) 3 (75.0%	0	1 (50.0%)	0 (0.0%)	1 (25.0%
3 0 (0.0%) 0 (0.0%) 0 (0.0% 4 0 (0.0%) 0 (0.0%) 0 (0.09 5 0 (0.0%) 0 (0.0%) 0 (0.09 6 1 (50.0%) 1 (50.0%) 2 (50.09 Missing 0 0 0 0 Symptomatic intracranial hemorrhage, n (%) No 2 (100.0%) 2 (100.0%) 4 (100.09 Yes 0 (0.0%) 0 (0.0%) 0 (0.09 Missing 0 0 0 0 Pneumonia,n (%) No 1 (50.0%) 1 (50.0%) 2 (50.09 Yes 1 (50.0%) 1 (50.0%) 2 (50.09 Urinary tract infection,n (%)	1	0 (0.0%)	1 (50.0%)	1 (25.0%
4 0 (0.0%) 0 (0.0%) 0 (0.0%) 5 0 (0.0%) 0 (0.0%) 0 (0.0%) 6 1 (50.0%) 1 (50.0%) 2 (50.0% Missing 0 0 0 0 Symptomatic intracranial hemorrhage, n (%) No 2 (100.0%) 2 (100.0%) 4 (100.0% Yes 0 (0.0%) 0 (0.0%) 0 (0.0%) Missing 0 0 0 0 Pneumonia,n (%) No 1 (50.0%) 1 (50.0%) 2 (50.0% Yes 1 (50.0%) 1 (50.0%) 2 (50.0% Yes 1 (50.0%) 3 (75.0%	2	0 (0.0%)	0 (0.0%)	0 (0.0%
5 0 (0.0%) 0 (0.0%) 0 (0.0%) 6 1 (50.0%) 1 (50.0%) 2 (50.0% Missing 0 0 0 0 Symptomatic intracranial hemorrhage, n (%) No 2 (100.0%) 2 (100.0%) 4 (100.0% Yes 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0% Missing 0 0 0 0 Pneumonia,n (%) No 1 (50.0%) 1 (50.0%) 2 (50.0% Yes 1 (50.0%) 1 (50.0%) 2 (50.0% Yes 1 (50.0%) 3 (75.0%	3	0 (0.0%)	0 (0.0%)	0 (0.0%
6 1 (50.0%) 1 (50.0%) 2 (50.0%) Missing 0 0 0 0 Symptomatic intracranial hemorrhage, n (%) No 2 (100.0%) 2 (100.0%) 4 (100.0%) Yes 0 (0.0%) 0 (0.0%) 0 (0.0%) Missing 0 0 0 0 Pneumonia,n (%) No 1 (50.0%) 1 (50.0%) 2 (50.0% Yes 1 (50.0%) 1 (50.0%) 2 (50.0% Yes 1 (50.0%) 3 (75.0%	4	0 (0.0%)	0 (0.0%)	0 (0.0%
Missing 0 0 0 0 Symptomatic intracranial hemorrhage, n (%) No 2 (100.0%) 2 (100.0%) 4 (100.0 Yes 0 (0.0%) 0 (0.0%) 0 (0.0%) Missing 0 0 0 0 Pneumonia,n (%) No 1 (50.0%) 1 (50.0%) 2 (50.0% Yes 1 (50.0%) 1 (50.0%) 2 (50.0% Urinary tract infection,n (%) No 1 (50.0%) 2 (100.0%) 3 (75.0%	5	0 (0.0%)	0 (0.0%)	0 (0.0%
No 2 (100.0%) 2 (100.0%) 4 (100.0%) Yes 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) Missing 0 0 0 0 0	6	1 (50.0%)	1 (50.0%)	2 (50.0%
No 2 (100.0%) 2 (100.0%) 4 (100.0%) Yes 0 (0.0%) 0 (0.0%) 0 (0.0%) Missing 0 0 0 Pneumonia,n (%) No 1 (50.0%) 1 (50.0%) 2 (50.0%) Yes 1 (50.0%) 1 (50.0%) 2 (50.0%) Urinary tract infection,n (%) No 1 (50.0%) 2 (100.0%) 3 (75.0%)	Missing	0	0	0
No 2 (100.0%) 2 (100.0%) 4 (100.0%) Yes 0 (0.0%) 0 (0.0%) 0 (0.0%) Missing 0 0 0 Pneumonia,n (%) No 1 (50.0%) 1 (50.0%) 2 (50.0%) Yes 1 (50.0%) 1 (50.0%) 2 (50.0%) Urinary tract infection,n (%) No 1 (50.0%) 2 (100.0%) 3 (75.0%)				
Yes 0 (0.0%) 0 (0.0%) 0 (0.0%) Missing 0 0 0 Pneumonia,n (%) No 1 (50.0%) 1 (50.0%) 2 (50.0%) Yes 1 (50.0%) 1 (50.0%) 2 (50.0%) Urinary tract infection,n (%) No 1 (50.0%) 2 (100.0%) 3 (75.0%)	Symptomatic intracranial hemorrhage, n (%)			
Missing 0 0 0 Pneumonia,n (%) No 1 (50.0%) 1 (50.0%) 2 (50.0%) Yes 1 (50.0%) 1 (50.0%) 2 (50.0%) Urinary tract infection,n (%) No 1 (50.0%) 2 (100.0%) 3 (75.0%)	No	2 (100.0%)	2 (100.0%)	4 (100.0%
Pneumonia,n (%) No 1 (50.0%) 1 (50.0%) 2 (50.0%) Yes 1 (50.0%) 1 (50.0%) 2 (50.0%) Urinary tract infection,n (%) No 1 (50.0%) 2 (100.0%) 3 (75.0%)	Yes	0 (0.0%)	0 (0.0%)	0 (0.0%
No 1 (50.0%) 1 (50.0%) 2 (50.0%) Yes 1 (50.0%) 1 (50.0%) 2 (50.0%) Urinary tract infection,n (%) No 1 (50.0%) 2 (100.0%) 3 (75.0%)	Missing	0	0	0
No 1 (50.0%) 1 (50.0%) 2 (50.0%) Yes 1 (50.0%) 1 (50.0%) 2 (50.0%) Urinary tract infection,n (%) No 1 (50.0%) 2 (100.0%) 3 (75.0%)				
Yes 1 (50.0%) 1 (50.0%) 2 (50.0%) Urinary tract infection,n (%) No 1 (50.0%) 2 (100.0%) 3 (75.0%)	Pneumonia,n (%)			
Urinary tract infection,n (%) No 1 (50.0%) 2 (100.0%) 3 (75.0%)	No	1 (50.0%)	1 (50.0%)	2 (50.0%
No 1 (50.0%) 2 (100.0%) 3 (75.0%)	Yes	1 (50.0%)	1 (50.0%)	2 (50.0%
No 1 (50.0%) 2 (100.0%) 3 (75.0%)				
	Urinary tract infection,n (%)			
Yes 1 (50.0%) 0 (0.0%) 1 (25.0%)	No	1 (50.0%)	2 (100.0%)	3 (75.0%
	Yes	1 (50.0%)	0 (0.0%)	1 (25.0%
	Other Infection,n (%)			

No	2 (100.0%)	2 (100.0%)	4 (100.0%)
Yes	0 (0.0%)	0 (0.0%)	0 (0.0%)
Gastrointestinal bleeding within 7 days after EVT,n			
(%)			
No	2 (100.0%)	2 (100.0%)	4 (100.0%)
Yes	0 (0.0%)	0 (0.0%)	0 (0.0%)
Puncture site hematomancture site complication,n			
(%)			
Embolism in other locations	0 (0.0%)	0 (0.0%)	0 (0.0%)
No	2 (100.0%)	2 (100.0%)	4 (100.0%)
Pseudoaneurysm	0 (0.0%)	0 (0.0%)	0 (0.0%)
Puncture site hematoma	0 (0.0%)	0 (0.0%)	0 (0.0%)
Insulin Use in Hospital Stay,n (%)	0 (400 00)	0 (400 00()	4 (400 00()
No	2 (100.0%)	2 (100.0%)	4 (100.0%)
Yes	0 (0.0%)	0 (0.0%)	0 (0.0%)
Cranicatomy n (9/)			
Craniectomy,n (%) No	1 (50 0%)	1 (50 0%)	2 (50 0%)
Yes	1 (50.0%) 1 (50.0%)	1 (50.0%) 1 (50.0%)	2 (50.0%) 2 (50.0%)
165	1 (30.0%)	1 (50.070)	2 (30.070)
Respiration Failure,n (%)			
No	1 (50.0%)	1 (50.0%)	2 (50.0%)
Yes	1 (50.0%)	1 (50.0%)	2 (50.0%)
	(,	(,	()
Circulation Failure, n (%)			
No	1 (50.0%)	0 (0.0%)	1 (25.0%)
Yes	1 (50.0%)	2 (100.0%)	3 (75.0%)
¹Chi-Square p-value;			
	C	enter Order	
		64	
	Group		
	Methylprednisolone	Placebo	Total
	(N=6)	(N=6)	(N=12)
modified Rankin Scale score at 90 days,n (%)			
0	0 (0.0%)	0 (0.0%)	0 (0.0%)
1	1 (16.7%)	0 (0.0%)	1 (8.3%)

0 (0.0%)

1 (16.7%)

1 (16.7%)

0 (0.0%)

1 (8.3%)

1 (8.3%)

2

3

4	2 (33.3%)	2 (33.3%)	4 (33.3%)
5	0 (0.0%)	0 (0.0%)	0 (0.0%)
6	2 (33.3%)	3 (50.0%)	5 (41.7%)
Missing	0	0	0
Symptomatic intracranial hemorrhage, n (%)			
No	5 (100.0%)	5 (83.3%)	10 (90.9%)
Yes	0 (0.0%)	1 (16.7%)	1 (9.1%)
Missing	1	0	1
Pneumonia,n (%)			
No	2 (33.3%)	2 (33.3%)	4 (33.3%)
Yes	4 (66.7%)	4 (66.7%)	8 (66.7%)
Urinary tract infection,n (%)			
No	5 (83.3%)	5 (83.3%)	10 (83.3%)
Yes	1 (16.7%)	1 (16.7%)	2 (16.7%)
Other Infection,n (%)			
No	6 (100.0%)	6 (100.0%)	12 (100.0%)
Yes	0 (0.0%)	0 (0.0%)	0 (0.0%)
Gastrointestinal bleeding within 7 days after EVT,n			
(%)			
No	6 (100.0%)	6 (100.0%)	12 (100.0%)
Yes	0 (0.0%)	0 (0.0%)	0 (0.0%)
	,	,	, ,
Puncture site hematomancture site complication,n			
(%)			
Embolism in other locations	0 (0.0%)	0 (0.0%)	0 (0.0%)
No	6 (100.0%)	6 (100.0%)	12 (100.0%)
Pseudoaneurysm	0 (0.0%)	0 (0.0%)	0 (0.0%)
Puncture site hematoma	0 (0.0%)	0 (0.0%)	0 (0.0%)
Insulin Use in Hospital Stay,n (%)			
No	5 (83.3%)	3 (50.0%)	8 (66.7%)
Yes	1 (16.7%)	3 (50.0%)	4 (33.3%)
Craniectomy,n (%)			
No	6 (100.0%)	6 (100.0%)	12 (100.0%)
Yes	0 (0.0%)	0 (0.0%)	0 (0.0%)
Respiration Failure,n (%)			
No	4 (66.7%)	2 (33.3%)	6 (50.0%)

Yes	2 (33.3%)	4 (66.7%)	6 (50.0%)
Circulation Failure, n (%)			
No	5 (83.3%)	2 (33.3%)	7 (58.3%)
Yes	1 (16.7%)	4 (66.7%)	5 (41.7%)

	C	enter Order	
		65	
	Group		
	Methylprednisolone	Placebo	Total
	(N=3)	(N=4)	(N=7)
modified Rankin Scale score at 90 days,n (%)			
0	0 (0.0%)	0 (0.0%)	0 (0.0%
1	0 (0.0%)	1 (25.0%)	1 (14.3%
2	0 (0.0%)	0 (0.0%)	0 (0.0%)
3	0 (0.0%)	1 (25.0%)	1 (14.3%
4	0 (0.0%)	0 (0.0%)	0 (0.0%
5	1 (33.3%)	0 (0.0%)	1 (14.3%
6	2 (66.7%)	2 (50.0%)	4 (57.1%
Missing	0	0	0
Symptomatic intracranial hemorrhage, n (%)			
No	3 (100.0%)	4 (100.0%)	7 (100.09
Yes	0 (0.0%)	0 (0.0%)	0 (0.0%
Missing	0	0	0
Pneumonia,n (%)			
No	1 (33.3%)	3 (75.0%)	4 (57.1%
Yes	2 (66.7%)	1 (25.0%)	3 (42.9%
	,	, ,	•
Urinary tract infection,n (%)			
No	3 (100.0%)	4 (100.0%)	7 (100.09
Yes	0 (0.0%)	0 (0.0%)	0 (0.0%
Other Infection,n (%)			
No	3 (100.0%)	4 (100.0%)	7 (100.09
Yes	0 (0.0%)	0 (0.0%)	0 (0.0%
	3 (3.070)	0 (0.070)	0 (0.070
Gastrointestinal bleeding within 7 days after EVT,n			
(%)			
No	3 (100.0%)	4 (100.0%)	7 (100.09

Yes	0 (0.0%)	0 (0.0%)	0 (0.0%)
Puncture site hematomancture site complication,n			
(%)			
Embolism in other locations	0 (0.0%)	0 (0.0%)	0 (0.0%)
No	3 (100.0%)	4 (100.0%)	7 (100.0%)
Pseudoaneurysm	0 (0.0%)	0 (0.0%)	0 (0.0%)
Puncture site hematoma	0 (0.0%)	0 (0.0%)	0 (0.0%)
Insulin Use in Hospital Stay,n (%)			
No	1 (33.3%)	4 (100.0%)	5 (71.4%)
Yes	2 (66.7%)	0 (0.0%)	2 (28.6%)
Craniectomy,n (%)			
No	2 (66.7%)	4 (100.0%)	6 (85.7%)
Yes	1 (33.3%)	0 (0.0%)	1 (14.3%)
Respiration Failure,n (%)			
No	1 (33.3%)	3 (75.0%)	4 (57.1%)
Yes	2 (66.7%)	1 (25.0%)	3 (42.9%)
Circulation Failure, n (%)			
No	1 (33.3%)	3 (75.0%)	4 (57.1%)
Yes	2 (66.7%)	1 (25.0%)	3 (42.9%)

¹Chi-Square p-value;

	Ce	enter Order	
	Methylprednisolone	Placebo	Total
	(N=5)	(N=4)	(N=9)
modified Rankin Scale score at 90 days,n (%)			
0	0 (0.0%)	0 (0.0%)	0 (0.0%)
1	0 (0.0%)	1 (25.0%)	1 (12.5%)
2	0 (0.0%)	1 (25.0%)	1 (12.5%)
3	1 (25.0%)	1 (25.0%)	2 (25.0%)
4	0 (0.0%)	1 (25.0%)	1 (12.5%)
5	2 (50.0%)	0 (0.0%)	2 (25.0%)
6	1 (25.0%)	0 (0.0%)	1 (12.5%)
Missing	1	0	1

Symptomatic intracranial hemorrhage, n (%)

No	5 (100.0%)	4 (100.0%)	9 (100.0%
Yes	0 (0.0%)	0 (0.0%)	0 (0.0%)
Missing	0	0	0
Pneumonia,n (%)			
No	3 (60.0%)	4 (100.0%)	7 (77.8%)
Yes	2 (40.0%)	0 (0.0%)	2 (22.2%)
Urinary tract infection,n (%)			
No	5 (100.0%)	4 (100.0%)	9 (100.0%
Yes	0 (0.0%)	0 (0.0%)	0 (0.0%)
Other Infection,n (%)			
No	4 (80.0%)	4 (100.0%)	8 (88.9%
Yes	1 (20.0%)	0 (0.0%)	1 (11.1%
Gastrointestinal bleeding within 7 days after EVT,n			
No	5 (100.0%)	4 (100.0%)	9 (100.0%
Yes	0 (0.0%)	0 (0.0%)	0 (0.0%)
Puncture site hematomancture site complication,n			
Embolism in other locations	0 (0.0%)	0 (0.0%)	0 (0.0%)
No	5 (100.0%)	4 (100.0%)	9 (100.0%
Pseudoaneurysm	0 (0.0%)	0 (0.0%)	0 (0.0%)
Puncture site hematoma	0 (0.0%)	0 (0.0%)	0 (0.0%)
nsulin Use in Hospital Stay,n (%)			
No	4 (80.0%)	4 (100.0%)	8 (88.9%
Yes	1 (20.0%)	0 (0.0%)	1 (11.1%
Craniectomy,n (%)			
No	5 (100.0%)	4 (100.0%)	9 (100.0%
Yes	0 (0.0%)	0 (0.0%)	0 (0.0%)
Respiration Failure,n (%)			
No	3 (60.0%)	2 (50.0%)	5 (55.6%
Yes	2 (40.0%)	2 (50.0%)	4 (44.4%
Circulation Failure, n (%)			
No	4 (80.0%)	4 (100.0%)	8 (88.9%
Yes	1 (20.0%)	0 (0.0%)	1 (11.1%

¹Chi-Square p-value;

	C	Center Order 68		
	Group			
	Methylprednisolone	Placebo	Total	
	(N=15)	(N=16)	(N=31)	
modified Rankin Scale score at 90 days,n (%)				
0	0 (0.0%)	2 (12.5%)	2 (6.5%)	
1	6 (40.0%)	1 (6.3%)	7 (22.6%	
2	2 (13.3%)	3 (18.8%)	5 (16.1%	
3	1 (6.7%)	1 (6.3%)	2 (6.5%)	
4	2 (13.3%)	2 (12.5%)	4 (12.9%	
5	1 (6.7%)	2 (12.5%)	3 (9.7%)	
6	3 (20.0%)	5 (31.3%)	8 (25.8%	
Missing	0	0	0	
Symptomatic intracranial hemorrhage, n (%)				
No	15 (100.0%)	12 (75.0%)	27 (87.1%	
Yes	0 (0.0%)	4 (25.0%)	4 (12.9%	
Missing	0	0	0	
2000-2010 v (0/)				
Pneumonia,n (%) No	4 (26 79/)	1 (6 20/)	E /16 10/	
	4 (26.7%)	1 (6.3%)	5 (16.1%	
Yes	11 (73.3%)	15 (93.8%)	26 (83.9%	
Urinary tract infection,n (%)				
No	12 (80.0%)	16 (100.0%)	28 (90.3%	
Yes	3 (20.0%)	0 (0.0%)	3 (9.7%)	
Other Infection n (0/)				
Other Infection,n (%) No	14 (93.3%)	14 (87.5%)	28 (90.3%	
Yes	1 (6.7%)	2 (12.5%)	3 (9.7%	
165	1 (0.778)	2 (12.070)	0 (0.170	
Gastrointestinal bleeding within 7 days after EVT,n				
%)				
No	14 (93.3%)	14 (87.5%)	28 (90.3%	
Yes	1 (6.7%)	2 (12.5%)	3 (9.7%)	
Puncture site hematomancture site complication,n				
%)				
Embolism in other locations	0 (0.0%)	0 (0.0%)	0 (0.0%)	
No	14 (93.3%)	15 (93.8%)	29 (93.5%	

Pseudoaneurysm	1 (6.7%)	0 (0.0%)	1 (3.2%)
Puncture site hematoma	0 (0.0%)	1 (6.3%)	1 (3.2%)
Insulin Use in Hospital Stay,n (%)			
No	14 (93.3%)	12 (75.0%)	26 (83.9%)
Yes	1 (6.7%)	4 (25.0%)	5 (16.1%)
Craniectomy,n (%)			
No	15 (100.0%)	16 (100.0%)	31 (100.0%)
Yes	0 (0.0%)	0 (0.0%)	0 (0.0%)
Respiration Failure,n (%)			
No	13 (86.7%)	10 (62.5%)	23 (74.2%)
Yes	2 (13.3%)	6 (37.5%)	8 (25.8%)
Circulation Failure, n (%)			
No	13 (86.7%)	13 (81.3%)	26 (83.9%)
Yes	2 (13.3%)	3 (18.8%)	5 (16.1%)

¹Chi-Square p-value;

	Ce	enter Order	
		69	
	Group		
	Methylprednisolone	Placebo	Total
	(N=6)	(N=7)	(N=13)
nodified Rankin Scale score at 90 days,n (%)			
0	0 (0.0%)	0 (0.0%)	0 (0.0%)
1	1 (16.7%)	0 (0.0%)	1 (7.7%)
2	1 (16.7%)	0 (0.0%)	1 (7.7%)
3	3 (50.0%)	0 (0.0%)	3 (23.1%
4	0 (0.0%)	2 (28.6%)	2 (15.4%
5	0 (0.0%)	0 (0.0%)	0 (0.0%)
6	1 (16.7%)	5 (71.4%)	6 (46.2%
Missing	0	0	0
Symptomatic intracranial hemorrhage, n (%)			
No	5 (83.3%)	4 (57.1%)	9 (69.2%
Yes	1 (16.7%)	3 (42.9%)	4 (30.8%
Missing	0	0	0
Pneumonia,n (%)			
No	6 (100.0%)	0 (0.0%)	6 (46.2%

0 (0.0%) 5 (83.3%) 1 (16.7%) 6 (100.0%)	7 (100.0%) 7 (100.0%) 0 (0.0%)	7 (53.8% 12 (92.3% 1 (7.7%)
1 (16.7%) 6 (100.0%)	, ,	,
1 (16.7%) 6 (100.0%)	, ,	,
6 (100.0%)	0 (0.0%)	1 (7.7%)
0 (0 00()	7 (100.0%)	13 (100.09
0 (0.0%)	0 (0.0%)	0 (0.0%)
6 (100 0%)	5 (71 4%)	11 (84.6%
	2 (28.6%)	2 (15.4%
,	, ,	,
0 (0.0%)	0 (0.0%)	0 (0.0%)
6 (100.0%)	7 (100.0%)	13 (100.0
0 (0.0%)	0 (0.0%)	0 (0.0%)
0 (0.0%)	0 (0.0%)	0 (0.0%)
5 (83.3%)	6 (85.7%)	11 (84.6%
1 (16.7%)	1 (14.3%)	2 (15.4%
6 (100.0%)	7 (100.0%)	13 (100.0
0 (0.0%)	0 (0.0%)	0 (0.0%)
4 (66.7%)	1 (14.3%)	5 (38.5%
2 (33.3%)	6 (85.7%)	8 (61.5%
5 (83.3%)	3 (42.9%)	8 (61.5%
1 (16.7%)	4 (57.1%)	5 (38.5%
Center Order		
	70	
_		
Group Methylprednisolone	Placebo	Total
	6 (100.0%) 0 (0.0%) 5 (83.3%) 1 (16.7%) 6 (100.0%) 0 (0.0%) 4 (66.7%) 2 (33.3%) 5 (83.3%) 1 (16.7%)	0 (0.0%) 2 (28.6%) 0 (0.0%) 0 (0.0%) 6 (100.0%) 7 (100.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 5 (83.3%) 6 (85.7%) 1 (16.7%) 1 (14.3%) 6 (100.0%) 7 (100.0%) 0 (0.0%) 0 (0.0%) 4 (66.7%) 1 (14.3%) 2 (33.3%) 6 (85.7%) 5 (83.3%) 3 (42.9%) 1 (16.7%) 4 (57.1%)

edified Rankin Scale score at 90 days,n (%)	(N=2) 2 (100.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%)	0 (0.0%) 0 (0.0%) 0 (0.0%)	(N=4) 2 (50.0%) 0 (0.0%)
2	0 (0.0%) 0 (0.0%) 0 (0.0%)	0 (0.0%) 0 (0.0%)	
2 3 4	0 (0.0%) 0 (0.0%) 0 (0.0%)	0 (0.0%) 0 (0.0%)	
2 3 1	0 (0.0%) 0 (0.0%)	0 (0.0%)	0 (0.0%)
3 L	0 (0.0%)		0 (0 00()
		0 (0 00()	0 (0.0%)
	0 (0.0%)	0 (0.0%)	0 (0.0%)
	0 (0 00()	0 (0.0%)	0 (0.0%)
	0 (0.0%)	1 (50.0%)	1 (25.0%)
	0 (0.0%)	1 (50.0%)	1 (25.0%)
Missing	0	0	0
mptomatic intracranial hemorrhage, n (%)			
No	2 (100.0%)	2 (100.0%)	4 (100.0%
/es	0 (0.0%)	0 (0.0%)	0 (0.0%)
Missing	0	0	0
eumonia,n (%)			
No	2 (100.0%)	0 (0.0%)	2 (50.0%)
'es	0 (0.0%)	2 (100.0%)	2 (50.0%)
nary tract infection,n (%)			
No	2 (100.0%)	2 (100.0%)	4 (100.0%
/es	0 (0.0%)	0 (0.0%)	0 (0.0%)
ner Infection,n (%)			
No	2 (100.0%)	2 (100.0%)	4 (100.0%
⁄es	0 (0.0%)	0 (0.0%)	0 (0.0%)
strointestinal bleeding within 7 days after EVT,n			
No	2 (100.0%)	2 (100.0%)	4 (100.0%
/es	0 (0.0%)	0 (0.0%)	0 (0.0%)
ncture site hematomancture site complication,n			
Embolism in other locations	0 (0.0%)	0 (0.0%)	0 (0.0%)
No	2 (100.0%)	2 (100.0%)	4 (100.0%
Pseudoaneurysm	0 (0.0%)	0 (0.0%)	0 (0.0%)
Puncture site hematoma	0 (0.0%)	0 (0.0%)	0 (0.0%)
ulin Use in Hospital Stay,n (%)			
No.	2 (100.0%)	2 (100.0%)	4 (100.0%
/es	0 (0.0%)	0 (0.0%)	0 (0.0%)

Craniectomy,n (%)			
No	2 (100.0%)	2 (100.0%)	4 (100.0%)
Yes	0 (0.0%)	0 (0.0%)	0 (0.0%)
Respiration Failure,n (%)			
No	2 (100.0%)	1 (50.0%)	3 (75.0%)
Yes	0 (0.0%)	1 (50.0%)	1 (25.0%)
Circulation Failure, n (%)			
No	2 (100.0%)	1 (50.0%)	3 (75.0%)
Yes	0 (0.0%)	1 (50.0%)	1 (25.0%)

¹Chi-Square p-value;

	Ce	enter Order		
	71			
	Group			
	Methylprednisolone	Placebo	Total	
	(N=8)	(N=8)	(N=16)	
nodified Rankin Scale score at 90 days,n (%)				
0	1 (12.5%)	1 (12.5%)	2 (12.5%	
1	1 (12.5%)	1 (12.5%)	2 (12.5%	
2	2 (25.0%)	2 (25.0%)	4 (25.0%	
3	0 (0.0%)	0 (0.0%)	0 (0.0%	
4	1 (12.5%)	2 (25.0%)	3 (18.8%	
5	1 (12.5%)	1 (12.5%)	2 (12.5%	
6	2 (25.0%)	1 (12.5%)	3 (18.8%	
Missing	0	0	0	
Symptomatic intracranial hemorrhage, n (%)				
No	7 (87.5%)	7 (87.5%)	14 (87.5%	
Yes	1 (12.5%)	1 (12.5%)	2 (12.5%	
Missing	0	0	0	
Pneumonia,n (%)				
No	3 (37.5%)	4 (50.0%)	7 (43.8%	
Yes	5 (62.5%)	4 (50.0%)	9 (56.3%	
Jrinary tract infection,n (%)				
No	8 (100.0%)	8 (100.0%)	16 (100.0°	
Yes	0 (0.0%)	0 (0.0%)	0 (0.0%)	

No	8 (100.0%)	8 (100.0%)	16 (100.0%
Yes	0 (0.0%)	0 (0.0%)	0 (0.0%)
165	0 (0.0%)	0 (0.070)	0 (0.070)
Gastrointestinal bleeding within 7 days after EVT,n			
%)			
No	5 (62.5%)	7 (87.5%)	12 (75.0%
Yes	3 (37.5%)	1 (12.5%)	4 (25.0%
Puncture site hematomancture site complication,n			
%)			
Embolism in other locations	0 (0.0%)	0 (0.0%)	0 (0.0%)
No	8 (100.0%)	8 (100.0%)	16 (100.09
Pseudoaneurysm	0 (0.0%)	0 (0.0%)	0 (0.0%)
Puncture site hematoma	0 (0.0%)	0 (0.0%)	0 (0.0%)
manific Has in Hasnifal Charry (0/)			
nsulin Use in Hospital Stay,n (%) No	F (60 FN)	0 (400 00/)	40 (04 00
	5 (62.5%)	8 (100.0%)	13 (81.3%
Yes	3 (37.5%)	0 (0.0%)	3 (18.8%
Craniectomy,n (%)			
No	8 (100.0%)	8 (100.0%)	16 (100.0
Yes	0 (0.0%)	0 (0.0%)	0 (0.0%)
Respiration Failure,n (%)			
No	0 (0.0%)	6 (75.0%)	6 (37.5%
Yes	8 (100.0%)	2 (25.0%)	10 (62.5%
Circulation Failure, n (%)			
No No	8 (100.0%)	8 (100.0%)	16 (100.09
Yes	0 (0.0%)	0 (0.0%)	0 (0.0%)

	Ce	enter Order	
		72	
	Group		
	Methylprednisolone	Placebo	Total
	(N=7)	(N=8)	(N=15)
modified Rankin Scale score at 90 days,n (%)			
0	1 (14.3%)	0 (0.0%)	1 (6.7%)
1	1 (14.3%)	1 (12.5%)	2 (13.3%)
2	1 (14.3%)	1 (12.5%)	2 (13.3%)

3	2 (20 60/)	4 (40 50/)	2 (20 00()
4	2 (28.6%)	1 (12.5%)	3 (20.0%)
5	0 (0.0%)	1 (12.5%)	1 (6.7%)
6	0 (0.0%)	0 (0.0%)	0 (0.0%)
	2 (28.6%)	4 (50.0%)	6 (40.0%)
Missing	0	0	0
Symptomatic intracranial hemorrhage, n (%)			
No	7 (100.0%)	4 (57.1%)	11 (78.6%
Yes	0 (0.0%)	3 (42.9%)	3 (21.4%
Missing	0	1	1
Pneumonia,n (%)			
No	3 (42.9%)	3 (37.5%)	6 (40.0%
Yes	4 (57.1%)	5 (62.5%)	9 (60.0%
Jrinary tract infection,n (%)			
No	7 (100.0%)	8 (100.0%)	15 (100.09
Yes	0 (0.0%)	0 (0.0%)	0 (0.0%)
Other Infection,n (%)			
No	6 (85.7%)	8 (100.0%)	14 (93.3%
Yes	1 (14.3%)	0 (0.0%)	1 (6.7%)
Gastrointestinal bleeding within 7 days after EVT,n			
%)			
No	6 (85.7%)	6 (75.0%)	12 (80.0%
Yes	1 (14.3%)	2 (25.0%)	3 (20.0%
Puncture site hematomancture site complication,n			
%)			
Embolism in other locations	0 (0.0%)	0 (0.0%)	0 (0.0%)
No	7 (100.0%)	8 (100.0%)	15 (100.09
Pseudoaneurysm	0 (0.0%)	0 (0.0%)	0 (0.0%)
Puncture site hematoma	0 (0.0%)	0 (0.0%)	0 (0.0%)
nsulin Use in Hospital Stay,n (%)			
No	6 (85.7%)	7 (87.5%)	13 (86.7%
Yes	1 (14.3%)	1 (12.5%)	2 (13.3%
Craniectomy,n (%)			
No	7 (100.0%)	8 (100.0%)	15 (100.09
Yes	0 (0.0%)	0 (0.0%)	0 (0.0%)
Respiration Failure,n (%)			
, ,			

No	5 (71.4%)	3 (37.5%)	8 (53.3%)
Yes	2 (28.6%)	5 (62.5%)	7 (46.7%)
Circulation Failure, n (%)			
No	5 (71.4%)	5 (62.5%)	10 (66.7%)
Yes	2 (28.6%)	3 (37.5%)	5 (33.3%)

¹Chi-Square p-value;

Methylpred (N=2) Methylpred	(N=4) (0.0%) (N=4) (0.0%) (0.0%) (0.0%) (0.0%) (0.0%) (0.0%) (0.0%) (0.0%)	(N=8)) 2 (25.0%)) 1 (12.5%) 1 (12.5%) 1 (12.5%) 2 (25.0%) 0 (0.0%)
N=4 Color	%) 1 (25.0% %) 1 (25.0% %) 0 (0.0%) %) 0 (0.0%) %) 1 (25.0% %) 1 (25.0% %) 1 (25.0%	(N=8)) 2 (25.0%)) 1 (12.5%) 1 (12.5%) 2 (25.0%) 0 (0.0%)) 1 (12.5%)
N=4 Color	(N=4)	(N=8)) 2 (25.0%)) 1 (12.5%) 1 (12.5%) 2 (25.0%) 0 (0.0%)) 1 (12.5%)
dified Rankin Scale score at 90 days,n (%) 1 (25.0 0 (0.0 1 (25.0 1 (25.0 0 (0	%) 1 (25.0% %) 1 (25.0% %) 0 (0.0%) %) 0 (0.0%) %) 1 (25.0% %) 1 (25.0%) 2 (25.0%) 1 (12.5% 1 (12.5% 1 (12.5%) 2 (25.0% 0 (0.0%)) 1 (12.5%
1 (25.0 0 (0.0 1 (25.0 1(25.0 1 (25.0 1 (25.0 1(25.0 1 (25.0 1(25	%) 1 (25.0% %) 0 (0.0%) %) 0 (0.0%) %) 1 (25.0% %) 0 (0.0%) %) 1 (25.0%	1 (12.5% 1 (12.5% 1 (12.5% 2 (25.0% 0 (0.0%) 1 (12.5%
0 (0.0 1 (25.0 1 (25.0 1 (25.0 0 (0.0 0 (0.0 0 (0.0 nptomatic intracranial hemorrhage, n (%) o 4 (100. es 0 (0.0 lissing 0 sumonia,n (%) o 3 (75.0 es 1 (25.0 nary tract infection,n (%)	%) 1 (25.0% %) 0 (0.0%) %) 0 (0.0%) %) 1 (25.0% %) 0 (0.0%) %) 1 (25.0%	1 (12.5% 1 (12.5% 1 (12.5% 2 (25.0% 0 (0.0%) 1 (12.5%
1 (25.0 1 (25.0 1 (25.0 1 (25.0 0 (0.	%) 0 (0.0%) %) 0 (0.0%) %) 1 (25.0% %) 0 (0.0%) %) 1 (25.0%	1 (12.5% 1 (12.5% 2 (25.0% 0 (0.0%) 1 (12.5%
1 (25.0 1 (25.0 0 (0.0	%) 0 (0.0%) %) 1 (25.0% %) 0 (0.0%) %) 1 (25.0%	1 (12.5%) 2 (25.0%) 0 (0.0%) 1 (12.5%)
1 (25.0 0 (0.0 0	%) 1 (25.0% %) 0 (0.0%) %) 1 (25.0%) 2 (25.0% 0 (0.0%)) 1 (12.5%
0 (0.0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0	%) 0 (0.0%) %) 1 (25.0%	0 (0.0%)) 1 (12.5%
0 (0.0 Ilissing 0 Inptomatic intracranial hemorrhage, n (%) o 4 (100.0 es 0 (0.0 Ilissing 0 Ilis	%) 1 (25.0%) 1 (12.5%
Ilissing 0 Inptomatic intracranial hemorrhage, n (%) Inptomatic intracranial hemorrhage, n (%) Input		
nptomatic intracranial hemorrhage, n (%) o	0	0
4 (100.0 es 0 (0.0 lissing 0) bumonia,n (%) o 3 (75.0 es 1 (25.0) nary tract infection,n (%) o 4 (100.0)		
4 (100.0 es 0 (0.0 lissing 0) bumonia,n (%) o 3 (75.0 es 1 (25.0) nary tract infection,n (%) o 4 (100.0)		
es 0 (0.0 es 0 (
bumonia,n (%) o 3 (75.0 es 1 (25.0 es 1 (26.0 es 4 (100.0 es 1 (1	0%) 3 (75.0%	7 (87.5%
eumonia,n (%) o 3 (75.0 es 1 (25.0 es 1 (26.0 es 4 (100.0 es 1)))	%) 1 (25.0%) 1 (12.5%
o 3 (75.0 es 1 (25.0 es 1 (26.0 es 4 (100.0 es 1)))	0	0
o 3 (75.0 es 1 (25.0 es 1 (26.0 es 4 (100.0 es 1)))		
nary tract infection,n (%) o 4 (100.	%) 3 (75.0%) 6 (75.0%
nary tract infection,n (%) o 4 (100)		
0 4 (100.	%) 1 (25.0%) 2 (25.0%
es 0 (0.0	0%) 4 (100.0%	8 (100.0%
		0 (0.0%)
	%) 0 (0.0%)	
er Infection,n (%)	%) 0 (0.0%)	
o 4 (100.		8 (100.0%
es 0 (0.0		, 3 (100.07
stanistantinal blooding within 7 days of the DVF	0%) 4 (100.0%	, ,
strointestinal bleeding within 7 days after EVT,n	0%) 4 (100.0%	, ,

No	4 (100.0%)	4 (100.0%)	8 (100.0%)
Yes	0 (0.0%)	0 (0.0%)	0 (0.0%)
Puncture site hematomancture site complication,n			
(%)			
Embolism in other locations	0 (0.0%)	0 (0.0%)	0 (0.0%)
No	4 (100.0%)	4 (100.0%)	8 (100.0%)
Pseudoaneurysm	0 (0.0%)	0 (0.0%)	0 (0.0%)
Puncture site hematoma	0 (0.0%)	0 (0.0%)	0 (0.0%)
Insulin Use in Hospital Stay,n (%)			
No	4 (100.0%)	3 (75.0%)	7 (87.5%)
Yes	0 (0.0%)	1 (25.0%)	1 (12.5%)
Craniectomy,n (%)			
No	4 (100.0%)	4 (100.0%)	8 (100.0%)
Yes	0 (0.0%)	0 (0.0%)	0 (0.0%)
Respiration Failure,n (%)			
No	4 (100.0%)	3 (75.0%)	7 (87.5%)
Yes	0 (0.0%)	1 (25.0%)	1 (12.5%)
Circulation Failure, n (%)			
No	4 (100.0%)	3 (75.0%)	7 (87.5%)
Yes	0 (0.0%)	1 (25.0%)	1 (12.5%)

¹Chi-Square p-value;

	Ce	Center Order 74		
	Group	Group		
	Methylprednisolone	Placebo	Total	
	(N=16)	(N=15)	(N=31)	
modified Rankin Scale score at 90 days,n (%)				
0	2 (12.5%)	1 (6.7%)	3 (9.7%)	
1	2 (12.5%)	2 (13.3%)	4 (12.9%)	
2	5 (31.3%)	2 (13.3%)	7 (22.6%)	
3	1 (6.3%)	3 (20.0%)	4 (12.9%)	
4	2 (12.5%)	0 (0.0%)	2 (6.5%)	
5	0 (0.0%)	1 (6.7%)	1 (3.2%)	
6	4 (25.0%)	6 (40.0%)	10 (32.3%)	
Missing	0	0	0	

Symptomatic intracranial hemorrhage, n (%)			
No	15 (93.8%)	13 (86.7%)	28 (90.3%)
Yes	1 (6.3%)	2 (13.3%)	3 (9.7%)
Missing	0	0	0
Pneumonia,n (%)			
No	8 (50.0%)	6 (40.0%)	14 (45.2%)
Yes	8 (50.0%)	9 (60.0%)	17 (54.8%
Urinary tract infection,n (%)			
No	16 (100.0%)	12 (80.0%)	28 (90.3%
Yes	0 (0.0%)	3 (20.0%)	3 (9.7%)
Other Infection p. (0/.)			
Other Infection,n (%) No	16 (100.0%)	15 (100.0%)	31 (100.0%
Yes	0 (0.0%)	0 (0.0%)	0 (0.0%)
res	0 (0.0%)	0 (0.0%)	0 (0.0%)
Gastrointestinal bleeding within 7 days after EVT,n			
%)	4.4 (07. 50()	45 (400 00()	00 (00 50)
No Yes	14 (87.5%) 2 (12.5%)	15 (100.0%) 0 (0.0%)	29 (93.5% 2 (6.5%)
	(,	,	,
Puncture site hematomancture site complication,n (%)			
Embolism in other locations	0 (0.0%)	0 (0.0%)	0 (0.0%)
No	16 (100.0%)	13 (86.7%)	29 (93.5%
Pseudoaneurysm	0 (0.0%)	1 (6.7%)	1 (3.2%)
Puncture site hematoma	0 (0.0%)	1 (6.7%)	1 (3.2%)
Insulin Use in Hospital Stay,n (%)			
No	11 (68.8%)	13 (86.7%)	24 (77.4%
Yes	5 (31.3%)	2 (13.3%)	7 (22.6%)
Craniectomy,n (%)			
No	16 (100.0%)	14 (93.3%)	30 (96.8%
Yes	0 (0.0%)	1 (6.7%)	1 (3.2%)
Respiration Failure,n (%)			
No	12 (75.0%)	10 (66.7%)	22 (71.0%
Yes	4 (25.0%)	5 (33.3%)	9 (29.0%)
Circulation Failure, n (%)			
No	15 (93.8%)	11 (73.3%)	26 (83.9%
Yes	1 (6.3%)	4 (26.7%)	5 (16.1%)
163	1 (0.570)	4 (20.770)	3 (10.1%)

	Center Order		
	75 Group		
	Methylprednisolone	Placebo (N=49)	Total (N=98)
	(N=49)		
modified Rankin Scale score at 90 days,n (%)			
0	3 (6.1%)	4 (8.2%)	7 (7.1%)
1	4 (8.2%)	9 (18.4%)	13 (13.3%)
2	13 (26.5%)	10 (20.4%)	23 (23.5%)
3	7 (14.3%)	7 (14.3%)	14 (14.3%)
4	5 (10.2%)	3 (6.1%)	8 (8.2%)
5	3 (6.1%)	3 (6.1%)	6 (6.1%)
6	14 (28.6%)	13 (26.5%)	27 (27.6%)
Missing	0	0	0
Symptomatic intracranial hemorrhage, n (%)			
No	42 (87.5%)	42 (85.7%)	84 (86.6%)
Yes	6 (12.5%)	7 (14.3%)	13 (13.4%)
Missing	1	0	1
Pneumonia,n (%)			
No No	27 (55.1%)	20 (40.8%)	47 (48.0%)
Yes	22 (44.9%)	29 (59.2%)	51 (52.0%)
	22 (, ,	20 (00:270)	0. (02.070)
Urinary tract infection,n (%)			
No	48 (98.0%)	47 (95.9%)	95 (96.9%)
Yes	1 (2.0%)	2 (4.1%)	3 (3.1%)
	,	, ,	, ,
Other Infection,n (%)			
No	47 (95.9%)	48 (98.0%)	95 (96.9%)
Yes	2 (4.1%)	1 (2.0%)	3 (3.1%)
Gastrointestinal bleeding within 7 days after EVT,n			
(%)			
No	48 (98.0%)	47 (95.9%)	95 (96.9%)
Yes	1 (2.0%)	2 (4.1%)	3 (3.1%)
Puncture site hematomancture site complication,n			
(%)			
Embolism in other locations	0 (0.0%)	1 (2.0%)	1 (1.0%)

No	45 (91.8%)	45 (91.8%)	90 (91.8%)
Pseudoaneurysm	3 (6.1%)	1 (2.0%)	4 (4.1%)
Puncture site hematoma	1 (2.0%)	2 (4.1%)	3 (3.1%)
Insulin Use in Hospital Stay,n (%)			
No	35 (71.4%)	44 (89.8%)	79 (80.6%)
Yes	14 (28.6%)	5 (10.2%)	19 (19.4%)
Craniectomy,n (%)			
No	49 (100.0%)	46 (93.9%)	95 (96.9%)
Yes	0 (0.0%)	3 (6.1%)	3 (3.1%)
Respiration Failure,n (%)			
No	31 (63.3%)	38 (77.6%)	69 (70.4%)
Yes	18 (36.7%)	11 (22.4%)	29 (29.6%)
Circulation Failure, n (%)			
No	43 (87.8%)	43 (87.8%)	86 (87.8%)
Yes	6 (12.2%)	6 (12.2%)	12 (12.2%)
101 : 0			

101-: 0-			
1Chi-Sq	luare	p-va	ıue:

	Ce	enter Order	
		76	
	Group		
	Methylprednisolone	Placebo	Total
	(N=8)	(N=8)	(N=16)
nodified Rankin Scale score at 90 days,n (%)			
0	0 (0.0%)	0 (0.0%)	0 (0.0%)
1	1 (12.5%)	2 (25.0%)	3 (18.8%
2	2 (25.0%)	1 (12.5%)	3 (18.8%
3	1 (12.5%)	2 (25.0%)	3 (18.8%
4	1 (12.5%)	1 (12.5%)	2 (12.5%
5	1 (12.5%)	0 (0.0%)	1 (6.3%)
6	2 (25.0%)	2 (25.0%)	4 (25.0%
Missing	0	0	0
Symptomatic intracranial hemorrhage, n (%)			
No	6 (75.0%)	8 (100.0%)	14 (87.5%
Yes	2 (25.0%)	0 (0.0%)	2 (12.5%
Missing	0	0	0

No	6 (75.0%)	4 (50.0%)	10 (62.5%
		, ,	
Yes	2 (25.0%)	4 (50.0%)	6 (37.5%
Luinany tract infaction n (0/)			
Urinary tract infection,n (%) No	9 (400 09/)	7 (07 50/)	1E (O2 90)
	8 (100.0%)	7 (87.5%)	15 (93.8%
Yes	0 (0.0%)	1 (12.5%)	1 (6.3%)
Other Infection,n (%)			
No	8 (100.0%)	8 (100.0%)	16 (100.09
Yes	0 (0.0%)	0 (0.0%)	0 (0.0%)
Gastrointestinal bleeding within 7 days after EVT,n			
%)			
No	8 (100.0%)	8 (100.0%)	16 (100.09
Yes	0 (0.0%)	0 (0.0%)	0 (0.0%)
Puncture site hematomancture site complication,n			
%) Embolism in other locations	0 (0.0%)	0 (0.0%)	0 (0.0%)
No No	8 (100.0%)	8 (100.0%)	16 (100.09
Pseudoaneurysm	0 (0.0%)	0 (0.0%)	0 (0.0%
Puncture site hematoma	0 (0.0%)	0 (0.0%)	0 (0.0%
nsulin Use in Hospital Stay,n (%) No	7 (87.5%)	7 (87.5%)	14 (87.5%
Yes	1 (12.5%)	1 (12.5%)	2 (12.5%
Craniectomy,n (%)			
No	8 (100.0%)	7 (87.5%)	15 (93.8%
Yes	0 (0.0%)	1 (12.5%)	1 (6.3%)
Respiration Failure,n (%)			
No	5 (62.5%)	6 (75.0%)	11 (68.8%
Yes	3 (37.5%)	2 (25.0%)	5 (31.3%
Circulation Failure, n (%)			
No	7 (87.5%)	5 (62.5%)	12 (75.0%
Yes	1 (12.5%)	3 (37.5%)	4 (25.0%
Chi-Square p-value;			
		77	
	Group		
	Methylprednisolone	Placebo	Total

	(N=2)	(N=2)	(N=4)
modified Rankin Scale score at 90 days,n (%)			
0	0 (0.0%)	0 (0.0%)	0 (0.0%)
1	0 (0.0%)	1 (50.0%)	1 (25.0%)
2	0 (0.0%)	1 (50.0%)	1 (25.0%)
3	1 (50.0%)	0 (0.0%)	1 (25.0%)
4	1 (50.0%)	0 (0.0%)	1 (25.0%)
5	0 (0.0%)	0 (0.0%)	0 (0.0%)
6	0 (0.0%)	0 (0.0%)	0 (0.0%)
Missing	0	0	0
Symptomatic intracranial hemorrhage, n (%)			
No	2 (100.0%)	2 (100.0%)	4 (100.0%)
Yes	0 (0.0%)	0 (0.0%)	0 (0.0%)
Missing	0	0	0
Pneumonia,n (%)			
No	1 (50.0%)	1 (50.0%)	2 (50.0%)
Yes	1 (50.0%)	1 (50.0%)	2 (50.0%)
Urinary tract infection,n (%)			
No	2 (100.0%)	1 (50.0%)	3 (75.0%)
Yes	0 (0.0%)	1 (50.0%)	1 (25.0%)
Other Infection,n (%)			
No	2 (100.0%)	2 (100.0%)	4 (100.0%)
Yes	0 (0.0%)	0 (0.0%)	0 (0.0%)
100	0 (0.070)	0 (0.070)	0 (0.070)
Gastrointestinal bleeding within 7 days after EVT,n			
(%) No	2 (100.0%)	2 (100.0%)	4 (100.0%)
Yes	0 (0.0%)	0 (0.0%)	0 (0.0%)
165	0 (0.070)	0 (0.070)	0 (0.070)
Puncture site hematomancture site complication,n			
(%)	0 (0 00()	0. (0. 00(.)	0 (0 00()
Embolism in other locations	0 (0.0%)	0 (0.0%)	0 (0.0%)
No	2 (100.0%)	2 (100.0%)	4 (100.0%)
Pseudoaneurysm	0 (0.0%)	0 (0.0%)	0 (0.0%)
Puncture site hematoma	0 (0.0%)	0 (0.0%)	0 (0.0%)
Insulin Use in Hospital Stay,n (%)			
No	1 (50.0%)	2 (100.0%)	3 (75.0%)
Yes	1 (50.0%)	0 (0.0%)	1 (25.0%)

No				
No	Craniectomy,n (%)			
No	No	2 (100.0%)	2 (100.0%)	4 (100.0%
No 2 (100.0%) 2 (100.0%) 4 (100.0%) Yes 0 (0.0%) 0 (0.0%) 0 (0.0%) Circulation Failure, n (%) No 2 (100.0%) 2 (100.0%) 4 (100.0%) Yes 0 (0.0%) 2 (100.0%) 4 (100.0%) Circulation Failure, n (%) Yes 0 (0.0%) 2 (100.0%) 4 (100.0% Circulation Failure, n (%) Circulation Failure, n	Yes	0 (0.0%)	0 (0.0%)	0 (0.0%)
No	D : 4: F !! (01)			
Circulation Failure, n (%)		0 (400 00()	0 (400 00()	4 (400 00)
No				
No 2 (100.0%) 2 (100.0%) 4 (100.0%) Yes 0 (0.0%) 0 (0.0%) 0 (0.0%) Center Order 78	Yes	0 (0.0%)	0 (0.0%)	0 (0.0%)
Yes	Circulation Failure, n (%)			
	No	2 (100.0%)	2 (100.0%)	4 (100.0%
Methylprednisolone	Yes	0 (0.0%)	0 (0.0%)	0 (0.0%)
Methylprednisolone				
Group Methylprednisolone Placebo Total (N=5) (N=5) (N=10) ((Center Order	
Methylprednisolone Placebo Total (N=5) (N=10)			78	
(N=5)		Group		
Missing		Methylprednisolone	Placebo	Total
1 (20.0%) 0 (0.0%) 1 (10.0%) 1 (10.0%) 1 (10.0%) 0 (0.0%) 1 (10.0%) 2 1 (20.0%) 3 (60.0%) 4 (40.0%) 3 1 (20.0%) 0 (0.0%) 1 (10.0%) 4 1 (20.0%) 0 (0.0%) 1 (10.0%) 5 0 (0.0%) 1 (20.0%) 1 (10.0%) 6 0 (0.0%) 1 (20.0%) 1 (10.0%) Missing 0 0 0 0 Symptomatic intracranial hemorrhage, n (%) No 5 (100.0%) 5 (100.0%) 10 (100.0%) Yes 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) Missing 0 0 0 0 Preumonia,n (%) No 4 (80.0%) 3 (60.0%) 7 (70.0%) Yes 1 (20.0%) 3 (30.0%) Urinary tract infection,n (%) No 5 (100.0%) 5 (100.0%) 3 (30.0%) Other Infection,n (%)		(N=5)	(N=5)	(N=10)
1	modified Rankin Scale score at 90 days,n (%)			
1 (20.0%) 3 (60.0%) 4 (40.0%) 3 (60.0%) 4 (40.0%) 4 (1 (20.0%) 0 (0.0%) 1 (10.0%) 4 (1 (20.0%) 0 (0.0%) 1 (10.0%) 5 (0 (0.0%) 1 (20.0%) 1 (10.0%) 6 (0 (0.0%) 1 (20.0%) 1 (10.0%) 6 (0 (0.0%) 1 (20.0%) 1 (10.0%) 6 (0 (0.0%) 1 (20.0%) 1 (10.0%) 6 (0 (0.0%) 0 (0.0%) 1 (10.0%) 7 (1 (0.0%) 1 (100.0%) 7 (1 (0.0%) 1 (100.0%) 8 (1 (0.0%) 1 (100.0%) 1 (100.0%) 9 (1 (0.0%) 1 (100.0%) 9 (1 (0.0	0	1 (20.0%)	0 (0.0%)	1 (10.0%
1 (20.0%) 0 (0.0%) 1 (10.0% 4 1 (20.0%) 0 (0.0%) 1 (10.0% 5 0 (0.0%) 1 (20.0%) 1 (10.0% 6 0 (0.0%) 1 (20.0%) 1 (10.0% Missing 0 0 0 0 Symptomatic intracranial hemorrhage, n (%) No 5 (100.0%) 5 (100.0%) 10 (100.0% Yes 0 (0.0%) 0 (0.0%) 0 (0.0% Missing 0 0 0 0 Pneumonia,n (%) No 4 (80.0%) 3 (60.0%) 7 (70.0% Yes 1 (20.0%) 2 (40.0%) 3 (30.0% Urinary tract infection,n (%) No 5 (100.0%) 5 (100.0%) 10 (100.0% Yes 0 (0.0%) 0 (0.0%) 0 (0.0% Other Infection,n (%)	1	1 (20.0%)	0 (0.0%)	1 (10.0%
1 (20.0%) 0 (0.0%) 1 (10.0%) 5 0 (0.0%) 1 (20.0%) 1 (10.0%) 6 0 (0.0%) 1 (20.0%) 1 (10.0%) Missing 0 0 0 0 Symptomatic intracranial hemorrhage, n (%) No 5 (100.0%) 5 (100.0%) 10 (100.0%) Yes 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) Missing 0 0 0 0 Pneumonia,n (%) No 4 (80.0%) 3 (60.0%) 7 (70.0% Yes 1 (20.0%) 2 (40.0%) 3 (30.0% Urinary tract infection,n (%) No 5 (100.0%) 5 (100.0%) 10 (100.0% Yes 0 (0.0%) 0 (0.0%) 0 (0.0%) Other Infection,n (%)	2	1 (20.0%)	3 (60.0%)	4 (40.0%
5 0 (0.0%) 1 (20.0%) 1 (10.0% 6 0 (0.0%) 1 (20.0%) 1 (10.0% 6 0 (0.0%) 1 (20.0%) 1 (10.0% 6 0 (0.0%) 1 (20.0%) 1 (10.0% 6 0 (0.0%) 1 (20.0%) 1 (10.0% 6 0 (0.0%) 1 (100.0% 6 0 (0	3	1 (20.0%)	0 (0.0%)	1 (10.0%
6 0 (0.0%) 1 (20.0%) 1 (10.0% Missing 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0	4	1 (20.0%)	0 (0.0%)	1 (10.0%
Missing 0 0 0 0 Symptomatic intracranial hemorrhage, n (%) No 5 (100.0%) 5 (100.0%) 10 (100.0%) Yes 0 (0.0%) 0 (0.0%) 0 (0.0%) Missing 0 0 0 0 Pneumonia,n (%) No 4 (80.0%) 3 (60.0%) 7 (70.0% Yes 1 (20.0%) 2 (40.0%) 3 (30.0% Urinary tract infection,n (%) No 5 (100.0%) 5 (100.0%) 10 (100.0% Yes 0 (0.0%) 0 (0.0%) 0 (0.0% Other Infection,n (%)	5	0 (0.0%)	1 (20.0%)	1 (10.0%
Symptomatic intracranial hemorrhage, n (%) No 5 (100.0%) 5 (100.0%) 10 (100.0%) Yes 0 (0.0%) 0 (0.0%) 0 (0.0%) Missing 0 0 0 0 Pneumonia,n (%) No 4 (80.0%) 3 (60.0%) 7 (70.0% Yes 1 (20.0%) 2 (40.0%) 3 (30.0% Urinary tract infection,n (%) No 5 (100.0%) 5 (100.0%) 10 (100.0% Yes 0 (0.0%) 0 (0.0%) 0 (0.0%)	6	0 (0.0%)	1 (20.0%)	1 (10.0%
No 5 (100.0%) 5 (100.0%) 10 (100.0°) Yes 0 (0.0%) 0 (0.0%) 0 (0.0%) Missing 0 0 0 Pneumonia,n (%) No 4 (80.0%) 3 (60.0%) 7 (70.0%) Yes 1 (20.0%) 2 (40.0%) 3 (30.0%) Urinary tract infection,n (%) No 5 (100.0%) 5 (100.0%) 10 (100.0%) Yes 0 (0.0%) 0 (0.0%) 0 (0.0%)	Missing	0	0	0
No 5 (100.0%) 5 (100.0%) 10 (100.0°) Yes 0 (0.0%) 0 (0.0%) 0 (0.0%) Missing 0 0 0 Pneumonia,n (%) No 4 (80.0%) 3 (60.0%) 7 (70.0%) Yes 1 (20.0%) 2 (40.0%) 3 (30.0%) Urinary tract infection,n (%) No 5 (100.0%) 5 (100.0%) 10 (100.0%) Yes 0 (0.0%) 0 (0.0%) 0 (0.0%)				
Yes 0 (0.0%) 0 (0.0%) 0 (0.0%) Missing 0 0 0 Pneumonia,n (%) No 4 (80.0%) 3 (60.0%) 7 (70.0%) Yes 1 (20.0%) 2 (40.0%) 3 (30.0%) Urinary tract infection,n (%) No 5 (100.0%) 5 (100.0%) 10 (100.0%) Yes 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%)		5 (400 00())	5 (400 00()	40 (400 0)
Missing 0 0 0 Pneumonia,n (%) No 4 (80.0%) 3 (60.0%) 7 (70.0% Yes 1 (20.0%) 2 (40.0%) 3 (30.0% Urinary tract infection,n (%) No 5 (100.0%) 5 (100.0%) 10 (100.0% Yes 0 (0.0%) 0 (0.0%) 0 (0.0%)				
Pneumonia,n (%) No 4 (80.0%) 3 (60.0%) 7 (70.0% Yes 1 (20.0%) 2 (40.0%) 3 (30.0% Urinary tract infection,n (%) No 5 (100.0%) 5 (100.0%) 10 (100.0% Yes 0 (0.0%) 0 (0.0%) 0 (0.0%)				
No 4 (80.0%) 3 (60.0%) 7 (70.0%) Yes 1 (20.0%) 2 (40.0%) 3 (30.0%) Urinary tract infection,n (%) No 5 (100.0%) 5 (100.0%) 10 (100.0%) Yes 0 (0.0%) 0 (0.0%) 0 (0.0%) Other Infection,n (%)	IVIIOOII IĞ	Ü	U	O
Yes 1 (20.0%) 2 (40.0%) 3 (30.0%) Urinary tract infection,n (%) No 5 (100.0%) 5 (100.0%) 10 (100.0%) Yes 0 (0.0%) 0 (0.0%) 0 (0.0%)	Pneumonia,n (%)			
Urinary tract infection,n (%) No 5 (100.0%) 5 (100.0%) 10 (100.0° Yes 0 (0.0%) 0 (0.0%) 0 (0.0%) Other Infection,n (%)	No	4 (80.0%)	3 (60.0%)	7 (70.0%
No 5 (100.0%) 5 (100.0%) 10 (100.0%) Yes 0 (0.0%) 0 (0.0%) 0 (0.0%) Other Infection,n (%)	Yes	1 (20.0%)	2 (40.0%)	3 (30.0%
No 5 (100.0%) 5 (100.0%) 10 (100.0%) Yes 0 (0.0%) 0 (0.0%) 0 (0.0%) Other Infection,n (%)	Urinary tract infection n (%)			
Yes 0 (0.0%) 0 (0.0%) 0 (0.0%) Other Infection,n (%)		5 (100 0%)	5 (100 0%)	10 (100 0
Other Infection,n (%)				
	165	0 (0.0%)	0 (0.0%)	0 (0.0%)
No 4 (80.0%) 5 (100.0%) 9 (90.0%	Other Infection,n (%)			
	No	4 (80.0%)	5 (100.0%)	9 (90.0%

Yes	1 (20.0%)	0 (0.0%)	1 (10.0%)
Sastrointestinal bleeding within 7 days after EVT,n			
%)			
No	5 (100.0%)	5 (100.0%)	10 (100.0%)
Yes	0 (0.0%)	0 (0.0%)	0 (0.0%)
Puncture site hematomancture site complication,n %)			
Embolism in other locations	0 (0.0%)	0 (0.0%)	0 (0.0%)
No	5 (100.0%)	5 (100.0%)	10 (100.0%)
Pseudoaneurysm	0 (0.0%)	0 (0.0%)	0 (0.0%)
Puncture site hematoma	0 (0.0%)	0 (0.0%)	0 (0.0%)
nsulin Use in Hospital Stay,n (%)			
No	4 (80.0%)	5 (100.0%)	9 (90.0%)
Yes	1 (20.0%)	0 (0.0%)	1 (10.0%)
Craniectomy,n (%)	= (400 00()	5 (400 00()	40 (400 00()
No	5 (100.0%)	5 (100.0%)	10 (100.0%)
Yes	0 (0.0%)	0 (0.0%)	0 (0.0%)
espiration Failure,n (%)			
No	5 (100.0%)	4 (80.0%)	9 (90.0%)
Yes	0 (0.0%)	1 (20.0%)	1 (10.0%)
	2 (2.2.1.)	(_0.0.0.)	(() ()
Firculation Failure, n (%)			
No	5 (100.0%)	4 (80.0%)	9 (90.0%)
Yes	0 (0.0%)	1 (20.0%)	1 (10.0%)
	C	enter Order	
		79	
	Group		
	Methylprednisolone	Placebo	Total
	(N=14)	(N=13)	(N=27)
nodified Rankin Scale score at 90 days,n (%)			
0	1 (7.1%)	1 (7.7%)	2 (7.4%)
1	3 (21.4%)	2 (15.4%)	5 (18.5%)
2	1 (7.1%)	1 (7.7%)	2 (7.4%)
3	3 (21.4%)	2 (15.4%)	5 (18.5%)
4	2 (14.3%)	2 (15.4%)	4 (14.8%)
5	0 (0.0%)	2 (15.4%)	2 (7.4%)
6	4 (28.6%)	3 (23.1%)	7 (25.9%)
	(20.070)	0 (20.170)	(20.070)

Missing	0	0	0
Symptomatic intracranial hemorrhage, n (%)			
No	14 (100.0%)	12 (92.3%)	26 (96.3%)
Yes	0 (0.0%)	1 (7.7%)	1 (3.7%)
Missing	0	0	0
Pneumonia,n (%)			
No	5 (35.7%)	3 (23.1%)	8 (29.6%)
Yes	9 (64.3%)	10 (76.9%)	19 (70.4%
Urinary tract infection,n (%)			
No	14 (100.0%)	13 (100.0%)	27 (100.0%
Yes	0 (0.0%)	0 (0.0%)	0 (0.0%)
Other Infection,n (%)			
No	13 (92.9%)	13 (100.0%)	26 (96.3%
Yes	1 (7.1%)	0 (0.0%)	1 (3.7%)
Gastrointestinal bleeding within 7 days after EVT,n			
(%)			
No	11 (78.6%)	12 (92.3%)	23 (85.2%
Yes	3 (21.4%)	1 (7.7%)	4 (14.8%)
Puncture site hematomancture site complication,n			
(%)			
Embolism in other locations	0 (0.0%)	0 (0.0%)	0 (0.0%)
No	14 (100.0%)	13 (100.0%)	27 (100.09
Pseudoaneurysm	0 (0.0%)	0 (0.0%)	0 (0.0%)
Puncture site hematoma	0 (0.0%)	0 (0.0%)	0 (0.0%)
Insulin Use in Hospital Stay,n (%)			
No	10 (71.4%)	12 (92.3%)	22 (81.5%
Yes	4 (28.6%)	1 (7.7%)	5 (18.5%
Craniectomy,n (%)			
No	14 (100.0%)	13 (100.0%)	27 (100.09
Yes	0 (0.0%)	0 (0.0%)	0 (0.0%)
Respiration Failure,n (%)			
No	7 (50.0%)	6 (46.2%)	13 (48.1%
Yes	7 (50.0%)	7 (53.8%)	14 (51.9%
Circulation Failure, n (%)			
a			

No	11 (78.6%)	11 (84.6%)	22 (81.5%)
Yes	3 (21.4%)	2 (15.4%)	5 (18.5%)

Center Order		
80		
Group		_
Methylprednisolone	Placebo	Total
(N=8)	(N=8)	(N=16)

modified Rankin Scale score at 90 days,n (%)

0	2 (25.0%)	1 (12.5%)	3 (18.8%)
1	0 (0.0%)	0 (0.0%)	0 (0.0%)
2	0 (0.0%)	3 (37.5%)	3 (18.8%)
3	1 (12.5%)	2 (25.0%)	3 (18.8%)
4	2 (25.0%)	2 (25.0%)	4 (25.0%)
5	2 (25.0%)	0 (0.0%)	2 (12.5%)
6	1 (12.5%)	0 (0.0%)	1 (6.3%)
Missing	0	0	0
Symptomatic intracranial hemorrhage, n (%)			
No	7 (87.5%)	7 (87.5%)	14 (87.5%)
Yes	1 (12.5%)	1 (12.5%)	2 (12.5%)
Missing	0	0	0
Pneumonia,n (%)			
No	4 (50.0%)	2 (25.0%)	6 (37.5%)
Yes	4 (50.0%)	6 (75.0%)	10 (62.5%)
Urinary tract infection,n (%)			

No	8 (100.0%)	8 (100.0%)	16 (100.0%)
Yes	0 (0.0%)	0 (0.0%)	0 (0.0%)
Other Infection,n (%)			
No	8 (100.0%)	8 (100.0%)	16 (100.0%)
Yes	0 (0.0%)	0 (0.0%)	0 (0.0%)
Gastrointestinal bleeding within 7 days after EVT,n			
(%)			
No	8 (100.0%)	7 (87.5%)	15 (93.8%)
Yes	0 (0.0%)	1 (12.5%)	1 (6.3%)
Puncture site hematomancture site complication,n			
(%)			
Embolism in other locations	0 (0.0%)	0 (0.0%)	0 (0.0%)
No	8 (100.0%)	7 (87.5%)	15 (93.8%)
Pseudoaneurysm	0 (0.0%)	1 (12.5%)	1 (6.3%)
Puncture site hematoma	0 (0.0%)	0 (0.0%)	0 (0.0%)
Insulin Use in Hospital Stay,n (%)			
No	4 (50.0%)	5 (62.5%)	9 (56.3%)
Yes	4 (50.0%)	3 (37.5%)	7 (43.8%)
Craniectomy,n (%)			
No	7 (87.5%)	7 (87.5%)	14 (87.5%)
Yes	1 (12.5%)	1 (12.5%)	2 (12.5%)
Respiration Failure,n (%)			
No	7 (87.5%)	8 (100.0%)	15 (93.8%)
Yes	1 (12.5%)	0 (0.0%)	1 (6.3%)
Circulation Failure, n (%)			
No	8 (100.0%)	8 (100.0%)	16 (100.0%)
Yes	0 (0.0%)	0 (0.0%)	0 (0.0%)
Yes ¹Chi-Square p-value;	0 (0.0%)	0 (0.0%)	0 (0.0%
	C	enter Order	
		81	
	Group		
	Methylprednisolone	Placebo	Total
	(N=8)	(N=8)	(N=16)

modified Rankin Scale score at 90 days,n (%)

0	0 (0.0%)	0 (0.0%)	0 (0.0%)	
1	2 (25.0%)	1 (12.5%)	3 (18.8%)	
2	1 (12.5%)	1 (12.5%)	2 (12.5%)	
3	2 (25.0%) 2 (25.0%)		4 (25.0%) 2 (12.5%) 2 (12.5%)	
4	1 (12.5%) 1 (12.5%)			
5	1 (12.5%) 1 (12.5%)			
6	1 (12.5%)	2 (25.0%)	3 (18.8%)	
Missing	0	0	0	
Symptomatic intracranial hemorrhage, n (%)				
No	7 (87.5%)	5 (62.5%)	12 (75.0%)	
Yes	1 (12.5%)	3 (37.5%)	4 (25.0%)	
Missing	0	0	0	
Pneumonia,n (%)				
No	7 (87.5%)	3 (37.5%)	10 (62.5%)	
Yes	1 (12.5%)	5 (62.5%)	6 (37.5%)	
Urinary tract infection,n (%)				
No	8 (100.0%)	8 (100.0%)	16 (100.0%)	
Yes	0 (0.0%)	0 (0.0%)	0 (0.0%)	
Other Infection,n (%)				
No	8 (100.0%)	8 (100.0%)	16 (100.0%)	
Yes	0 (0.0%)	0 (0.0%)	0 (0.0%)	
Gastrointestinal bleeding within 7 days after EVT,n				
(%)				
No	8 (100.0%)	7 (87.5%)	15 (93.8%)	
Yes	0 (0.0%)	1 (12.5%)	1 (6.3%)	
Puncture site hematomancture site complication,n				
(%)				
Embolism in other locations	0 (0.0%)	0 (0.0%)	0 (0.0%)	
No	8 (100.0%)	8 (100.0%)	16 (100.0%)	
Pseudoaneurysm	0 (0.0%)	0 (0.0%)	0 (0.0%)	
Puncture site hematoma	0 (0.0%)	0 (0.0%)	0 (0.0%)	
Insulin Use in Hospital Stay,n (%)				
No	5 (62.5%)	7 (87.5%)	12 (75.0%)	
Yes	3 (37.5%)	1 (12.5%)	4 (25.0%)	
Craniectomy,n (%)				
No	7 (87.5%)	8 (100.0%)	15 (93.8%)	

Yes	1 (12.5%)	0 (0.0%)	1 (6.3%)
Respiration Failure,n (%)			
No	7 (87.5%)	5 (62.5%)	12 (75.0%)
Yes	1 (12.5%)	3 (37.5%)	4 (25.0%)
Circulation Failure, n (%)			
No	8 (100.0%)	7 (87.5%)	15 (93.8%)
Yes	0 (0.0%)	1 (12.5%)	1 (6.3%)

¹Chi-Square p-value;

	Center Order					
	82					
	Group					
	Methylprednisolone Placebo		Total			
	(N=4)	(N=4)	(N=8)			
nodified Rankin Scale score at 90 days,n (%)						
0	0 (0.0%)	2 (50.0%)	2 (25.0%			
1	1 (25.0%)	1 (25.0%)	2 (25.0%			
2	0 (0.0%)	0 (0.0%)	0 (0.0%)			
3	2 (50.0%)	1 (25.0%)	3 (37.5%			
4	0 (0.0%)	0 (0.0%)	0 (0.0%)			
5	0 (0.0%)	0 (0.0%)	0 (0.0%)			
6	1 (25.0%)	0 (0.0%)	1 (12.5%			
Missing	0	0	0			
Symptomatic intracranial hemorrhage, n (%)						
No	4 (100.0%)	4 (100.0%)	8 (100.0%			
Yes	0 (0.0%)	0 (0.0%)	0 (0.0%)			
Missing	0	0	0			
Pneumonia,n (%)			_ ,			
No	2 (50.0%)	3 (75.0%)	5 (62.5%			
Yes	2 (50.0%)	1 (25.0%)	3 (37.5%			
Jrinary tract infection,n (%)						
No	3 (75.0%)	3 (75.0%)	6 (75.0%			
Yes	1 (25.0%)	1 (25.0%)	2 (25.0%			
Other Infection,n (%)						
No	4 (100.0%)	4 (100.0%)	8 (100.0%			
Yes	0 (0.0%)	0 (0.0%)	0 (0.0%)			

Gastrointestinal bleeding within 7 days after EVT,n				
aujo and Evi,				
(%)				
No	3 (75.0%)	4 (100.0%)	7 (87.5%)	
Yes	1 (25.0%)	0 (0.0%)	1 (12.5%	
Puncture site hematomancture site complication,n				
(%)				
Embolism in other locations	0 (0.0%)	0 (0.0%)	0 (0.0%)	
No	4 (100.0%)	4 (100.0%)	8 (100.0%	
Pseudoaneurysm	0 (0.0%)	0 (0.0%)	0 (0.0%)	
Puncture site hematoma	0 (0.0%)	0 (0.0%)	0 (0.0%)	
nsulin Use in Hospital Stay,n (%)				
No	4 (100.0%)	3 (75.0%)	7 (87.5%	
Yes	0 (0.0%)	1 (25.0%)	1 (12.5%	
	, ,	,	,	
Craniectomy,n (%)				
No	3 (75.0%)	4 (100.0%)	7 (87.5%	
Yes	1 (25.0%)	0 (0.0%)	1 (12.5%	
Respiration Failure,n (%)				
No	2 (50.0%)	4 (100.0%)	6 (75.0%	
Yes	2 (50.0%)	0 (0.0%)	2 (25.0%	
Circulation Failure, n (%)				
Circulation Failure, n (%) No	4 (100.0%)	4 (100.0%)	8 (100.0%	
	4 (100.0%) 0 (0.0%)	4 (100.0%) 0 (0.0%)		
	0 (0.0%)			
No Yes	0 (0.0%)	0 (0.0%)	8 (100.0%) 0 (0.0%) 50, 54, 57, 6	
No Yes	0 (0.0%)	0 (0.0%)	0 (0.0%)	
No Yes	0 (0.0%)	0 (0.0%) enter Order 9, 21, 30, 31, 47,	0 (0.0%)	
No Yes	0 (0.0%) Co	0 (0.0%) enter Order 9, 21, 30, 31, 47,	0 (0.0%)	
No Yes	O (0.0%) Co Merge of Center 7,16, 1	0 (0.0%) enter Order 19, 21, 30, 31, 47,	0 (0.0%)	
No Yes Chi-Square p-value;	O (0.0%) Co Merge of Center 7,16, 1 Group Methylprednisolone	0 (0.0%) enter Order 19, 21, 30, 31, 47, 66 Placebo	0 (0.0%) 50, 54, 57, 6	
No Yes Chi-Square p-value;	O (0.0%) Co Merge of Center 7,16, 1 Group Methylprednisolone	0 (0.0%) enter Order 19, 21, 30, 31, 47, 66 Placebo	0 (0.0%) 50, 54, 57, 6 Total (N=30)	
No Yes Chi-Square p-value; modified Rankin Scale score at 90 days,n (%)	O (0.0%) Compared to the content of	0 (0.0%) enter Order 19, 21, 30, 31, 47, 66 Placebo (N=18)	0 (0.0%) 50, 54, 57, 6	
No Yes Chi-Square p-value; modified Rankin Scale score at 90 days,n (%)	O (0.0%) Compared to the content of	0 (0.0%) enter Order 19, 21, 30, 31, 47, 66 Placebo (N=18)	0 (0.0%) 50, 54, 57, 6 Total (N=30)	
No Yes Chi-Square p-value; modified Rankin Scale score at 90 days,n (%) 0 1	O (0.0%) Comparison of Center 7,16, 1 Group Methylprednisolone (N=12) 4 (33.3%) 1 (8.3%)	0 (0.0%) enter Order 19, 21, 30, 31, 47, 66 Placebo (N=18) 0 (0.0%) 3 (16.7%)	0 (0.0%) 50, 54, 57, 6 Total (N=30) 4 (13.3%	


5	0 (0.0%)	1 (5.6%)	1 (3.3%)
6	1 (8.3%)	5 (27.8%)	6 (20.0%)
Missing	0	0	0
Symptomatic intracranial hemorrhage, n (%)			
No	11 (91.7%)	12 (66.7%)	23 (76.7%)
Yes	1 (8.3%)	6 (33.3%)	7 (23.3%)
Missing	0	0	0
•			
Pneumonia,n (%)			
No	6 (50.0%)	7 (38.9%)	13 (43.3%)
Yes	6 (50.0%)	11 (61.1%)	17 (56.7%)
Urinary tract infection,n (%)			
No	12 (100.0%)	18 (100.0%)	30 (100.0%)
Yes	0 (0.0%)	0 (0.0%)	0 (0.0%)
Other Infection,n (%)			
No	12 (100.0%)	18 (100.0%)	30 (100.0%)
Yes	0 (0.0%)	0 (0.0%)	0 (0.0%)
Gastrointestinal bleeding within 7 days after EVT,n			
(%)			
No	11 (91.7%)	16 (88.9%)	27 (90.0%)
Yes	1 (8.3%)	2 (11.1%)	3 (10.0%)
Puncture site hematomancture site complication,n			
(%) Embolism in other locations	0 (0.0%)	0 (0.0%)	0 (0.0%)
No No	12 (100.0%)	18 (100.0%)	
Pseudoaneurysm	0 (0.0%)	0 (0.0%)	30 (100.0%) 0 (0.0%)
Puncture site hematoma	0 (0.0%)	0 (0.0%)	0 (0.0%)
Tallotate dite Homatoma	0 (0.070)	0 (0.070)	0 (0.070)
Insulin Use in Hospital Stay,n (%)			
No	7 (58.3%)	16 (88.9%)	23 (76.7%)
Yes	5 (41.7%)	2 (11.1%)	7 (23.3%)
	,	, , ,	, ,
Craniectomy,n (%)			
No	12 (100.0%)	17 (94.4%)	29 (96.7%)
Yes	0 (0.0%)	1 (5.6%)	1 (3.3%)
Respiration Failure,n (%)			
No	8 (66.7%)	13 (72.2%)	21 (70.0%)
Yes	4 (33.3%)	5 (27.8%)	9 (30.0%)


Circulation Failure, n (%)			
No	11 (91.7%)	14 (77.8%)	25 (83.3%)
Yes	1 (8.3%)	4 (22.2%)	5 (16.7%)

¹Chi-Square p-value;

eFigures

eFigure 1. Flowchart






eFigure 2. Distribution of 82 Enrolling Centers in 17 Provinces in China


Shown was the distribution of the 82 enrolling centers in 17 Provinces in China.

eFigure 3. Distribution of the Modified Rankin Scale Score at 90 Days (Per-protocol Population).



The distribution of the modified Rankin scale score among patients in the tirofiban group and the aspirin group. Scores range from 0 to 6, with 0 indicating no symptoms, 1, no clinically significant disability, 2, slight disability, 3, moderate disability, 4, moderately severe disability, 5, severe disability, and 6, death. Numbers indicate rounded proportions. 7 patients lost to follow up were not included in the per-protocol analysis.

eFigure 4. Kaplan-Meier Estimates of Survival Probability (Full Analysis Set)



Adjusted Hazard Ratio was 0.82; 95% Confidence Interval, 0.71 to 0.93, P = 0.003). The proportional harzard assumption was satisfied (p > 0.05). Cox regression model was adjusted for age, baseline NIHSS score, pre-stroke mRS, baseline ASPECTS score, use of intravenous thrombolysis, time from onset to randomization, and occlusion location using the inverse probability treatment weighting method.

eFigure 5. Subgroup Analysis of Death (Safety Population).

Subgroup	No. of patients	Methylprednisolone group Events, n/N (%)	Placebo group Events, n/N (%)		Adjusted RR (95% CI)
Overall	1673	194/835 (23.23)	239/838 (28.52)	HEH	0.84 (0.71 to 0.98
Age					
≤ 69	871	76/449 (16.93)	88/422 (20.85)	-	0.83 (0.63 to 1.09
> 69	802	118/386 (30.57)	151/416 (36.30)	+ = -	0.84 (0.69 to 1.02)
Sex					
Female	723	96/356 (26.97)	111/367 (30.25)	-	0.90 (0.72 to 1.14
Male	950	98/479 (20.46)	128/471 (27.18)	⊢= -(0.78 (0.62 to 0.98
Baseline NIHSS score					
≤ 19	926	69/463 (14.90)	86/463 (18.57)		0.83 (0.62 to 1.11)
> 19	747	125/372 (33.60)	153/375 (40.80)	+■ +	0.84 (0.69 to 1.01)
Pre-stroke mRS					
0	1613	182/799 (22.78)	230/814 (28.26)	H E -(0.83 (0.70 to 0.98)
1	42	10/28 (35.71)	6/14 (42.86)		0.86 (0.39 to 1.88
2 or more	18	2/8 (25.00)	3/10 (30.00)	• • • • • • • • • • • • • • • • • • • •	→ 0.82 (0.17 to 3.89)
Baseline ASPECTS score					
≤5	819	120/413 (29.06)	140/406 (34.48)	H ari e	0.86 (0.71 to 1.06)
> 5	848	73/419 (17.42)	97/429 (22.61)	H	0.80 (0.61 to 1.05
Intravenous Thrombolysis					
Yes	627	66/294 (22.45)	92/333 (27.63)		0.84 (0.63 to 1.10)
No	1046	128/541 (23.66)	147/505(29.11)	⊢= →	0.84 (0.68 to 1.03)
Time from stroke onset to randomization	(min)				
≤ 362	844	102/427 (23.89)	126/417 (30.22)		0.81 (0.65 to 1.01)
>362	829	92/408 (22.55)	113/421 (26.84)		0.86 (0.68 to 1.10
Occlusion Location					
ICA	577	92/284 (32.39)	111/293 (37.88)	H-844	0.87 (0.69 to 1.08
M1	873	84/450 (18.67)	96/423 (22.70)		0.85 (0.65 to 1.11
M2	221	17/99 (17.17)	32/122 (26.23)		0.66 (0.39 to 1.12
Reperfusion					
Yes	1188	107/598 (17.89)	140/590 (23.73)	HE-4	0.78 (0.62 to 0.97
No	483	87/236 (36.86)	98/247 (39.68)	-	0.94 (0.75 to 1.18
COVID					
Control	892	95/443 (21.44)	141/449 (31.40)	HEH-1	0.70 (0.56 to 0.88)
Exposed	781	99/392 (25.26)	98/389 (25.19)		1.03 (0.81 to 1.31)
-5 M 127 -				20.5 1 1.5	2 2.5

* Interactions of methylprednisolone treatment effect with each of the subgroup variables was explored by adding interactions of the subgroup variables with treatment to the modified Poisson regression. The models were adjusted for age, baseline NIHSS score, pre-stroke mRS, baseline ASPECTS score, use of intravenous thrombolysis, time from onset to randomization, and occlusion location using the inverse probability treatment weighting method and were not adjusted for multiple comparisons.

eFigure 6 Subgroup Analysis of sICH (Safety Population).

Subgroup	No. of patients	Methylprednisolone group Events, n/N (%)	Placebl group Events, n/N (%)				Adjusted RR (95% CI)
Overall	1653	71/823 (8.63)	97/830 (11.69)				0.74 (0.55 to 0.99
Age							
≤ 69	861	31/443 (7)	48/418 (11.48)				0.6 (0.39 to 0.93)
> 69	792	40/380(10.53)	49/412 (11.89)		→		0.88 (0.59 to 1.3)
Sex				- 1			
Female	715	31/352 (8.81)	38/363 (10.47)		⊸		0.84 (0.53 to 1.32
Male	938	40/471 (8.49)	59/467 (12.63)	-			0.68 (0.46 to 0.99
Baseline NIHSS score							
≤ 19	923	38/462 (8.23)	45/461 (9.76)	-	→		0.86 (0.57 to 1.29
> 19	730	33/361 (9.14)	52/369 (14.09)				0.64 (0.42 to 0.97
Pre-stroke mRS							
0	1593	67/787 (8.51)	92/806 (11.41)				0.75 (0.56 to 1.01
1	42	2/28 (7.14)	5/14 (35.71)				0.19 (0.04 to 0.86
2 or more	18	0/10 (0.00)	2/8 (25.00)				-
Baseline ASPECTS score							
≤ 5	807	47/406 (11.58)	55/401 (13.72)		→		0.85 (0.59 to 1.22
> 5	841	23/414 (5.56)	41/427 (9.6)	-			0.58 (0.35 to 0.95
Intravenous Thrombolysis				1			
Yes	615	18/285 (6.32)	37/330 (11.21)	-			0.58 (0.34 to 1)
No	1038	53/538 (9.85)	60/500 (12.00)		4		0.82 (0.58 to 1.17
Time from stroke onset to randomization (min)						
≤ 362	829	34/418 (8.13)	44/411 (10.71)		•		0.76 (0.5 to 1.17)
> 362	824	37/405 (9.14)	53/419 (12.65)	-			0.72 (0.49 to 1.08
Occlusion Location							
ICA	567	26/277 (9.39)	45/290 (15.52)	-			0.6 (0.38 to 0.94)
M1	866	36/446 (8.07)	37/420 (8.81)		⊸		0.91 (0.58 to 1.41
M2	218	9/98 (9.18)	15/120 (12.50)				0.75 (0.34 to 1.64
Reperfusion							
Yes	1180	41/592 (6.93)	58/588 (9.86)				0.71 (0.48 to 1.04
No	471	30/230 (13.04)	38/241 (15.77)		→		0.81 (0.52 to 1.27
COVID							
Control	885	29/440 (6.59)	54/445 (12.13)	-			0.54 (0.35 to 0.83
Exposed	768	42/383 (10.97)	43/385 (11.17)	-	—		0.99 (0.66 to 1.49
				0.20.5 1	1.5	2	2.5

^{*} Interactions of methylprednisolone treatment effect with each of the subgroup variables were explored by adding interactions of the subgroup variables with treatment to the modified Poisson regression. The models were adjusted for age, baseline NIHSS score, pre-stroke mRS, baseline ASPECTS score, use of intravenous thrombolysis, time from onset to randomization, and occlusion location using the inverse probability treatment weighting method and were not adjusted for multiple comparisons.